#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Brain structure differences among male schizophrenic patients with history of serious violent acts: an MRI voxel-based morphometric study
#Text=Background
#Text=The biological underpinnings of serious violent behaviors in patients with schizophrenia remain unclear.
1-1	0-5	Brain	_	
1-2	6-15	structure	_	
1-3	16-27	differences	_	
1-4	28-33	among	_	
1-5	34-38	male	_	
1-6	39-52	schizophrenic	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
1-7	53-61	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
1-8	62-66	with	_	
1-9	67-74	history	_	
1-10	75-77	of	_	
1-11	78-85	serious	_	
1-12	86-93	violent	_	
1-13	94-98	acts	_	
1-14	98-99	:	_	
1-15	100-102	an	_	
1-16	103-106	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument	
1-17	107-118	voxel-based	_	
1-18	119-131	morphometric	_	
1-19	132-137	study	_	
1-20	138-148	Background	_	
1-21	149-152	The	_	
1-22	153-163	biological	_	
1-23	164-177	underpinnings	_	
1-24	178-180	of	_	
1-25	181-188	serious	_	
1-26	189-196	violent	_	
1-27	197-206	behaviors	_	
1-28	207-209	in	_	
1-29	210-218	patients	_	
1-30	219-223	with	_	
1-31	224-237	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-32	238-244	remain	_	
1-33	245-252	unclear	_	
1-34	252-253	.	_	

#Text=The aim of this study was to identify the characteristics of brain morphometry in patients with schizophrenia and a history of serious violent acts, who were being treated under relatively new legislation for offenders with mental illness in Japan where their relevant action should be strongly associated with their mental illness.
2-1	254-257	The	_	
2-2	258-261	aim	_	
2-3	262-264	of	_	
2-4	265-269	this	_	
2-5	270-275	study	_	
2-6	276-279	was	_	
2-7	280-282	to	_	
2-8	283-291	identify	_	
2-9	292-295	the	_	
2-10	296-311	characteristics	_	
2-11	312-314	of	_	
2-12	315-320	brain	_	
2-13	321-332	morphometry	_	
2-14	333-335	in	_	
2-15	336-344	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]	
2-16	345-349	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]	
2-17	350-363	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]	
2-18	364-367	and	_	
2-19	368-369	a	_	
2-20	370-377	history	_	
2-21	378-380	of	_	
2-22	381-388	serious	_	
2-23	389-396	violent	_	
2-24	397-401	acts	_	
2-25	401-402	,	_	
2-26	403-406	who	_	
2-27	407-411	were	_	
2-28	412-417	being	_	
2-29	418-425	treated	_	
2-30	426-431	under	_	
2-31	432-442	relatively	_	
2-32	443-446	new	_	
2-33	447-458	legislation	_	
2-34	459-462	for	_	
2-35	463-472	offenders	_	
2-36	473-477	with	_	
2-37	478-484	mental	_	
2-38	485-492	illness	_	
2-39	493-495	in	_	
2-40	496-501	Japan	_	
2-41	502-507	where	_	
2-42	508-513	their	_	
2-43	514-522	relevant	_	
2-44	523-529	action	_	
2-45	530-536	should	_	
2-46	537-539	be	_	
2-47	540-548	strongly	_	
2-48	549-559	associated	_	
2-49	560-564	with	_	
2-50	565-570	their	_	
2-51	571-577	mental	_	
2-52	578-585	illness	_	
2-53	585-586	.	_	

#Text=We also investigated whether morphometric changes would depend on types of serious violent actions or not.
3-1	587-589	We	_	
3-2	590-594	also	_	
3-3	595-607	investigated	_	
3-4	608-615	whether	_	
3-5	616-628	morphometric	_	
3-6	629-636	changes	_	
3-7	637-642	would	_	
3-8	643-649	depend	_	
3-9	650-652	on	_	
3-10	653-658	types	_	
3-11	659-661	of	_	
3-12	662-669	serious	_	
3-13	670-677	violent	_	
3-14	678-685	actions	_	
3-15	686-688	or	_	
3-16	689-692	not	_	
3-17	692-693	.	_	

#Text=Methods
#Text=Thirty-four male patients with schizophrenia who were hospitalized after committing serious violent acts were compared with 23 male outpatients or inpatients with schizophrenia and no history of violent acts.
4-1	694-701	Methods	_	
4-2	702-713	Thirty-four	_	
4-3	714-718	male	_	
4-4	719-727	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
4-5	728-732	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
4-6	733-746	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
4-7	747-750	who	_	
4-8	751-755	were	_	
4-9	756-768	hospitalized	_	
4-10	769-774	after	_	
4-11	775-785	committing	_	
4-12	786-793	serious	_	
4-13	794-801	violent	_	
4-14	802-806	acts	_	
4-15	807-811	were	_	
4-16	812-820	compared	_	
4-17	821-825	with	_	
4-18	826-828	23	_	
4-19	829-833	male	_	
4-20	834-845	outpatients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
4-21	846-848	or	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
4-22	849-859	inpatients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
4-23	860-864	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
4-24	865-878	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
4-25	879-882	and	_	
4-26	883-885	no	_	
4-27	886-893	history	_	
4-28	894-896	of	_	
4-29	897-904	violent	_	
4-30	905-909	acts	_	
4-31	909-910	.	_	

#Text=T1-weighted magnetic resonance imaging (MRI) with voxel-based morphometry was used to assess gray matter volume.
5-1	911-913	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[5]	
5-2	913-914	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[5]	
5-3	914-922	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[5]	
5-4	923-931	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[5]	
5-5	932-941	resonance	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[5]	
5-6	942-949	imaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[5]	
5-7	950-951	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[5]	
5-8	951-954	MRI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[5]	
5-9	954-955	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[5]	
5-10	956-960	with	_	
5-11	961-972	voxel-based	_	
5-12	973-984	morphometry	_	
5-13	985-988	was	_	
5-14	989-993	used	_	
5-15	994-996	to	_	
5-16	997-1003	assess	_	
5-17	1004-1008	gray	_	
5-18	1009-1015	matter	_	
5-19	1016-1022	volume	_	
5-20	1022-1023	.	_	

#Text=Additionally, patients with violent acts were divided based on whether their relevant actions were premeditated or not.
6-1	1024-1036	Additionally	_	
6-2	1036-1037	,	_	
6-3	1038-1046	patients	_	
6-4	1047-1051	with	_	
6-5	1052-1059	violent	_	
6-6	1060-1064	acts	_	
6-7	1065-1069	were	_	
6-8	1070-1077	divided	_	
6-9	1078-1083	based	_	
6-10	1084-1086	on	_	
6-11	1087-1094	whether	_	
6-12	1095-1100	their	_	
6-13	1101-1109	relevant	_	
6-14	1110-1117	actions	_	
6-15	1118-1122	were	_	
6-16	1123-1135	premeditated	_	
6-17	1136-1138	or	_	
6-18	1139-1142	not	_	
6-19	1142-1143	.	_	

#Text=The regional volumes of these two groups were compared to those of the control patient group.
7-1	1144-1147	The	_	
7-2	1148-1156	regional	_	
7-3	1157-1164	volumes	_	
7-4	1165-1167	of	_	
7-5	1168-1173	these	_	
7-6	1174-1177	two	_	
7-7	1178-1184	groups	_	
7-8	1185-1189	were	_	
7-9	1190-1198	compared	_	
7-10	1199-1201	to	_	
7-11	1202-1207	those	_	
7-12	1208-1210	of	_	
7-13	1211-1214	the	_	
7-14	1215-1222	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
7-15	1223-1230	patient	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
7-16	1231-1236	group	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
7-17	1236-1237	.	_	

#Text=Results
#Text=Patients with schizophrenia and a history of serious violent acts showed significantly smaller regional volumes of the right inferior temporal area expanded to the middle temporal gyrus and the temporal pole, and the right insular area compared to patients without a history of violence.
8-1	1238-1245	Results	_	
8-2	1246-1254	Patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]	
8-3	1255-1259	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]	
8-4	1260-1273	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]	
8-5	1274-1277	and	_	
8-6	1278-1279	a	_	
8-7	1280-1287	history	_	
8-8	1288-1290	of	_	
8-9	1291-1298	serious	_	
8-10	1299-1306	violent	_	
8-11	1307-1311	acts	_	
8-12	1312-1318	showed	_	
8-13	1319-1332	significantly	_	
8-14	1333-1340	smaller	_	
8-15	1341-1349	regional	_	
8-16	1350-1357	volumes	_	
8-17	1358-1360	of	_	
8-18	1361-1364	the	_	
8-19	1365-1370	right	_	
8-20	1371-1379	inferior	_	
8-21	1380-1388	temporal	_	
8-22	1389-1393	area	_	
8-23	1394-1402	expanded	_	
8-24	1403-1405	to	_	
8-25	1406-1409	the	_	
8-26	1410-1416	middle	_	
8-27	1417-1425	temporal	_	
8-28	1426-1431	gyrus	_	
8-29	1432-1435	and	_	
8-30	1436-1439	the	_	
8-31	1440-1448	temporal	_	
8-32	1449-1453	pole	_	
8-33	1453-1454	,	_	
8-34	1455-1458	and	_	
8-35	1459-1462	the	_	
8-36	1463-1468	right	_	
8-37	1469-1476	insular	_	
8-38	1477-1481	area	_	
8-39	1482-1490	compared	_	
8-40	1491-1493	to	_	
8-41	1494-1502	patients	_	
8-42	1503-1510	without	_	
8-43	1511-1512	a	_	
8-44	1513-1520	history	_	
8-45	1521-1523	of	_	
8-46	1524-1532	violence	_	
8-47	1532-1533	.	_	

#Text=Patients with premeditated violent acts showed significantly smaller regional volumes of the right inferior temporal area, the right insular area, the left planum polare area including the insula, and the bilateral precuneus area including the posterior cingulate gyrus than those without a history of violence, whereas patients with impulsive violent acts showed significantly smaller volumes of only the right inferior temporal area compared to those without a history of violence.
9-1	1534-1542	Patients	_	
9-2	1543-1547	with	_	
9-3	1548-1560	premeditated	_	
9-4	1561-1568	violent	_	
9-5	1569-1573	acts	_	
9-6	1574-1580	showed	_	
9-7	1581-1594	significantly	_	
9-8	1595-1602	smaller	_	
9-9	1603-1611	regional	_	
9-10	1612-1619	volumes	_	
9-11	1620-1622	of	_	
9-12	1623-1626	the	_	
9-13	1627-1632	right	_	
9-14	1633-1641	inferior	_	
9-15	1642-1650	temporal	_	
9-16	1651-1655	area	_	
9-17	1655-1656	,	_	
9-18	1657-1660	the	_	
9-19	1661-1666	right	_	
9-20	1667-1674	insular	_	
9-21	1675-1679	area	_	
9-22	1679-1680	,	_	
9-23	1681-1684	the	_	
9-24	1685-1689	left	_	
9-25	1690-1696	planum	_	
9-26	1697-1703	polare	_	
9-27	1704-1708	area	_	
9-28	1709-1718	including	_	
9-29	1719-1722	the	_	
9-30	1723-1729	insula	_	
9-31	1729-1730	,	_	
9-32	1731-1734	and	_	
9-33	1735-1738	the	_	
9-34	1739-1748	bilateral	_	
9-35	1749-1758	precuneus	_	
9-36	1759-1763	area	_	
9-37	1764-1773	including	_	
9-38	1774-1777	the	_	
9-39	1778-1787	posterior	_	
9-40	1788-1797	cingulate	_	
9-41	1798-1803	gyrus	_	
9-42	1804-1808	than	_	
9-43	1809-1814	those	_	
9-44	1815-1822	without	_	
9-45	1823-1824	a	_	
9-46	1825-1832	history	_	
9-47	1833-1835	of	_	
9-48	1836-1844	violence	_	
9-49	1844-1845	,	_	
9-50	1846-1853	whereas	_	
9-51	1854-1862	patients	_	
9-52	1863-1867	with	_	
9-53	1868-1877	impulsive	_	
9-54	1878-1885	violent	_	
9-55	1886-1890	acts	_	
9-56	1891-1897	showed	_	
9-57	1898-1911	significantly	_	
9-58	1912-1919	smaller	_	
9-59	1920-1927	volumes	_	
9-60	1928-1930	of	_	
9-61	1931-1935	only	_	
9-62	1936-1939	the	_	
9-63	1940-1945	right	_	
9-64	1946-1954	inferior	_	
9-65	1955-1963	temporal	_	
9-66	1964-1968	area	_	
9-67	1969-1977	compared	_	
9-68	1978-1980	to	_	
9-69	1981-1986	those	_	
9-70	1987-1994	without	_	
9-71	1995-1996	a	_	
9-72	1997-2004	history	_	
9-73	2005-2007	of	_	
9-74	2008-2016	violence	_	
9-75	2016-2017	.	_	

#Text=Conclusions
#Text=Patients with schizophrenia and a history of serious violent acts showed structural differences in some brain regions compared to those with schizophrenia and no history of violence.
10-1	2018-2029	Conclusions	_	
10-2	2030-2038	Patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[8]	
10-3	2039-2043	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[8]	
10-4	2044-2057	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[8]	
10-5	2058-2061	and	_	
10-6	2062-2063	a	_	
10-7	2064-2071	history	_	
10-8	2072-2074	of	_	
10-9	2075-2082	serious	_	
10-10	2083-2090	violent	_	
10-11	2091-2095	acts	_	
10-12	2096-2102	showed	_	
10-13	2103-2113	structural	_	
10-14	2114-2125	differences	_	
10-15	2126-2128	in	_	
10-16	2129-2133	some	_	
10-17	2134-2139	brain	_	
10-18	2140-2147	regions	_	
10-19	2148-2156	compared	_	
10-20	2157-2159	to	_	
10-21	2160-2165	those	_	
10-22	2166-2170	with	_	
10-23	2171-2184	schizophrenia	_	
10-24	2185-2188	and	_	
10-25	2189-2191	no	_	
10-26	2192-2199	history	_	
10-27	2200-2202	of	_	
10-28	2203-2211	violence	_	
10-29	2211-2212	.	_	

#Text=Abnormalities in the right inferior temporal area were relatively common but did not depend on whether the violent actions were premeditated or not, and abnormalities in a wider range may be attributed to not only planning the violent action against others but also to maintaining that plan.
11-1	2213-2226	Abnormalities	_	
11-2	2227-2229	in	_	
11-3	2230-2233	the	_	
11-4	2234-2239	right	_	
11-5	2240-2248	inferior	_	
11-6	2249-2257	temporal	_	
11-7	2258-2262	area	_	
11-8	2263-2267	were	_	
11-9	2268-2278	relatively	_	
11-10	2279-2285	common	_	
11-11	2286-2289	but	_	
11-12	2290-2293	did	_	
11-13	2294-2297	not	_	
11-14	2298-2304	depend	_	
11-15	2305-2307	on	_	
11-16	2308-2315	whether	_	
11-17	2316-2319	the	_	
11-18	2320-2327	violent	_	
11-19	2328-2335	actions	_	
11-20	2336-2340	were	_	
11-21	2341-2353	premeditated	_	
11-22	2354-2356	or	_	
11-23	2357-2360	not	_	
11-24	2360-2361	,	_	
11-25	2362-2365	and	_	
11-26	2366-2379	abnormalities	_	
11-27	2380-2382	in	_	
11-28	2383-2384	a	_	
11-29	2385-2390	wider	_	
11-30	2391-2396	range	_	
11-31	2397-2400	may	_	
11-32	2401-2403	be	_	
11-33	2404-2414	attributed	_	
11-34	2415-2417	to	_	
11-35	2418-2421	not	_	
11-36	2422-2426	only	_	
11-37	2427-2435	planning	_	
11-38	2436-2439	the	_	
11-39	2440-2447	violent	_	
11-40	2448-2454	action	_	
11-41	2455-2462	against	_	
11-42	2463-2469	others	_	
11-43	2470-2473	but	_	
11-44	2474-2478	also	_	
11-45	2479-2481	to	_	
11-46	2482-2493	maintaining	_	
11-47	2494-2498	that	_	
11-48	2499-2503	plan	_	
11-49	2503-2504	.	_	

#Text=Trial registration
#Text=UMIN.ac.jp UMIN000008065.
12-1	2505-2510	Trial	_	
12-2	2511-2523	registration	_	
12-3	2524-2534	UMIN.ac.jp	_	
12-4	2535-2548	UMIN000008065	_	
12-5	2548-2549	.	_	

#Text=Registered 2012/05/31.
13-1	2550-2560	Registered	_	
13-2	2561-2565	2012	_	
13-3	2565-2566	/	_	
13-4	2566-2568	05	_	
13-5	2568-2569	/	_	
13-6	2569-2571	31	_	
13-7	2571-2572	.	_	

#Text=Background
#Text=Although many individuals with schizophrenia do not show any antisocial behaviors, they hold a significant risk for violent acts compared to the general population.
14-1	2573-2583	Background	_	
14-2	2584-2592	Although	_	
14-3	2593-2597	many	_	
14-4	2598-2609	individuals	_	
14-5	2610-2614	with	_	
14-6	2615-2628	schizophrenia	_	
14-7	2629-2631	do	_	
14-8	2632-2635	not	_	
14-9	2636-2640	show	_	
14-10	2641-2644	any	_	
14-11	2645-2655	antisocial	_	
14-12	2656-2665	behaviors	_	
14-13	2665-2666	,	_	
14-14	2667-2671	they	_	
14-15	2672-2676	hold	_	
14-16	2677-2678	a	_	
14-17	2679-2690	significant	_	
14-18	2691-2695	risk	_	
14-19	2696-2699	for	_	
14-20	2700-2707	violent	_	
14-21	2708-2712	acts	_	
14-22	2713-2721	compared	_	
14-23	2722-2724	to	_	
14-24	2725-2728	the	_	
14-25	2729-2736	general	_	
14-26	2737-2747	population	_	
14-27	2747-2748	.	_	

#Text=Violent offenses are not necessarily among the general characteristics of schizophrenia, but a considerable number of patients with schizophrenia tend to repeat violent behaviors.
15-1	2749-2756	Violent	_	
15-2	2757-2765	offenses	_	
15-3	2766-2769	are	_	
15-4	2770-2773	not	_	
15-5	2774-2785	necessarily	_	
15-6	2786-2791	among	_	
15-7	2792-2795	the	_	
15-8	2796-2803	general	_	
15-9	2804-2819	characteristics	_	
15-10	2820-2822	of	_	
15-11	2823-2836	schizophrenia	_	
15-12	2836-2837	,	_	
15-13	2838-2841	but	_	
15-14	2842-2843	a	_	
15-15	2844-2856	considerable	_	
15-16	2857-2863	number	_	
15-17	2864-2866	of	_	
15-18	2867-2875	patients	_	
15-19	2876-2880	with	_	
15-20	2881-2894	schizophrenia	_	
15-21	2895-2899	tend	_	
15-22	2900-2902	to	_	
15-23	2903-2909	repeat	_	
15-24	2910-2917	violent	_	
15-25	2918-2927	behaviors	_	
15-26	2927-2928	.	_	

#Text=The differences between patients with violent actions and those without remain unclear.
16-1	2929-2932	The	_	
16-2	2933-2944	differences	_	
16-3	2945-2952	between	_	
16-4	2953-2961	patients	_	
16-5	2962-2966	with	_	
16-6	2967-2974	violent	_	
16-7	2975-2982	actions	_	
16-8	2983-2986	and	_	
16-9	2987-2992	those	_	
16-10	2993-3000	without	_	
16-11	3001-3007	remain	_	
16-12	3008-3015	unclear	_	
16-13	3015-3016	.	_	

#Text=Several factors have been suggested to distinguish the violent and non-violent groups, such as positive symptoms of schizophrenia, premorbid antisocial traits, and co-morbidity with substance disorders.
17-1	3017-3024	Several	_	
17-2	3025-3032	factors	_	
17-3	3033-3037	have	_	
17-4	3038-3042	been	_	
17-5	3043-3052	suggested	_	
17-6	3053-3055	to	_	
17-7	3056-3067	distinguish	_	
17-8	3068-3071	the	_	
17-9	3072-3079	violent	_	
17-10	3080-3083	and	_	
17-11	3084-3095	non-violent	_	
17-12	3096-3102	groups	_	
17-13	3102-3103	,	_	
17-14	3104-3108	such	_	
17-15	3109-3111	as	_	
17-16	3112-3120	positive	_	
17-17	3121-3129	symptoms	_	
17-18	3130-3132	of	_	
17-19	3133-3146	schizophrenia	_	
17-20	3146-3147	,	_	
17-21	3148-3157	premorbid	_	
17-22	3158-3168	antisocial	_	
17-23	3169-3175	traits	_	
17-24	3175-3176	,	_	
17-25	3177-3180	and	_	
17-26	3181-3193	co-morbidity	_	
17-27	3194-3198	with	_	
17-28	3199-3208	substance	_	
17-29	3209-3218	disorders	_	
17-30	3218-3219	.	_	

#Text=Genetic influences have also been proposed to have a significant impact on the risk of violence in schizophrenia.
18-1	3220-3227	Genetic	_	
18-2	3228-3238	influences	_	
18-3	3239-3243	have	_	
18-4	3244-3248	also	_	
18-5	3249-3253	been	_	
18-6	3254-3262	proposed	_	
18-7	3263-3265	to	_	
18-8	3266-3270	have	_	
18-9	3271-3272	a	_	
18-10	3273-3284	significant	_	
18-11	3285-3291	impact	_	
18-12	3292-3294	on	_	
18-13	3295-3298	the	_	
18-14	3299-3303	risk	_	
18-15	3304-3306	of	_	
18-16	3307-3315	violence	_	
18-17	3316-3318	in	_	
18-18	3319-3332	schizophrenia	_	
18-19	3332-3333	.	_	

#Text=It is suggested that biological and psychosocial factors may be intricately intertwined for forming a violent trait in schizophrenia.
19-1	3334-3336	It	_	
19-2	3337-3339	is	_	
19-3	3340-3349	suggested	_	
19-4	3350-3354	that	_	
19-5	3355-3365	biological	_	
19-6	3366-3369	and	_	
19-7	3370-3382	psychosocial	_	
19-8	3383-3390	factors	_	
19-9	3391-3394	may	_	
19-10	3395-3397	be	_	
19-11	3398-3409	intricately	_	
19-12	3410-3421	intertwined	_	
19-13	3422-3425	for	_	
19-14	3426-3433	forming	_	
19-15	3434-3435	a	_	
19-16	3436-3443	violent	_	
19-17	3444-3449	trait	_	
19-18	3450-3452	in	_	
19-19	3453-3466	schizophrenia	_	
19-20	3466-3467	.	_	

#Text=The biological aspects of violent traits have been relatively well described among individuals with antisocial disorder and psychopathy, which are also strongly associated with violent traits.
20-1	3468-3471	The	_	
20-2	3472-3482	biological	_	
20-3	3483-3490	aspects	_	
20-4	3491-3493	of	_	
20-5	3494-3501	violent	_	
20-6	3502-3508	traits	_	
20-7	3509-3513	have	_	
20-8	3514-3518	been	_	
20-9	3519-3529	relatively	_	
20-10	3530-3534	well	_	
20-11	3535-3544	described	_	
20-12	3545-3550	among	_	
20-13	3551-3562	individuals	_	
20-14	3563-3567	with	_	
20-15	3568-3578	antisocial	_	
20-16	3579-3587	disorder	_	
20-17	3588-3591	and	_	
20-18	3592-3603	psychopathy	_	
20-19	3603-3604	,	_	
20-20	3605-3610	which	_	
20-21	3611-3614	are	_	
20-22	3615-3619	also	_	
20-23	3620-3628	strongly	_	
20-24	3629-3639	associated	_	
20-25	3640-3644	with	_	
20-26	3645-3652	violent	_	
20-27	3653-3659	traits	_	
20-28	3659-3660	.	_	

#Text=Historically, a violent trait has been thought to be associated with frontal lobe dysfunction.
21-1	3661-3673	Historically	_	
21-2	3673-3674	,	_	
21-3	3675-3676	a	_	
21-4	3677-3684	violent	_	
21-5	3685-3690	trait	_	
21-6	3691-3694	has	_	
21-7	3695-3699	been	_	
21-8	3700-3707	thought	_	
21-9	3708-3710	to	_	
21-10	3711-3713	be	_	
21-11	3714-3724	associated	_	
21-12	3725-3729	with	_	
21-13	3730-3737	frontal	_	
21-14	3738-3742	lobe	_	
21-15	3743-3754	dysfunction	_	
21-16	3754-3755	.	_	

#Text=Some patients with organic frontal damage show similar behaviors to psychopathy, and frontal abnormalities have been reported in patients with antisocial personality disorder or psychopathy.
22-1	3756-3760	Some	_	
22-2	3761-3769	patients	_	
22-3	3770-3774	with	_	
22-4	3775-3782	organic	_	
22-5	3783-3790	frontal	_	
22-6	3791-3797	damage	_	
22-7	3798-3802	show	_	
22-8	3803-3810	similar	_	
22-9	3811-3820	behaviors	_	
22-10	3821-3823	to	_	
22-11	3824-3835	psychopathy	_	
22-12	3835-3836	,	_	
22-13	3837-3840	and	_	
22-14	3841-3848	frontal	_	
22-15	3849-3862	abnormalities	_	
22-16	3863-3867	have	_	
22-17	3868-3872	been	_	
22-18	3873-3881	reported	_	
22-19	3882-3884	in	_	
22-20	3885-3893	patients	_	
22-21	3894-3898	with	_	
22-22	3899-3909	antisocial	_	
22-23	3910-3921	personality	_	
22-24	3922-3930	disorder	_	
22-25	3931-3933	or	_	
22-26	3934-3945	psychopathy	_	
22-27	3945-3946	.	_	

#Text=Morphological abnormalities in other regions such as the temporal pole, anterior cingulate cortex, nucleus accumbens, amygdala, and hippocampus were also reported in individuals with psychopathy or antisocial personality disorder.
23-1	3947-3960	Morphological	_	
23-2	3961-3974	abnormalities	_	
23-3	3975-3977	in	_	
23-4	3978-3983	other	_	
23-5	3984-3991	regions	_	
23-6	3992-3996	such	_	
23-7	3997-3999	as	_	
23-8	4000-4003	the	_	
23-9	4004-4012	temporal	_	
23-10	4013-4017	pole	_	
23-11	4017-4018	,	_	
23-12	4019-4027	anterior	_	
23-13	4028-4037	cingulate	_	
23-14	4038-4044	cortex	_	
23-15	4044-4045	,	_	
23-16	4046-4053	nucleus	_	
23-17	4054-4063	accumbens	_	
23-18	4063-4064	,	_	
23-19	4065-4073	amygdala	_	
23-20	4073-4074	,	_	
23-21	4075-4078	and	_	
23-22	4079-4090	hippocampus	_	
23-23	4091-4095	were	_	
23-24	4096-4100	also	_	
23-25	4101-4109	reported	_	
23-26	4110-4112	in	_	
23-27	4113-4124	individuals	_	
23-28	4125-4129	with	_	
23-29	4130-4141	psychopathy	_	
23-30	4142-4144	or	_	
23-31	4145-4155	antisocial	_	
23-32	4156-4167	personality	_	
23-33	4168-4176	disorder	_	
23-34	4176-4177	.	_	

#Text=However, to what extent these abnormalities are shared among individuals with schizophrenia and violent traits remains unclear.
24-1	4178-4185	However	_	
24-2	4185-4186	,	_	
24-3	4187-4189	to	_	
24-4	4190-4194	what	_	
24-5	4195-4201	extent	_	
24-6	4202-4207	these	_	
24-7	4208-4221	abnormalities	_	
24-8	4222-4225	are	_	
24-9	4226-4232	shared	_	
24-10	4233-4238	among	_	
24-11	4239-4250	individuals	_	
24-12	4251-4255	with	_	
24-13	4256-4269	schizophrenia	_	
24-14	4270-4273	and	_	
24-15	4274-4281	violent	_	
24-16	4282-4288	traits	_	
24-17	4289-4296	remains	_	
24-18	4297-4304	unclear	_	
24-19	4304-4305	.	_	

#Text=A few studies have examined the relationships between structural abnormalities and violent traits in patients with schizophrenia.
25-1	4306-4307	A	_	
25-2	4308-4311	few	_	
25-3	4312-4319	studies	_	
25-4	4320-4324	have	_	
25-5	4325-4333	examined	_	
25-6	4334-4337	the	_	
25-7	4338-4351	relationships	_	
25-8	4352-4359	between	_	
25-9	4360-4370	structural	_	
25-10	4371-4384	abnormalities	_	
25-11	4385-4388	and	_	
25-12	4389-4396	violent	_	
25-13	4397-4403	traits	_	
25-14	4404-4406	in	_	
25-15	4407-4415	patients	_	
25-16	4416-4420	with	_	
25-17	4421-4434	schizophrenia	_	
25-18	4434-4435	.	_	

#Text=Concerning the relationships between schizophrenia and aggression, several findings were reported, such as relationships between orbitofrontal cortex volumes, caudate volumes, and aggression using the Overt Aggression Scale in treatment-resistant patients with schizophrenia or schizoaffective disorder, as well as the correlation between cortical thinning in ventral prefrontal regions, urgency scores and the Aggression Questionnaire total score in patients with schizophrenia or schizoaffective disorder.
26-1	4436-4446	Concerning	_	
26-2	4447-4450	the	_	
26-3	4451-4464	relationships	_	
26-4	4465-4472	between	_	
26-5	4473-4486	schizophrenia	_	
26-6	4487-4490	and	_	
26-7	4491-4501	aggression	_	
26-8	4501-4502	,	_	
26-9	4503-4510	several	_	
26-10	4511-4519	findings	_	
26-11	4520-4524	were	_	
26-12	4525-4533	reported	_	
26-13	4533-4534	,	_	
26-14	4535-4539	such	_	
26-15	4540-4542	as	_	
26-16	4543-4556	relationships	_	
26-17	4557-4564	between	_	
26-18	4565-4578	orbitofrontal	_	
26-19	4579-4585	cortex	_	
26-20	4586-4593	volumes	_	
26-21	4593-4594	,	_	
26-22	4595-4602	caudate	_	
26-23	4603-4610	volumes	_	
26-24	4610-4611	,	_	
26-25	4612-4615	and	_	
26-26	4616-4626	aggression	_	
26-27	4627-4632	using	_	
26-28	4633-4636	the	_	
26-29	4637-4642	Overt	_	
26-30	4643-4653	Aggression	_	
26-31	4654-4659	Scale	_	
26-32	4660-4662	in	_	
26-33	4663-4682	treatment-resistant	_	
26-34	4683-4691	patients	_	
26-35	4692-4696	with	_	
26-36	4697-4710	schizophrenia	_	
26-37	4711-4713	or	_	
26-38	4714-4729	schizoaffective	_	
26-39	4730-4738	disorder	_	
26-40	4738-4739	,	_	
26-41	4740-4742	as	_	
26-42	4743-4747	well	_	
26-43	4748-4750	as	_	
26-44	4751-4754	the	_	
26-45	4755-4766	correlation	_	
26-46	4767-4774	between	_	
26-47	4775-4783	cortical	_	
26-48	4784-4792	thinning	_	
26-49	4793-4795	in	_	
26-50	4796-4803	ventral	_	
26-51	4804-4814	prefrontal	_	
26-52	4815-4822	regions	_	
26-53	4822-4823	,	_	
26-54	4824-4831	urgency	_	
26-55	4832-4838	scores	_	
26-56	4839-4842	and	_	
26-57	4843-4846	the	_	
26-58	4847-4857	Aggression	_	
26-59	4858-4871	Questionnaire	_	
26-60	4872-4877	total	_	
26-61	4878-4883	score	_	
26-62	4884-4886	in	_	
26-63	4887-4895	patients	_	
26-64	4896-4900	with	_	
26-65	4901-4914	schizophrenia	_	
26-66	4915-4917	or	_	
26-67	4918-4933	schizoaffective	_	
26-68	4934-4942	disorder	_	
26-69	4942-4943	.	_	

#Text=Several studies have included patients with a history of serious violence in addition to schizophrenia and/or antisocial personality disorder, and these studies reported volumetric abnormalities in brain regions including the medial temporal lobe.
27-1	4944-4951	Several	_	
27-2	4952-4959	studies	_	
27-3	4960-4964	have	_	
27-4	4965-4973	included	_	
27-5	4974-4982	patients	_	
27-6	4983-4987	with	_	
27-7	4988-4989	a	_	
27-8	4990-4997	history	_	
27-9	4998-5000	of	_	
27-10	5001-5008	serious	_	
27-11	5009-5017	violence	_	
27-12	5018-5020	in	_	
27-13	5021-5029	addition	_	
27-14	5030-5032	to	_	
27-15	5033-5046	schizophrenia	_	
27-16	5047-5050	and	_	
27-17	5050-5051	/	_	
27-18	5051-5053	or	_	
27-19	5054-5064	antisocial	_	
27-20	5065-5076	personality	_	
27-21	5077-5085	disorder	_	
27-22	5085-5086	,	_	
27-23	5087-5090	and	_	
27-24	5091-5096	these	_	
27-25	5097-5104	studies	_	
27-26	5105-5113	reported	_	
27-27	5114-5124	volumetric	_	
27-28	5125-5138	abnormalities	_	
27-29	5139-5141	in	_	
27-30	5142-5147	brain	_	
27-31	5148-5155	regions	_	
27-32	5156-5165	including	_	
27-33	5166-5169	the	_	
27-34	5170-5176	medial	_	
27-35	5177-5185	temporal	_	
27-36	5186-5190	lobe	_	
27-37	5190-5191	.	_	

#Text=For patients with schizophrenia and a history of serious violence, Barkataki et al. reported reduced whole brain and increased putamen sizes compared with normal controls and non-violent patients with schizophrenia as well as reduced hippocampal volumes compared with normal controls and the antisocial personality disorder group.
28-1	5192-5195	For	_	
28-2	5196-5204	patients	_	
28-3	5205-5209	with	_	
28-4	5210-5223	schizophrenia	_	
28-5	5224-5227	and	_	
28-6	5228-5229	a	_	
28-7	5230-5237	history	_	
28-8	5238-5240	of	_	
28-9	5241-5248	serious	_	
28-10	5249-5257	violence	_	
28-11	5257-5258	,	_	
28-12	5259-5268	Barkataki	_	
28-13	5269-5271	et	_	
28-14	5272-5274	al	_	
28-15	5274-5275	.	_	
28-16	5276-5284	reported	_	
28-17	5285-5292	reduced	_	
28-18	5293-5298	whole	_	
28-19	5299-5304	brain	_	
28-20	5305-5308	and	_	
28-21	5309-5318	increased	_	
28-22	5319-5326	putamen	_	
28-23	5327-5332	sizes	_	
28-24	5333-5341	compared	_	
28-25	5342-5346	with	_	
28-26	5347-5353	normal	_	
28-27	5354-5362	controls	_	
28-28	5363-5366	and	_	
28-29	5367-5378	non-violent	_	
28-30	5379-5387	patients	_	
28-31	5388-5392	with	_	
28-32	5393-5406	schizophrenia	_	
28-33	5407-5409	as	_	
28-34	5410-5414	well	_	
28-35	5415-5417	as	_	
28-36	5418-5425	reduced	_	
28-37	5426-5437	hippocampal	_	
28-38	5438-5445	volumes	_	
28-39	5446-5454	compared	_	
28-40	5455-5459	with	_	
28-41	5460-5466	normal	_	
28-42	5467-5475	controls	_	
28-43	5476-5479	and	_	
28-44	5480-5483	the	_	
28-45	5484-5494	antisocial	_	
28-46	5495-5506	personality	_	
28-47	5507-5515	disorder	_	
28-48	5516-5521	group	_	
28-49	5521-5522	.	_	

#Text=Kumari et al. found elevated impulsiveness scores in participants with schizophrenia and a history of serious violence compared to non-violent patients and normal controls as well as a negative correlation between these factors and orbitofrontal gray matter volume and hippocampal volume in participants with schizophrenia and a history of violence.
29-1	5523-5529	Kumari	_	
29-2	5530-5532	et	_	
29-3	5533-5535	al	_	
29-4	5535-5536	.	_	
29-5	5537-5542	found	_	
29-6	5543-5551	elevated	_	
29-7	5552-5565	impulsiveness	_	
29-8	5566-5572	scores	_	
29-9	5573-5575	in	_	
29-10	5576-5588	participants	_	
29-11	5589-5593	with	_	
29-12	5594-5607	schizophrenia	_	
29-13	5608-5611	and	_	
29-14	5612-5613	a	_	
29-15	5614-5621	history	_	
29-16	5622-5624	of	_	
29-17	5625-5632	serious	_	
29-18	5633-5641	violence	_	
29-19	5642-5650	compared	_	
29-20	5651-5653	to	_	
29-21	5654-5665	non-violent	_	
29-22	5666-5674	patients	_	
29-23	5675-5678	and	_	
29-24	5679-5685	normal	_	
29-25	5686-5694	controls	_	
29-26	5695-5697	as	_	
29-27	5698-5702	well	_	
29-28	5703-5705	as	_	
29-29	5706-5707	a	_	
29-30	5708-5716	negative	_	
29-31	5717-5728	correlation	_	
29-32	5729-5736	between	_	
29-33	5737-5742	these	_	
29-34	5743-5750	factors	_	
29-35	5751-5754	and	_	
29-36	5755-5768	orbitofrontal	_	
29-37	5769-5773	gray	_	
29-38	5774-5780	matter	_	
29-39	5781-5787	volume	_	
29-40	5788-5791	and	_	
29-41	5792-5803	hippocampal	_	
29-42	5804-5810	volume	_	
29-43	5811-5813	in	_	
29-44	5814-5826	participants	_	
29-45	5827-5831	with	_	
29-46	5832-5845	schizophrenia	_	
29-47	5846-5849	and	_	
29-48	5850-5851	a	_	
29-49	5852-5859	history	_	
29-50	5860-5862	of	_	
29-51	5863-5871	violence	_	
29-52	5871-5872	.	_	

#Text=Reduced hippocampal and parahippocampal volume among murderers with schizophrenia relative to non-murderers with schizophrenia was also reported by another group.
30-1	5873-5880	Reduced	_	
30-2	5881-5892	hippocampal	_	
30-3	5893-5896	and	_	
30-4	5897-5912	parahippocampal	_	
30-5	5913-5919	volume	_	
30-6	5920-5925	among	_	
30-7	5926-5935	murderers	_	
30-8	5936-5940	with	_	
30-9	5941-5954	schizophrenia	_	
30-10	5955-5963	relative	_	
30-11	5964-5966	to	_	
30-12	5967-5980	non-murderers	_	
30-13	5981-5985	with	_	
30-14	5986-5999	schizophrenia	_	
30-15	6000-6003	was	_	
30-16	6004-6008	also	_	
30-17	6009-6017	reported	_	
30-18	6018-6020	by	_	
30-19	6021-6028	another	_	
30-20	6029-6034	group	_	
30-21	6034-6035	.	_	

#Text=Volumetric abnormalities in other brain areas have also been reported, such as reduced thalamic volume in participants with schizophrenia or antisocial personality disorder and a history of psychosocial deprivation, as well as lower anterior cingulate volume in subjects with antisocial personality and/or schizophrenia and a history of serious violence, but not in patients with non-violent schizophrenia relative to normal subjects.
31-1	6036-6046	Volumetric	_	
31-2	6047-6060	abnormalities	_	
31-3	6061-6063	in	_	
31-4	6064-6069	other	_	
31-5	6070-6075	brain	_	
31-6	6076-6081	areas	_	
31-7	6082-6086	have	_	
31-8	6087-6091	also	_	
31-9	6092-6096	been	_	
31-10	6097-6105	reported	_	
31-11	6105-6106	,	_	
31-12	6107-6111	such	_	
31-13	6112-6114	as	_	
31-14	6115-6122	reduced	_	
31-15	6123-6131	thalamic	_	
31-16	6132-6138	volume	_	
31-17	6139-6141	in	_	
31-18	6142-6154	participants	_	
31-19	6155-6159	with	_	
31-20	6160-6173	schizophrenia	_	
31-21	6174-6176	or	_	
31-22	6177-6187	antisocial	_	
31-23	6188-6199	personality	_	
31-24	6200-6208	disorder	_	
31-25	6209-6212	and	_	
31-26	6213-6214	a	_	
31-27	6215-6222	history	_	
31-28	6223-6225	of	_	
31-29	6226-6238	psychosocial	_	
31-30	6239-6250	deprivation	_	
31-31	6250-6251	,	_	
31-32	6252-6254	as	_	
31-33	6255-6259	well	_	
31-34	6260-6262	as	_	
31-35	6263-6268	lower	_	
31-36	6269-6277	anterior	_	
31-37	6278-6287	cingulate	_	
31-38	6288-6294	volume	_	
31-39	6295-6297	in	_	
31-40	6298-6306	subjects	_	
31-41	6307-6311	with	_	
31-42	6312-6322	antisocial	_	
31-43	6323-6334	personality	_	
31-44	6335-6338	and	_	
31-45	6338-6339	/	_	
31-46	6339-6341	or	_	
31-47	6342-6355	schizophrenia	_	
31-48	6356-6359	and	_	
31-49	6360-6361	a	_	
31-50	6362-6369	history	_	
31-51	6370-6372	of	_	
31-52	6373-6380	serious	_	
31-53	6381-6389	violence	_	
31-54	6389-6390	,	_	
31-55	6391-6394	but	_	
31-56	6395-6398	not	_	
31-57	6399-6401	in	_	
31-58	6402-6410	patients	_	
31-59	6411-6415	with	_	
31-60	6416-6427	non-violent	_	
31-61	6428-6441	schizophrenia	_	
31-62	6442-6450	relative	_	
31-63	6451-6453	to	_	
31-64	6454-6460	normal	_	
31-65	6461-6469	subjects	_	
31-66	6469-6470	.	_	

#Text=Regarding cortical thickness, Narayan et al. showed that violence was associated with cortical thinning in the medial inferior frontal and lateral sensory motor cortex, as only violent subjects with antisocial personality disorder exhibited cortical thinning in inferior mesial frontal cortices.
32-1	6471-6480	Regarding	_	
32-2	6481-6489	cortical	_	
32-3	6490-6499	thickness	_	
32-4	6499-6500	,	_	
32-5	6501-6508	Narayan	_	
32-6	6509-6511	et	_	
32-7	6512-6514	al	_	
32-8	6514-6515	.	_	
32-9	6516-6522	showed	_	
32-10	6523-6527	that	_	
32-11	6528-6536	violence	_	
32-12	6537-6540	was	_	
32-13	6541-6551	associated	_	
32-14	6552-6556	with	_	
32-15	6557-6565	cortical	_	
32-16	6566-6574	thinning	_	
32-17	6575-6577	in	_	
32-18	6578-6581	the	_	
32-19	6582-6588	medial	_	
32-20	6589-6597	inferior	_	
32-21	6598-6605	frontal	_	
32-22	6606-6609	and	_	
32-23	6610-6617	lateral	_	
32-24	6618-6625	sensory	_	
32-25	6626-6631	motor	_	
32-26	6632-6638	cortex	_	
32-27	6638-6639	,	_	
32-28	6640-6642	as	_	
32-29	6643-6647	only	_	
32-30	6648-6655	violent	_	
32-31	6656-6664	subjects	_	
32-32	6665-6669	with	_	
32-33	6670-6680	antisocial	_	
32-34	6681-6692	personality	_	
32-35	6693-6701	disorder	_	
32-36	6702-6711	exhibited	_	
32-37	6712-6720	cortical	_	
32-38	6721-6729	thinning	_	
32-39	6730-6732	in	_	
32-40	6733-6741	inferior	_	
32-41	6742-6748	mesial	_	
32-42	6749-6756	frontal	_	
32-43	6757-6765	cortices	_	
32-44	6765-6766	.	_	

#Text=However, the study settings (i.e., community setting, or forensic ward-based) in these studies have varied, as did the groups compared (i.e., non-violent schizophrenia, antisocial personality disorder, and normal controls), and types of serious violent actions have not been well studied.
33-1	6767-6774	However	_	
33-2	6774-6775	,	_	
33-3	6776-6779	the	_	
33-4	6780-6785	study	_	
33-5	6786-6794	settings	_	
33-6	6795-6796	(	_	
33-7	6796-6799	i.e	_	
33-8	6799-6800	.	_	
33-9	6800-6801	,	_	
33-10	6802-6811	community	_	
33-11	6812-6819	setting	_	
33-12	6819-6820	,	_	
33-13	6821-6823	or	_	
33-14	6824-6832	forensic	_	
33-15	6833-6843	ward-based	_	
33-16	6843-6844	)	_	
33-17	6845-6847	in	_	
33-18	6848-6853	these	_	
33-19	6854-6861	studies	_	
33-20	6862-6866	have	_	
33-21	6867-6873	varied	_	
33-22	6873-6874	,	_	
33-23	6875-6877	as	_	
33-24	6878-6881	did	_	
33-25	6882-6885	the	_	
33-26	6886-6892	groups	_	
33-27	6893-6901	compared	_	
33-28	6902-6903	(	_	
33-29	6903-6906	i.e	_	
33-30	6906-6907	.	_	
33-31	6907-6908	,	_	
33-32	6909-6920	non-violent	_	
33-33	6921-6934	schizophrenia	_	
33-34	6934-6935	,	_	
33-35	6936-6946	antisocial	_	
33-36	6947-6958	personality	_	
33-37	6959-6967	disorder	_	
33-38	6967-6968	,	_	
33-39	6969-6972	and	_	
33-40	6973-6979	normal	_	
33-41	6980-6988	controls	_	
33-42	6988-6989	)	_	
33-43	6989-6990	,	_	
33-44	6991-6994	and	_	
33-45	6995-7000	types	_	
33-46	7001-7003	of	_	
33-47	7004-7011	serious	_	
33-48	7012-7019	violent	_	
33-49	7020-7027	actions	_	
33-50	7028-7032	have	_	
33-51	7033-7036	not	_	
33-52	7037-7041	been	_	
33-53	7042-7046	well	_	
33-54	7047-7054	studied	_	
33-55	7054-7055	.	_	

#Text=Thus, whether specific structural abnormalities are related to violent traits in individuals with schizophrenia remains unknown.
34-1	7056-7060	Thus	_	
34-2	7060-7061	,	_	
34-3	7062-7069	whether	_	
34-4	7070-7078	specific	_	
34-5	7079-7089	structural	_	
34-6	7090-7103	abnormalities	_	
34-7	7104-7107	are	_	
34-8	7108-7115	related	_	
34-9	7116-7118	to	_	
34-10	7119-7126	violent	_	
34-11	7127-7133	traits	_	
34-12	7134-7136	in	_	
34-13	7137-7148	individuals	_	
34-14	7149-7153	with	_	
34-15	7154-7167	schizophrenia	_	
34-16	7168-7175	remains	_	
34-17	7176-7183	unknown	_	
34-18	7183-7184	.	_	

#Text=A background of violent behaviors in schizophrenia consists of several factors.
35-1	7185-7186	A	_	
35-2	7187-7197	background	_	
35-3	7198-7200	of	_	
35-4	7201-7208	violent	_	
35-5	7209-7218	behaviors	_	
35-6	7219-7221	in	_	
35-7	7222-7235	schizophrenia	_	
35-8	7236-7244	consists	_	
35-9	7245-7247	of	_	
35-10	7248-7255	several	_	
35-11	7256-7263	factors	_	
35-12	7263-7264	.	_	

#Text=For example, murder based on delusion of persecution (i.e., goal-directed behavior) and physical attack during psychomotor excitement (i.e., impulsive behavior) may have different backgrounds, both on a psychological and a biological level.
36-1	7265-7268	For	_	
36-2	7269-7276	example	_	
36-3	7276-7277	,	_	
36-4	7278-7284	murder	_	
36-5	7285-7290	based	_	
36-6	7291-7293	on	_	
36-7	7294-7302	delusion	_	
36-8	7303-7305	of	_	
36-9	7306-7317	persecution	_	
36-10	7318-7319	(	_	
36-11	7319-7322	i.e	_	
36-12	7322-7323	.	_	
36-13	7323-7324	,	_	
36-14	7325-7338	goal-directed	_	
36-15	7339-7347	behavior	_	
36-16	7347-7348	)	_	
36-17	7349-7352	and	_	
36-18	7353-7361	physical	_	
36-19	7362-7368	attack	_	
36-20	7369-7375	during	_	
36-21	7376-7387	psychomotor	_	
36-22	7388-7398	excitement	_	
36-23	7399-7400	(	_	
36-24	7400-7403	i.e	_	
36-25	7403-7404	.	_	
36-26	7404-7405	,	_	
36-27	7406-7415	impulsive	_	
36-28	7416-7424	behavior	_	
36-29	7424-7425	)	_	
36-30	7426-7429	may	_	
36-31	7430-7434	have	_	
36-32	7435-7444	different	_	
36-33	7445-7456	backgrounds	_	
36-34	7456-7457	,	_	
36-35	7458-7462	both	_	
36-36	7463-7465	on	_	
36-37	7466-7467	a	_	
36-38	7468-7481	psychological	_	
36-39	7482-7485	and	_	
36-40	7486-7487	a	_	
36-41	7488-7498	biological	_	
36-42	7499-7504	level	_	
36-43	7504-7505	.	_	

#Text=Thus, the results of studies of violent behaviors in individuals with schizophrenia may depend on the definition of the violent behaviors or the sampling of subjects, particularly subjects from a forensic setting vs. a community setting.
37-1	7506-7510	Thus	_	
37-2	7510-7511	,	_	
37-3	7512-7515	the	_	
37-4	7516-7523	results	_	
37-5	7524-7526	of	_	
37-6	7527-7534	studies	_	
37-7	7535-7537	of	_	
37-8	7538-7545	violent	_	
37-9	7546-7555	behaviors	_	
37-10	7556-7558	in	_	
37-11	7559-7570	individuals	_	
37-12	7571-7575	with	_	
37-13	7576-7589	schizophrenia	_	
37-14	7590-7593	may	_	
37-15	7594-7600	depend	_	
37-16	7601-7603	on	_	
37-17	7604-7607	the	_	
37-18	7608-7618	definition	_	
37-19	7619-7621	of	_	
37-20	7622-7625	the	_	
37-21	7626-7633	violent	_	
37-22	7634-7643	behaviors	_	
37-23	7644-7646	or	_	
37-24	7647-7650	the	_	
37-25	7651-7659	sampling	_	
37-26	7660-7662	of	_	
37-27	7663-7671	subjects	_	
37-28	7671-7672	,	_	
37-29	7673-7685	particularly	_	
37-30	7686-7694	subjects	_	
37-31	7695-7699	from	_	
37-32	7700-7701	a	_	
37-33	7702-7710	forensic	_	
37-34	7711-7718	setting	_	
37-35	7719-7721	vs	_	
37-36	7721-7722	.	_	
37-37	7723-7724	a	_	
37-38	7725-7734	community	_	
37-39	7735-7742	setting	_	
37-40	7742-7743	.	_	

#Text=We examined hospitalized subjects with schizophrenia who had demonstrated serious physically violent behaviors, such as murder, attempted murder, and serious injury in community life, and were being treated under the Medical Treatment and Supervision Act (MTSA; also known as the Act on Medical Care and Treatment for Persons Who Have Caused Serious Cases Under the Condition of Insanity).
38-1	7744-7746	We	_	
38-2	7747-7755	examined	_	
38-3	7756-7768	hospitalized	_	
38-4	7769-7777	subjects	_	
38-5	7778-7782	with	_	
38-6	7783-7796	schizophrenia	_	
38-7	7797-7800	who	_	
38-8	7801-7804	had	_	
38-9	7805-7817	demonstrated	_	
38-10	7818-7825	serious	_	
38-11	7826-7836	physically	_	
38-12	7837-7844	violent	_	
38-13	7845-7854	behaviors	_	
38-14	7854-7855	,	_	
38-15	7856-7860	such	_	
38-16	7861-7863	as	_	
38-17	7864-7870	murder	_	
38-18	7870-7871	,	_	
38-19	7872-7881	attempted	_	
38-20	7882-7888	murder	_	
38-21	7888-7889	,	_	
38-22	7890-7893	and	_	
38-23	7894-7901	serious	_	
38-24	7902-7908	injury	_	
38-25	7909-7911	in	_	
38-26	7912-7921	community	_	
38-27	7922-7926	life	_	
38-28	7926-7927	,	_	
38-29	7928-7931	and	_	
38-30	7932-7936	were	_	
38-31	7937-7942	being	_	
38-32	7943-7950	treated	_	
38-33	7951-7956	under	_	
38-34	7957-7960	the	_	
38-35	7961-7968	Medical	_	
38-36	7969-7978	Treatment	_	
38-37	7979-7982	and	_	
38-38	7983-7994	Supervision	_	
38-39	7995-7998	Act	_	
38-40	7999-8000	(	_	
38-41	8000-8004	MTSA	_	
38-42	8004-8005	;	_	
38-43	8006-8010	also	_	
38-44	8011-8016	known	_	
38-45	8017-8019	as	_	
38-46	8020-8023	the	_	
38-47	8024-8027	Act	_	
38-48	8028-8030	on	_	
38-49	8031-8038	Medical	_	
38-50	8039-8043	Care	_	
38-51	8044-8047	and	_	
38-52	8048-8057	Treatment	_	
38-53	8058-8061	for	_	
38-54	8062-8069	Persons	_	
38-55	8070-8073	Who	_	
38-56	8074-8078	Have	_	
38-57	8079-8085	Caused	_	
38-58	8086-8093	Serious	_	
38-59	8094-8099	Cases	_	
38-60	8100-8105	Under	_	
38-61	8106-8109	the	_	
38-62	8110-8119	Condition	_	
38-63	8120-8122	of	_	
38-64	8123-8131	Insanity	_	
38-65	8131-8132	)	_	
38-66	8132-8133	.	_	

#Text=This is relatively new legislation for offenders with mental disorders in Japan, which aims to promote the rehabilitation of persons who committed serious harm to others (homicide, robbery, bodily injury, arson, or a sex crime) while in a state of insanity or diminished responsibility and who are considered to be responsive to psychiatric treatment.
39-1	8134-8138	This	_	
39-2	8139-8141	is	_	
39-3	8142-8152	relatively	_	
39-4	8153-8156	new	_	
39-5	8157-8168	legislation	_	
39-6	8169-8172	for	_	
39-7	8173-8182	offenders	_	
39-8	8183-8187	with	_	
39-9	8188-8194	mental	_	
39-10	8195-8204	disorders	_	
39-11	8205-8207	in	_	
39-12	8208-8213	Japan	_	
39-13	8213-8214	,	_	
39-14	8215-8220	which	_	
39-15	8221-8225	aims	_	
39-16	8226-8228	to	_	
39-17	8229-8236	promote	_	
39-18	8237-8240	the	_	
39-19	8241-8255	rehabilitation	_	
39-20	8256-8258	of	_	
39-21	8259-8266	persons	_	
39-22	8267-8270	who	_	
39-23	8271-8280	committed	_	
39-24	8281-8288	serious	_	
39-25	8289-8293	harm	_	
39-26	8294-8296	to	_	
39-27	8297-8303	others	_	
39-28	8304-8305	(	_	
39-29	8305-8313	homicide	_	
39-30	8313-8314	,	_	
39-31	8315-8322	robbery	_	
39-32	8322-8323	,	_	
39-33	8324-8330	bodily	_	
39-34	8331-8337	injury	_	
39-35	8337-8338	,	_	
39-36	8339-8344	arson	_	
39-37	8344-8345	,	_	
39-38	8346-8348	or	_	
39-39	8349-8350	a	_	
39-40	8351-8354	sex	_	
39-41	8355-8360	crime	_	
39-42	8360-8361	)	_	
39-43	8362-8367	while	_	
39-44	8368-8370	in	_	
39-45	8371-8372	a	_	
39-46	8373-8378	state	_	
39-47	8379-8381	of	_	
39-48	8382-8390	insanity	_	
39-49	8391-8393	or	_	
39-50	8394-8404	diminished	_	
39-51	8405-8419	responsibility	_	
39-52	8420-8423	and	_	
39-53	8424-8427	who	_	
39-54	8428-8431	are	_	
39-55	8432-8442	considered	_	
39-56	8443-8445	to	_	
39-57	8446-8448	be	_	
39-58	8449-8459	responsive	_	
39-59	8460-8462	to	_	
39-60	8463-8474	psychiatric	_	
39-61	8475-8484	treatment	_	
39-62	8484-8485	.	_	

#Text=This new legislation should apply to subjects whose relevant action has been strongly associated with their mental illness.
40-1	8486-8490	This	_	
40-2	8491-8494	new	_	
40-3	8495-8506	legislation	_	
40-4	8507-8513	should	_	
40-5	8514-8519	apply	_	
40-6	8520-8522	to	_	
40-7	8523-8531	subjects	_	
40-8	8532-8537	whose	_	
40-9	8538-8546	relevant	_	
40-10	8547-8553	action	_	
40-11	8554-8557	has	_	
40-12	8558-8562	been	_	
40-13	8563-8571	strongly	_	
40-14	8572-8582	associated	_	
40-15	8583-8587	with	_	
40-16	8588-8593	their	_	
40-17	8594-8600	mental	_	
40-18	8601-8608	illness	_	
40-19	8608-8609	.	_	

#Text=Therefore, we were able to sample subjects whose relationship between their relevant action and mental illness had been well examined, and investigate the association of types of their violent actions with morphometric characteristics.
41-1	8610-8619	Therefore	_	
41-2	8619-8620	,	_	
41-3	8621-8623	we	_	
41-4	8624-8628	were	_	
41-5	8629-8633	able	_	
41-6	8634-8636	to	_	
41-7	8637-8643	sample	_	
41-8	8644-8652	subjects	_	
41-9	8653-8658	whose	_	
41-10	8659-8671	relationship	_	
41-11	8672-8679	between	_	
41-12	8680-8685	their	_	
41-13	8686-8694	relevant	_	
41-14	8695-8701	action	_	
41-15	8702-8705	and	_	
41-16	8706-8712	mental	_	
41-17	8713-8720	illness	_	
41-18	8721-8724	had	_	
41-19	8725-8729	been	_	
41-20	8730-8734	well	_	
41-21	8735-8743	examined	_	
41-22	8743-8744	,	_	
41-23	8745-8748	and	_	
41-24	8749-8760	investigate	_	
41-25	8761-8764	the	_	
41-26	8765-8776	association	_	
41-27	8777-8779	of	_	
41-28	8780-8785	types	_	
41-29	8786-8788	of	_	
41-30	8789-8794	their	_	
41-31	8795-8802	violent	_	
41-32	8803-8810	actions	_	
41-33	8811-8815	with	_	
41-34	8816-8828	morphometric	_	
41-35	8829-8844	characteristics	_	
41-36	8844-8845	.	_	

#Text=We analyzed high- resolution magnetic resonance imaging (MRI) findings with automated data processing, using voxel-based morphometry to detect regions associated with serious violent behaviors in patients with schizophrenia compared to non-violent patients with schizophrenia.
42-1	8846-8848	We	_	
42-2	8849-8857	analyzed	_	
42-3	8858-8862	high	_	
42-4	8862-8863	-	_	
42-5	8864-8874	resolution	_	
42-6	8875-8883	magnetic	_	
42-7	8884-8893	resonance	_	
42-8	8894-8901	imaging	_	
42-9	8902-8903	(	_	
42-10	8903-8906	MRI	_	
42-11	8906-8907	)	_	
42-12	8908-8916	findings	_	
42-13	8917-8921	with	_	
42-14	8922-8931	automated	_	
42-15	8932-8936	data	_	
42-16	8937-8947	processing	_	
42-17	8947-8948	,	_	
42-18	8949-8954	using	_	
42-19	8955-8966	voxel-based	_	
42-20	8967-8978	morphometry	_	
42-21	8979-8981	to	_	
42-22	8982-8988	detect	_	
42-23	8989-8996	regions	_	
42-24	8997-9007	associated	_	
42-25	9008-9012	with	_	
42-26	9013-9020	serious	_	
42-27	9021-9028	violent	_	
42-28	9029-9038	behaviors	_	
42-29	9039-9041	in	_	
42-30	9042-9050	patients	_	
42-31	9051-9055	with	_	
42-32	9056-9069	schizophrenia	_	
42-33	9070-9078	compared	_	
42-34	9079-9081	to	_	
42-35	9082-9093	non-violent	_	
42-36	9094-9102	patients	_	
42-37	9103-9107	with	_	
42-38	9108-9121	schizophrenia	_	
42-39	9121-9122	.	_	

#Text=We hypothesized that regional volume changes would depend on the types of serious violent actions, and we performed subgroup analysis by dividing patients with a history of serious violence into two groups according to whether their relevant actions were premeditated or not.
43-1	9123-9125	We	_	
43-2	9126-9138	hypothesized	_	
43-3	9139-9143	that	_	
43-4	9144-9152	regional	_	
43-5	9153-9159	volume	_	
43-6	9160-9167	changes	_	
43-7	9168-9173	would	_	
43-8	9174-9180	depend	_	
43-9	9181-9183	on	_	
43-10	9184-9187	the	_	
43-11	9188-9193	types	_	
43-12	9194-9196	of	_	
43-13	9197-9204	serious	_	
43-14	9205-9212	violent	_	
43-15	9213-9220	actions	_	
43-16	9220-9221	,	_	
43-17	9222-9225	and	_	
43-18	9226-9228	we	_	
43-19	9229-9238	performed	_	
43-20	9239-9247	subgroup	_	
43-21	9248-9256	analysis	_	
43-22	9257-9259	by	_	
43-23	9260-9268	dividing	_	
43-24	9269-9277	patients	_	
43-25	9278-9282	with	_	
43-26	9283-9284	a	_	
43-27	9285-9292	history	_	
43-28	9293-9295	of	_	
43-29	9296-9303	serious	_	
43-30	9304-9312	violence	_	
43-31	9313-9317	into	_	
43-32	9318-9321	two	_	
43-33	9322-9328	groups	_	
43-34	9329-9338	according	_	
43-35	9339-9341	to	_	
43-36	9342-9349	whether	_	
43-37	9350-9355	their	_	
43-38	9356-9364	relevant	_	
43-39	9365-9372	actions	_	
43-40	9373-9377	were	_	
43-41	9378-9390	premeditated	_	
43-42	9391-9393	or	_	
43-43	9394-9397	not	_	
43-44	9397-9398	.	_	

#Text=The regional volumes of these two groups were compared to those of the control patient group.
44-1	9399-9402	The	_	
44-2	9403-9411	regional	_	
44-3	9412-9419	volumes	_	
44-4	9420-9422	of	_	
44-5	9423-9428	these	_	
44-6	9429-9432	two	_	
44-7	9433-9439	groups	_	
44-8	9440-9444	were	_	
44-9	9445-9453	compared	_	
44-10	9454-9456	to	_	
44-11	9457-9462	those	_	
44-12	9463-9465	of	_	
44-13	9466-9469	the	_	
44-14	9470-9477	control	_	
44-15	9478-9485	patient	_	
44-16	9486-9491	group	_	
44-17	9491-9492	.	_	

#Text=Methods
#Text=Subjects
#Text=Thirty-four male patients with schizophrenia who had a history of seriously violent behaviors against others (the forensic group) were recruited from inpatients at the forensic unit of the National Center of Neurology and Psychiatry Hospital, Tokyo, Japan under the MTSA.
45-1	9493-9500	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[9]	
45-2	9501-9509	Subjects	http://www.case.edu/ProvCaRe/provcare#StudyMethod[9]	
45-3	9510-9521	Thirty-four	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
45-4	9522-9526	male	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
45-5	9527-9535	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
45-6	9536-9540	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
45-7	9541-9554	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
45-8	9555-9558	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
45-9	9559-9562	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
45-10	9563-9564	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
45-11	9565-9572	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
45-12	9573-9575	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
45-13	9576-9585	seriously	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
45-14	9586-9593	violent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
45-15	9594-9603	behaviors	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
45-16	9604-9611	against	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
45-17	9612-9618	others	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
45-18	9619-9620	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
45-19	9620-9623	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
45-20	9624-9632	forensic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
45-21	9633-9638	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
45-22	9638-9639	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
45-23	9640-9644	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-24	9645-9654	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-25	9655-9659	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-26	9660-9670	inpatients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-27	9671-9673	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-28	9674-9677	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-29	9678-9686	forensic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-30	9687-9691	unit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-31	9692-9694	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-32	9695-9698	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-33	9699-9707	National	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-34	9708-9714	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-35	9715-9717	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-36	9718-9727	Neurology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-37	9728-9731	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-38	9732-9742	Psychiatry	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-39	9743-9751	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-40	9751-9752	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-41	9753-9758	Tokyo	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-42	9758-9759	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-43	9760-9765	Japan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-44	9766-9771	under	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-45	9772-9775	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-46	9776-9780	MTSA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
45-47	9780-9781	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	

#Text=Twenty-three age-matched male control patients with schizophrenia who had no history of violent behaviors (the control patient group) were recruited among inpatients and outpatients (10:13, respectively) at the National Center of Neurology and Psychiatry Hospital.
46-1	9782-9794	Twenty-three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-2	9795-9806	age-matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-3	9807-9811	male	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-4	9812-9819	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]	
46-5	9820-9828	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]	
46-6	9829-9833	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]	
46-7	9834-9847	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]	
46-8	9848-9851	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-9	9852-9855	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-10	9856-9858	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-11	9859-9866	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-12	9867-9869	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-13	9870-9877	violent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-14	9878-9887	behaviors	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-15	9888-9889	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-16	9889-9892	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-17	9893-9900	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-18	9901-9908	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-19	9909-9914	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-20	9914-9915	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-21	9916-9920	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-22	9921-9930	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-23	9931-9936	among	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-24	9937-9947	inpatients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-25	9948-9951	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-26	9952-9963	outpatients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-27	9964-9965	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-28	9965-9967	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-29	9967-9968	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-30	9968-9970	13	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-31	9970-9971	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-32	9972-9984	respectively	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-33	9984-9985	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-34	9986-9988	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-35	9989-9992	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-36	9993-10001	National	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-37	10002-10008	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-38	10009-10011	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-39	10012-10021	Neurology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-40	10022-10025	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-41	10026-10036	Psychiatry	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-42	10037-10045	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-43	10045-10046	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Because there were few female patients with schizophrenia and a history of serious violent acts, female subjects were excluded from this study.
47-1	10047-10054	Because	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-2	10055-10060	there	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-3	10061-10065	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-4	10066-10069	few	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-5	10070-10076	female	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-6	10077-10085	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-7	10086-10090	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-8	10091-10104	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-9	10105-10108	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-10	10109-10110	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-11	10111-10118	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-12	10119-10121	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-13	10122-10129	serious	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-14	10130-10137	violent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-15	10138-10142	acts	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-16	10142-10143	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-17	10144-10150	female	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-18	10151-10159	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-19	10160-10164	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-20	10165-10173	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-21	10174-10178	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-22	10179-10183	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-23	10184-10189	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-24	10189-10190	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Inclusion criteria for both groups were as follows: (1) ages 20 to 60 years; (2) right-handed; (3) a diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision.
48-1	10191-10200	Inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-2	10201-10209	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-3	10210-10213	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-4	10214-10218	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-5	10219-10225	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-6	10226-10230	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-7	10231-10233	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-8	10234-10241	follows	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-9	10241-10242	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-10	10243-10244	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-11	10244-10245	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-12	10245-10246	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-13	10247-10251	ages	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-14	10252-10254	20	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-15	10255-10257	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-16	10258-10260	60	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-17	10260-10261	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-18	10261-10266	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-19	10266-10267	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-20	10268-10269	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-21	10269-10270	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-22	10270-10271	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-23	10272-10284	right-handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-24	10284-10285	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-25	10286-10287	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-26	10287-10288	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-27	10288-10289	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-28	10290-10291	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-29	10292-10301	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-30	10302-10304	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-31	10305-10318	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-32	10319-10328	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-33	10329-10331	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-34	10332-10335	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-35	10336-10346	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-36	10347-10350	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-37	10351-10362	Statistical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-38	10363-10369	Manual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-39	10370-10372	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-40	10373-10379	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-41	10380-10389	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-42	10389-10390	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-43	10391-10397	Fourth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-44	10398-10405	Edition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-45	10405-10406	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-46	10407-10411	Text	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-47	10412-10420	Revision	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-48	10420-10421	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Exclusion criteria for both group were as follows: (4) a diagnosis of mental retardation; (5) a history of seizure; (6) a history of head trauma with loss of consciousness; (7) a history of neurological disorder.
49-1	10422-10431	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-2	10432-10440	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-3	10441-10444	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-4	10445-10449	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-5	10450-10455	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-6	10456-10460	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-7	10461-10463	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-8	10464-10471	follows	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-9	10471-10472	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-10	10473-10474	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-11	10474-10475	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-12	10475-10476	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-13	10477-10478	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-14	10479-10488	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-15	10489-10491	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-16	10492-10498	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-17	10499-10510	retardation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-18	10510-10511	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-19	10512-10513	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-20	10513-10514	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-21	10514-10515	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-22	10516-10517	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-23	10518-10525	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-24	10526-10528	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-25	10529-10536	seizure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-26	10536-10537	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-27	10538-10539	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-28	10539-10540	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-29	10540-10541	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-30	10542-10543	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-31	10544-10551	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-32	10552-10554	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-33	10555-10559	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-34	10560-10566	trauma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-35	10567-10571	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-36	10572-10576	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-37	10577-10579	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-38	10580-10593	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-39	10593-10594	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-40	10595-10596	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-41	10596-10597	7	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-42	10597-10598	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-43	10599-10600	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-44	10601-10608	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-45	10609-10611	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-46	10612-10624	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-47	10625-10633	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
49-48	10633-10634	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Forensic patients met the following criteria: (1) hospitalized under the MTSA; (2) had committed murder, attempted murder, or serious injury to others (relevant action) in a state of insanity or diminished responsibility; (3) were capable of participating in the study as determined through an evaluation by the multidisciplinary treatment team.
50-1	10635-10643	Forensic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-2	10644-10652	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-3	10653-10656	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-4	10657-10660	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-5	10661-10670	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-6	10671-10679	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-7	10679-10680	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-8	10681-10682	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-9	10682-10683	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-10	10683-10684	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-11	10685-10697	hospitalized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-12	10698-10703	under	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-13	10704-10707	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-14	10708-10712	MTSA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-15	10712-10713	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-16	10714-10715	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-17	10715-10716	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-18	10716-10717	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-19	10718-10721	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-20	10722-10731	committed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-21	10732-10738	murder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-22	10738-10739	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-23	10740-10749	attempted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-24	10750-10756	murder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-25	10756-10757	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-26	10758-10760	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-27	10761-10768	serious	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-28	10769-10775	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-29	10776-10778	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-30	10779-10785	others	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-31	10786-10787	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-32	10787-10795	relevant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-33	10796-10802	action	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-34	10802-10803	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-35	10804-10806	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-36	10807-10808	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-37	10809-10814	state	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-38	10815-10817	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-39	10818-10826	insanity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-40	10827-10829	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-41	10830-10840	diminished	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-42	10841-10855	responsibility	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-43	10855-10856	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-44	10857-10858	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-45	10858-10859	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-46	10859-10860	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-47	10861-10865	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-48	10866-10873	capable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-49	10874-10876	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-50	10877-10890	participating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-51	10891-10893	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-52	10894-10897	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-53	10898-10903	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-54	10904-10906	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-55	10907-10917	determined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-56	10918-10925	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-57	10926-10928	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-58	10929-10939	evaluation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-59	10940-10942	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-60	10943-10946	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-61	10947-10964	multidisciplinary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-62	10965-10974	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-63	10975-10979	team	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-64	10979-10980	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Control patients met the following criteria: (1) had never been hospitalized for harming others; (2) had no history of physical violence (score of ≤1 on the Gunn and Robertson Scale for Violence).
51-1	10981-10988	Control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-2	10989-10997	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-3	10998-11001	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-4	11002-11005	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-5	11006-11015	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-6	11016-11024	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-7	11024-11025	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-8	11026-11027	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-9	11027-11028	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-10	11028-11029	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-11	11030-11033	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-12	11034-11039	never	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-13	11040-11044	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-14	11045-11057	hospitalized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-15	11058-11061	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-16	11062-11069	harming	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-17	11070-11076	others	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-18	11076-11077	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-19	11078-11079	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-20	11079-11080	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-21	11080-11081	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-22	11082-11085	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-23	11086-11088	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-24	11089-11096	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-25	11097-11099	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-26	11100-11108	physical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-27	11109-11117	violence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-28	11118-11119	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-29	11119-11124	score	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-30	11125-11127	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-31	11128-11129	≤	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-32	11129-11130	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-33	11131-11133	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-34	11134-11137	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-35	11138-11142	Gunn	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-36	11143-11146	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-37	11147-11156	Robertson	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-38	11157-11162	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-39	11163-11166	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-40	11167-11175	Violence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-41	11175-11176	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-42	11176-11177	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Data on the duration of education, history of substance abuse, age at onset and duration of illness, duration of medication, duration of untreated psychosis, and medication use at the time of MRI scan were available for all subjects.
52-1	11178-11182	Data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-2	11183-11185	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-3	11186-11189	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-4	11190-11198	duration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Education[15]	
52-5	11199-11201	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Education[15]	
52-6	11202-11211	education	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Education[15]	
52-7	11211-11212	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-8	11213-11220	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-9	11221-11223	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-10	11224-11233	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-11	11234-11239	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-12	11239-11240	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-13	11241-11244	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-14	11245-11247	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-15	11248-11253	onset	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-16	11254-11257	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-17	11258-11266	duration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-18	11267-11269	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-19	11270-11277	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-20	11277-11278	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-21	11279-11287	duration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-22	11288-11290	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-23	11291-11301	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-24	11301-11302	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-25	11303-11311	duration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-26	11312-11314	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-27	11315-11324	untreated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-28	11325-11334	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-29	11334-11335	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-30	11336-11339	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-31	11340-11350	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[16]	
52-32	11351-11354	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[16]	
52-33	11355-11357	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-34	11358-11361	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-35	11362-11366	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-36	11367-11369	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-37	11370-11373	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[17]	
52-38	11374-11378	scan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[17]	
52-39	11379-11383	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-40	11384-11393	available	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-41	11394-11397	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-42	11398-11401	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-43	11402-11410	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
52-44	11410-11411	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Ten forensic patients and no control patients had a history of substance abuse.
53-1	11412-11415	Ten	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-2	11416-11424	forensic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-3	11425-11433	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-4	11434-11437	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-5	11438-11440	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-6	11441-11448	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-7	11449-11457	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-8	11458-11461	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-9	11462-11463	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-10	11464-11471	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-11	11472-11474	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-12	11475-11484	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-13	11485-11490	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-14	11490-11491	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=One forensic patient and 5 control patients received no antipsychotic medication, although all other patients from both groups were receiving antipsychotic medication when the MRI scan was acquired.
54-1	11492-11495	One	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-2	11496-11504	forensic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-3	11505-11512	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-4	11513-11516	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-5	11517-11518	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-6	11519-11526	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-7	11527-11535	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-8	11536-11544	received	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-9	11545-11547	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-10	11548-11561	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-11	11562-11572	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-12	11572-11573	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-13	11574-11582	although	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-14	11583-11586	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-15	11587-11592	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-16	11593-11601	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-17	11602-11606	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-18	11607-11611	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-19	11612-11618	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-20	11619-11623	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-21	11624-11633	receiving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-22	11634-11647	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-23	11648-11658	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-24	11659-11663	when	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-25	11664-11667	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-26	11668-11671	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[18]	
54-27	11672-11676	scan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[18]	
54-28	11677-11680	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[18]	
54-29	11681-11689	acquired	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[18]	
54-30	11689-11690	.	_	

#Text=Two forensic patients and no control patients were taking clozapine.
55-1	11691-11694	Two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
55-2	11695-11703	forensic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
55-3	11704-11712	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
55-4	11713-11716	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
55-5	11717-11719	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
55-6	11720-11727	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
55-7	11728-11736	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
55-8	11737-11741	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
55-9	11742-11748	taking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
55-10	11749-11758	clozapine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
55-11	11758-11759	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=There were no antipsychotic medication-naive patients in either group.
56-1	11760-11765	There	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
56-2	11766-11770	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
56-3	11771-11773	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
56-4	11774-11787	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
56-5	11788-11804	medication-naive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
56-6	11805-11813	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
56-7	11814-11816	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
56-8	11817-11823	either	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
56-9	11824-11829	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
56-10	11829-11830	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=All medication dosages were converted to chlorpromazine equivalents.
57-1	11831-11834	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
57-2	11835-11845	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
57-3	11846-11853	dosages	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
57-4	11854-11858	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
57-5	11859-11868	converted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
57-6	11869-11871	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
57-7	11872-11886	chlorpromazine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
57-8	11887-11898	equivalents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
57-9	11898-11899	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=Clinical symptoms of all patients were evaluated using the Positive and Negative Syndrome Scale (PANSS) within 2 months of the date of MRI.
58-1	11900-11908	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-2	11909-11917	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-3	11918-11920	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-4	11921-11924	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-5	11925-11933	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-6	11934-11938	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-7	11939-11948	evaluated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-8	11949-11954	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-9	11955-11958	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-10	11959-11967	Positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
58-11	11968-11971	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
58-12	11972-11980	Negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
58-13	11981-11989	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
58-14	11990-11995	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
58-15	11996-11997	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
58-16	11997-12002	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
58-17	12002-12003	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
58-18	12004-12010	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-19	12011-12012	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-20	12012-12013	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-21	12013-12019	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-22	12020-12022	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-23	12023-12026	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-24	12027-12031	date	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-25	12032-12034	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-26	12035-12038	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[21]	
58-27	12038-12039	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[21]	

#Text=The Wallwork/Fortgang five-factor model for PANSS was used for further analyses.
59-1	12040-12043	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-2	12044-12052	Wallwork	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-3	12052-12053	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-4	12053-12061	Fortgang	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-5	12062-12073	five-factor	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-6	12074-12079	model	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-7	12080-12083	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-8	12084-12089	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[22]	
59-9	12090-12093	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-10	12094-12098	used	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-11	12099-12102	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-12	12103-12110	further	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-13	12111-12119	analyses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-14	12119-12120	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=All forensic patients were hospitalized and had received psychiatric treatment for approximately 2 months prior to hospitalization under the MTSA to determine whether they should be treated under MTSA or not.
60-1	12121-12124	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-2	12125-12133	forensic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-3	12134-12142	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-4	12143-12147	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-5	12148-12160	hospitalized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-6	12161-12164	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-7	12165-12168	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-8	12169-12177	received	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-9	12178-12189	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-10	12190-12199	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-11	12200-12203	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-12	12204-12217	approximately	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-13	12218-12219	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-14	12219-12220	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-15	12220-12226	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-16	12227-12232	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-17	12233-12235	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-18	12236-12251	hospitalization	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-19	12252-12257	under	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-20	12258-12261	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-21	12262-12266	MTSA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-22	12267-12269	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-23	12270-12279	determine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-24	12280-12287	whether	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-25	12288-12292	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-26	12293-12299	should	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-27	12300-12302	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-28	12303-12310	treated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-29	12311-12316	under	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-30	12317-12321	MTSA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-31	12322-12324	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-32	12325-12328	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
60-33	12328-12329	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=The relationship between their relevant actions and mental disorder was evaluated in detail.
61-1	12330-12333	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-2	12334-12346	relationship	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-3	12347-12354	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-4	12355-12360	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-5	12361-12369	relevant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-6	12370-12377	actions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-7	12378-12381	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-8	12382-12388	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-9	12389-12397	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-10	12398-12401	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-11	12402-12411	evaluated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-12	12412-12414	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-13	12415-12421	detail	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-14	12421-12422	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	

#Text=Detailed clinical data were available for forensic patients during their hospitalization.
62-1	12423-12431	Detailed	_	
62-2	12432-12440	clinical	_	
62-3	12441-12445	data	_	
62-4	12446-12450	were	_	
62-5	12451-12460	available	_	
62-6	12461-12464	for	_	
62-7	12465-12473	forensic	_	
62-8	12474-12482	patients	_	
62-9	12483-12489	during	_	
62-10	12490-12495	their	_	
62-11	12496-12511	hospitalization	_	
62-12	12511-12512	.	_	

#Text=The forensic group was divided into two groups for additional analysis, depending on whether they had planned their relevant action of violence for a certain period of time or not.
63-1	12513-12516	The	_	
63-2	12517-12525	forensic	_	
63-3	12526-12531	group	_	
63-4	12532-12535	was	_	
63-5	12536-12543	divided	_	
63-6	12544-12548	into	_	
63-7	12549-12552	two	_	
63-8	12553-12559	groups	_	
63-9	12560-12563	for	_	
63-10	12564-12574	additional	_	
63-11	12575-12583	analysis	_	
63-12	12583-12584	,	_	
63-13	12585-12594	depending	_	
63-14	12595-12597	on	_	
63-15	12598-12605	whether	_	
63-16	12606-12610	they	_	
63-17	12611-12614	had	_	
63-18	12615-12622	planned	_	
63-19	12623-12628	their	_	
63-20	12629-12637	relevant	_	
63-21	12638-12644	action	_	
63-22	12645-12647	of	_	
63-23	12648-12656	violence	_	
63-24	12657-12660	for	_	
63-25	12661-12662	a	_	
63-26	12663-12670	certain	_	
63-27	12671-12677	period	_	
63-28	12678-12680	of	_	
63-29	12681-12685	time	_	
63-30	12686-12688	or	_	
63-31	12689-12692	not	_	
63-32	12692-12693	.	_	

#Text=Those who had premeditated their assaults prior to meeting with their victims on the day of their relevant actions or at least 1 hour before their actions were included in “the premeditated action group”; otherwise, the patients were included in "the impulsive group."
64-1	12694-12699	Those	_	
64-2	12700-12703	who	_	
64-3	12704-12707	had	_	
64-4	12708-12720	premeditated	_	
64-5	12721-12726	their	_	
64-6	12727-12735	assaults	_	
64-7	12736-12741	prior	_	
64-8	12742-12744	to	_	
64-9	12745-12752	meeting	_	
64-10	12753-12757	with	_	
64-11	12758-12763	their	_	
64-12	12764-12771	victims	_	
64-13	12772-12774	on	_	
64-14	12775-12778	the	_	
64-15	12779-12782	day	_	
64-16	12783-12785	of	_	
64-17	12786-12791	their	_	
64-18	12792-12800	relevant	_	
64-19	12801-12808	actions	_	
64-20	12809-12811	or	_	
64-21	12812-12814	at	_	
64-22	12815-12820	least	_	
64-23	12821-12822	1	_	
64-24	12823-12827	hour	_	
64-25	12828-12834	before	_	
64-26	12835-12840	their	_	
64-27	12841-12848	actions	_	
64-28	12849-12853	were	_	
64-29	12854-12862	included	_	
64-30	12863-12865	in	_	
64-31	12866-12867	“	_	
64-32	12867-12870	the	_	
64-33	12871-12883	premeditated	_	
64-34	12884-12890	action	_	
64-35	12891-12896	group	_	
64-36	12896-12897	”	_	
64-37	12897-12898	;	_	
64-38	12899-12908	otherwise	_	
64-39	12908-12909	,	_	
64-40	12910-12913	the	_	
64-41	12914-12922	patients	_	
64-42	12923-12927	were	_	
64-43	12928-12936	included	_	
64-44	12937-12939	in	_	
64-45	12940-12941	"	_	
64-46	12941-12944	the	_	
64-47	12945-12954	impulsive	_	
64-48	12955-12960	group	_	
64-49	12960-12961	.	_	
64-50	12961-12962	"	_	

#Text=The premeditated action group consisted of 15 subjects, including 4 patients with a history of substance abuse.
65-1	12963-12966	The	_	
65-2	12967-12979	premeditated	_	
65-3	12980-12986	action	_	
65-4	12987-12992	group	_	
65-5	12993-13002	consisted	_	
65-6	13003-13005	of	_	
65-7	13006-13008	15	_	
65-8	13009-13017	subjects	_	
65-9	13017-13018	,	_	
65-10	13019-13028	including	_	
65-11	13029-13030	4	_	
65-12	13031-13039	patients	_	
65-13	13040-13044	with	_	
65-14	13045-13046	a	_	
65-15	13047-13054	history	_	
65-16	13055-13057	of	_	
65-17	13058-13067	substance	_	
65-18	13068-13073	abuse	_	
65-19	13073-13074	.	_	

#Text=The impulsive group consisted of 19 subjects, including 6 patients with a history of substance abuse.
66-1	13075-13078	The	_	
66-2	13079-13088	impulsive	_	
66-3	13089-13094	group	_	
66-4	13095-13104	consisted	_	
66-5	13105-13107	of	_	
66-6	13108-13110	19	_	
66-7	13111-13119	subjects	_	
66-8	13119-13120	,	_	
66-9	13121-13130	including	_	
66-10	13131-13132	6	_	
66-11	13133-13141	patients	_	
66-12	13142-13146	with	_	
66-13	13147-13148	a	_	
66-14	13149-13156	history	_	
66-15	13157-13159	of	_	
66-16	13160-13169	substance	_	
66-17	13170-13175	abuse	_	
66-18	13175-13176	.	_	

#Text=Demographic data and clinical Information
#Text=
#Text=\t\t \tForensic group\t \t\t\t\t \tStatistical analysis\t \t\t \t\t\t \tTotal (\t \tn = 34)\t \t\t\t \tPremeditated action group (\t \tn = 15)\t \t\t\t \tImpulsive group (\t \tn = 19)\t \t\t\t \tControl patient group (\t \tn = 23)\t \t\t\t \tForensic (\t \tn = 34) vs.
67-1	13178-13189	Demographic	_	
67-2	13190-13194	data	_	
67-3	13195-13198	and	_	
67-4	13199-13207	clinical	_	
67-5	13208-13219	Information	_	
67-6	13225-13233	Forensic	_	
67-7	13234-13239	group	_	
67-8	13247-13258	Statistical	_	
67-9	13259-13267	analysis	_	
67-10	13277-13282	Total	_	
67-11	13283-13284	(	_	
67-12	13287-13288	n	_	
67-13	13288-13289	 	_	
67-14	13289-13290	=	_	
67-15	13290-13291	 	_	
67-16	13291-13293	34	_	
67-17	13293-13294	)	_	
67-18	13301-13313	Premeditated	_	
67-19	13314-13320	action	_	
67-20	13321-13326	group	_	
67-21	13327-13328	(	_	
67-22	13331-13332	n	_	
67-23	13332-13333	 	_	
67-24	13333-13334	=	_	
67-25	13334-13335	 	_	
67-26	13335-13337	15	_	
67-27	13337-13338	)	_	
67-28	13345-13354	Impulsive	_	
67-29	13355-13360	group	_	
67-30	13361-13362	(	_	
67-31	13365-13366	n	_	
67-32	13366-13367	 	_	
67-33	13367-13368	=	_	
67-34	13368-13369	 	_	
67-35	13369-13371	19	_	
67-36	13371-13372	)	_	
67-37	13379-13386	Control	_	
67-38	13387-13394	patient	_	
67-39	13395-13400	group	_	
67-40	13401-13402	(	_	
67-41	13405-13406	n	_	
67-42	13406-13407	 	_	
67-43	13407-13408	=	_	
67-44	13408-13409	 	_	
67-45	13409-13411	23	_	
67-46	13411-13412	)	_	
67-47	13419-13427	Forensic	_	
67-48	13428-13429	(	_	
67-49	13432-13433	n	_	
67-50	13433-13434	 	_	
67-51	13434-13435	=	_	
67-52	13435-13436	 	_	
67-53	13436-13438	34	_	
67-54	13438-13439	)	_	
67-55	13440-13442	vs	_	
67-56	13442-13443	.	_	

#Text=Control (\t \tn = 23)\t \ta\t\t \tPremeditated (\t \tn = 15) vs.
68-1	13444-13451	Control	_	
68-2	13452-13453	(	_	
68-3	13456-13457	n	_	
68-4	13457-13458	 	_	
68-5	13458-13459	=	_	
68-6	13459-13460	 	_	
68-7	13460-13462	23	_	
68-8	13462-13463	)	_	
68-9	13466-13467	a	_	
68-10	13471-13483	Premeditated	_	
68-11	13484-13485	(	_	
68-12	13488-13489	n	_	
68-13	13489-13490	 	_	
68-14	13490-13491	=	_	
68-15	13491-13492	 	_	
68-16	13492-13494	15	_	
68-17	13494-13495	)	_	
68-18	13496-13498	vs	_	
68-19	13498-13499	.	_	

#Text=Control\t \tb\t\t \tImpulsive (\t \tn = 19) vs.
69-1	13500-13507	Control	_	
69-2	13510-13511	b	_	
69-3	13515-13524	Impulsive	_	
69-4	13525-13526	(	_	
69-5	13529-13530	n	_	
69-6	13530-13531	 	_	
69-7	13531-13532	=	_	
69-8	13532-13533	 	_	
69-9	13533-13535	19	_	
69-10	13535-13536	)	_	
69-11	13537-13539	vs	_	
69-12	13539-13540	.	_	

#Text=Control\t \tc\t \t\t\t \tMean ± SD\t \t\t\t \tMean ± SD\t \t\t\t \tMean ± SD\t \t\t\t \tMean ± SD\t \t\t\t \tt or U\t \t\t\t \tdf\t \t\t\t \tp\t \t\t\t \tt or U\t \t\t\t \tdf\t \t\t\t \tp\t \t\t\t \tt or U\t \t\t\t \tdf\t \t\t\t \tp\t \t\t \t\t \tAge, years (range)\t \t\t\t \t40.6 ± 9.5 (22–58)\t \t\t\t \t44.1 ± 9.2\t \t\t\t \t37.9 ± 9.1\t \t\t\t \t36.8 ± 11.0 (20–53)\t \t\t\t \t1.385\t \t\t\t \t55\t \t\t\t \t0.172\t \t\t\t \t2.112\t \t\t\t \t36\t \t\t\t \t0.042\t \t\t\t \t0.338\t \t\t\t \t40\t \t\t\t \t0.737\t \t\t \t\t \tDuration of education, years\t \t\t\t \t12.4 ± 2.7\t \t\t\t \t11.9 ± 2.2\t \t\t\t \t12.9 ± 3.1\t \t\t\t \t14.4 ± 2.0\t \t\t\t \t2.965\t \t\t\t \t55\t \t\t\t \t0.004\t \t\t\t \t3.673\t \t\t\t \t36\t \t\t\t \t0.001\t \t\t\t \t1.939\t \t\t\t \t40\t \t\t\t \t0.060\t \t\t \t\t \tSubstance abuse, Alcohol/Others/Both\t \t\t\t \t2/6/2\t \t\t\t \t1/3/0\t \t\t\t \t1/3/2\t \t\t\t \t0/0/0\t \t\t\t\t\t\t\t\t\t\t\t \t\t \tAge of onset\t \t\t\t \t25.4 ± 7.2\t \t\t\t \t26.3 ± 8.5\t \t\t\t \t24.7 ± 6.1\t \t\t\t \t22.0 ± 6.7\t \t\t\t \t1.834\t \t\t\t \t55\t \t\t\t \t0.072\t \t\t\t \t1.743\t \t\t\t \t36\t \t\t\t \t0.090\t \t\t\t \t1.398\t \t\t\t \t40\t \t\t\t \t0.170\t \t\t \t\t \tDuration of illness, years\t \t\t\t \t15.6 ± 10.0\t \t\t\t \t18.0 ± 10.6\t \t\t\t \t13.8 ± 9.3\t \t\t\t \t15.0 ± 10.4\t \t\t\t \t0.227\t \t\t\t \t55\t \t\t\t \t0.822\t \t\t\t \t0.854\t \t\t\t \t36\t \t\t\t \t0.399\t \t\t\t \t0.403\t \t\t\t \t40\t \t\t\t \t0.689\t \t\t \t\t \tDuration of untreated psychosis, months\t \t\t\t \t26.2 ± 41.8\t \t\t\t \t36.2 ± 55.3\t \t\t\t \t18.3 ± 26.2\t \t\t\t \t18.8 ± 36.3\t \t\t\t \t465\t \t\t\t\t \t0.219\t \t\t\t \t216\t \t\t\t\t \t0.202\t \t\t\t \t249\t \t\t\t\t \t0.429\t \t\t \t\t \tDuration of medication\t \ta\t \t, years\t \t\t\t \t13.2 ± 10.2\t \t\t\t \t14.4 ± 10.5\t \t\t\t \t12.2 ± 10.1\t \t\t\t \t13.6 ± 10.1\t \t\t\t \t0.164\t \t\t\t \t55\t \t\t\t \t0.870\t \t\t\t \t0.233\t \t\t\t \t36\t \t\t\t \t0.817\t \t\t\t \t0.457\t \t\t\t \t40\t \t\t\t \t0.650\t \t\t \t\t \tMedication dose, mg\t \td\t\t \t706.9 ± 606.4\t \t\t\t \t682.3 ± 543.7\t \t\t\t \t726.3 ± 665.7\t \t\t\t \t477.3 ± 434.8\t \t\t\t \t476.5\t \t\t\t\t \t0.164\t \t\t\t \t212.5\t \t\t\t\t \t0.235\t \t\t\t \t264\t \t\t\t\t \t0.249\t \t\t \t\t \tMedication type, Typical/Atypical/Both/Non\t \t\t\t \t2/18/13/1\t \t\t\t \t1/5/8/1\t \t\t\t \t1/13/5/1\t \t\t\t \t2/12/4/5\t \t\t\t \t7.000\t \t\t\t \t3\t \t\t\t \t0.072\t \tf\t\t \t5.883\t \t\t\t \t3\t \t\t\t \t0.117\t \tf\t\t \t7.041\t \t\t\t \t3\t \t\t\t \t0.071\t \tf\t \t\t \tPANSS\t \te\t\t\t\t\t\t\t\t\t\t\t\t\t\t \t\t \tPositive\t \t\t\t \t12.2 ± 4.8\t \t\t\t \t14.3 ± 5.3\t \t\t\t \t10.5 ± 3.8\t \t\t\t \t9.4 ± 3.6\t \t\t\t \t2.356\t \t\t\t \t55\t \t\t\t \t0.022\t \t\t\t \t3.445\t \t\t\t \t36\t \t\t\t \t0.001\t \t\t\t \t0.952\t \t\t\t \t40\t \t\t\t \t0.347\t \t\t \t\t \tNegative\t \t\t\t \t17.1 ± 7.0\t \t\t\t \t19.7 ± 6.7\t \t\t\t \t15.0 ± 6.8\t \t\t\t \t14.7 ± 6.2\t \t\t\t \t1.292\t \t\t\t \t55\t \t\t\t \t0.202\t \t\t\t \t2.344\t \t\t\t \t36\t \t\t\t \t0.025\t \t\t\t \t0.130\t \t\t\t \t40\t \t\t\t \t0.897\t \t\t \t\t \tDisorganization\t \t\t\t \t8.4 ± 3.2\t \t\t\t \t9.2 ± 3.4\t \t\t\t \t7.7 ± 2.9\t \t\t\t \t6.8 ± 3.7\t \t\t\t \t1.737\t \t\t\t \t55\t \t\t\t \t0.088\t \t\t\t \t2.020\t \t\t\t \t36\t \t\t\t \t0.051\t \t\t\t \t0.910\t \t\t\t \t40\t \t\t\t \t0.368\t \t\t \t\t \tDepressive\t \t\t\t \t6.7 ± 2.6\t \t\t\t \t7.4 ± 2.9\t \t\t\t \t6.1 ± 2.3\t \t\t\t \t7.0 ± 3.2\t \t\t\t \t0.420\t \t\t\t \t55\t \t\t\t \t0.676\t \t\t\t \t0.395\t \t\t\t \t36\t \t\t\t \t0.695\t \t\t\t \t1.024\t \t\t\t \t40\t \t\t\t \t0.312\t \t\t \t\t \tExcitement\t \t\t\t \t8.3 ± 3.5\t \t\t\t \t8.4 ± 3.4\t \t\t\t \t8.2 ± 3.8\t \t\t\t \t6.7 ± 3.0\t \t\t\t \t1.775\t \t\t\t \t55\t \t\t\t \t0.081\t \t\t\t \t1.627\t \t\t\t \t36\t \t\t\t \t0.112\t \t\t\t \t1.450\t \t\t\t \t40\t \t\t\t \t0.155\t \t\t \t\t \tIntracranial volume, ml\t \t\t\t \t1619.8 ± 154.2\t \t\t\t \t1589.4 ± 173.6\t \t\t\t \t1643.7 ± 137.1\t \t\t\t \t1618.0 ± 136.8\t \t\t\t \t0.045\t \t\t\t \t55\t \t\t\t \t0.964\t \t\t\t \t0.565\t \t\t\t \t36\t \t\t\t \t0.576\t \t\t\t \t0.606\t \t\t\t \t40\t \t\t\t \t0.548\t \t\t \t
#Text=
#Text=a
#Text=Forensic group vs. control patient group
#Text=
#Text=
#Text=b
#Text=Premeditated action group vs control patient group
#Text=
#Text=
#Text=c
#Text=Impulsive group vs control patient group
#Text=
#Text=
#Text=d
#Text=Chlorpromazine equivalent
#Text=
#Text=
#Text=e
#Text=The Wallwork/Fortgang five-factor model for PANSS
#Text=
#Text=
#Text=f
#Text=Likelihood ratio test
#Text=
#Text=Demographic data and clinical information are shown in Table 1.
70-1	13541-13548	Control	_	
70-2	13551-13552	c	_	
70-3	13559-13563	Mean	_	
70-4	13563-13564	 	_	
70-5	13564-13565	±	_	
70-6	13565-13566	 	_	
70-7	13566-13568	SD	_	
70-8	13575-13579	Mean	_	
70-9	13579-13580	 	_	
70-10	13580-13581	±	_	
70-11	13581-13582	 	_	
70-12	13582-13584	SD	_	
70-13	13591-13595	Mean	_	
70-14	13595-13596	 	_	
70-15	13596-13597	±	_	
70-16	13597-13598	 	_	
70-17	13598-13600	SD	_	
70-18	13607-13611	Mean	_	
70-19	13611-13612	 	_	
70-20	13612-13613	±	_	
70-21	13613-13614	 	_	
70-22	13614-13616	SD	_	
70-23	13623-13624	t	_	
70-24	13625-13627	or	_	
70-25	13628-13629	U	_	
70-26	13636-13638	df	_	
70-27	13645-13646	p	_	
70-28	13653-13654	t	_	
70-29	13655-13657	or	_	
70-30	13658-13659	U	_	
70-31	13666-13668	df	_	
70-32	13675-13676	p	_	
70-33	13683-13684	t	_	
70-34	13685-13687	or	_	
70-35	13688-13689	U	_	
70-36	13696-13698	df	_	
70-37	13705-13706	p	_	
70-38	13715-13718	Age	_	
70-39	13718-13719	,	_	
70-40	13720-13725	years	_	
70-41	13726-13727	(	_	
70-42	13727-13732	range	_	
70-43	13732-13733	)	_	
70-44	13740-13744	40.6	_	
70-45	13744-13745	 	_	
70-46	13745-13746	±	_	
70-47	13746-13747	 	_	
70-48	13747-13750	9.5	_	
70-49	13751-13752	(	_	
70-50	13752-13754	22	_	
70-51	13754-13755	–	_	
70-52	13755-13757	58	_	
70-53	13757-13758	)	_	
70-54	13765-13769	44.1	_	
70-55	13769-13770	 	_	
70-56	13770-13771	±	_	
70-57	13771-13772	 	_	
70-58	13772-13775	9.2	_	
70-59	13782-13786	37.9	_	
70-60	13786-13787	 	_	
70-61	13787-13788	±	_	
70-62	13788-13789	 	_	
70-63	13789-13792	9.1	_	
70-64	13799-13803	36.8	_	
70-65	13803-13804	 	_	
70-66	13804-13805	±	_	
70-67	13805-13806	 	_	
70-68	13806-13810	11.0	_	
70-69	13811-13812	(	_	
70-70	13812-13814	20	_	
70-71	13814-13815	–	_	
70-72	13815-13817	53	_	
70-73	13817-13818	)	_	
70-74	13825-13830	1.385	_	
70-75	13837-13839	55	_	
70-76	13846-13851	0.172	_	
70-77	13858-13863	2.112	_	
70-78	13870-13872	36	_	
70-79	13879-13884	0.042	_	
70-80	13891-13896	0.338	_	
70-81	13903-13905	40	_	
70-82	13912-13917	0.737	_	
70-83	13926-13934	Duration	_	
70-84	13935-13937	of	_	
70-85	13938-13947	education	_	
70-86	13947-13948	,	_	
70-87	13949-13954	years	_	
70-88	13961-13965	12.4	_	
70-89	13965-13966	 	_	
70-90	13966-13967	±	_	
70-91	13967-13968	 	_	
70-92	13968-13971	2.7	_	
70-93	13978-13982	11.9	_	
70-94	13982-13983	 	_	
70-95	13983-13984	±	_	
70-96	13984-13985	 	_	
70-97	13985-13988	2.2	_	
70-98	13995-13999	12.9	_	
70-99	13999-14000	 	_	
70-100	14000-14001	±	_	
70-101	14001-14002	 	_	
70-102	14002-14005	3.1	_	
70-103	14012-14016	14.4	_	
70-104	14016-14017	 	_	
70-105	14017-14018	±	_	
70-106	14018-14019	 	_	
70-107	14019-14022	2.0	_	
70-108	14029-14034	2.965	_	
70-109	14041-14043	55	_	
70-110	14050-14055	0.004	_	
70-111	14062-14067	3.673	_	
70-112	14074-14076	36	_	
70-113	14083-14088	0.001	_	
70-114	14095-14100	1.939	_	
70-115	14107-14109	40	_	
70-116	14116-14121	0.060	_	
70-117	14130-14139	Substance	_	
70-118	14140-14145	abuse	_	
70-119	14145-14146	,	_	
70-120	14147-14154	Alcohol	_	
70-121	14154-14155	/	_	
70-122	14155-14161	Others	_	
70-123	14161-14162	/	_	
70-124	14162-14166	Both	_	
70-125	14173-14174	2	_	
70-126	14174-14175	/	_	
70-127	14175-14176	6	_	
70-128	14176-14177	/	_	
70-129	14177-14178	2	_	
70-130	14185-14186	1	_	
70-131	14186-14187	/	_	
70-132	14187-14188	3	_	
70-133	14188-14189	/	_	
70-134	14189-14190	0	_	
70-135	14197-14198	1	_	
70-136	14198-14199	/	_	
70-137	14199-14200	3	_	
70-138	14200-14201	/	_	
70-139	14201-14202	2	_	
70-140	14209-14210	0	_	
70-141	14210-14211	/	_	
70-142	14211-14212	0	_	
70-143	14212-14213	/	_	
70-144	14213-14214	0	_	
70-145	14232-14235	Age	_	
70-146	14236-14238	of	_	
70-147	14239-14244	onset	_	
70-148	14251-14255	25.4	_	
70-149	14255-14256	 	_	
70-150	14256-14257	±	_	
70-151	14257-14258	 	_	
70-152	14258-14261	7.2	_	
70-153	14268-14272	26.3	_	
70-154	14272-14273	 	_	
70-155	14273-14274	±	_	
70-156	14274-14275	 	_	
70-157	14275-14278	8.5	_	
70-158	14285-14289	24.7	_	
70-159	14289-14290	 	_	
70-160	14290-14291	±	_	
70-161	14291-14292	 	_	
70-162	14292-14295	6.1	_	
70-163	14302-14306	22.0	_	
70-164	14306-14307	 	_	
70-165	14307-14308	±	_	
70-166	14308-14309	 	_	
70-167	14309-14312	6.7	_	
70-168	14319-14324	1.834	_	
70-169	14331-14333	55	_	
70-170	14340-14345	0.072	_	
70-171	14352-14357	1.743	_	
70-172	14364-14366	36	_	
70-173	14373-14378	0.090	_	
70-174	14385-14390	1.398	_	
70-175	14397-14399	40	_	
70-176	14406-14411	0.170	_	
70-177	14420-14428	Duration	_	
70-178	14429-14431	of	_	
70-179	14432-14439	illness	_	
70-180	14439-14440	,	_	
70-181	14441-14446	years	_	
70-182	14453-14457	15.6	_	
70-183	14457-14458	 	_	
70-184	14458-14459	±	_	
70-185	14459-14460	 	_	
70-186	14460-14464	10.0	_	
70-187	14471-14475	18.0	_	
70-188	14475-14476	 	_	
70-189	14476-14477	±	_	
70-190	14477-14478	 	_	
70-191	14478-14482	10.6	_	
70-192	14489-14493	13.8	_	
70-193	14493-14494	 	_	
70-194	14494-14495	±	_	
70-195	14495-14496	 	_	
70-196	14496-14499	9.3	_	
70-197	14506-14510	15.0	_	
70-198	14510-14511	 	_	
70-199	14511-14512	±	_	
70-200	14512-14513	 	_	
70-201	14513-14517	10.4	_	
70-202	14524-14529	0.227	_	
70-203	14536-14538	55	_	
70-204	14545-14550	0.822	_	
70-205	14557-14562	0.854	_	
70-206	14569-14571	36	_	
70-207	14578-14583	0.399	_	
70-208	14590-14595	0.403	_	
70-209	14602-14604	40	_	
70-210	14611-14616	0.689	_	
70-211	14625-14633	Duration	_	
70-212	14634-14636	of	_	
70-213	14637-14646	untreated	_	
70-214	14647-14656	psychosis	_	
70-215	14656-14657	,	_	
70-216	14658-14664	months	_	
70-217	14671-14675	26.2	_	
70-218	14675-14676	 	_	
70-219	14676-14677	±	_	
70-220	14677-14678	 	_	
70-221	14678-14682	41.8	_	
70-222	14689-14693	36.2	_	
70-223	14693-14694	 	_	
70-224	14694-14695	±	_	
70-225	14695-14696	 	_	
70-226	14696-14700	55.3	_	
70-227	14707-14711	18.3	_	
70-228	14711-14712	 	_	
70-229	14712-14713	±	_	
70-230	14713-14714	 	_	
70-231	14714-14718	26.2	_	
70-232	14725-14729	18.8	_	
70-233	14729-14730	 	_	
70-234	14730-14731	±	_	
70-235	14731-14732	 	_	
70-236	14732-14736	36.3	_	
70-237	14743-14746	465	_	
70-238	14754-14759	0.219	_	
70-239	14766-14769	216	_	
70-240	14777-14782	0.202	_	
70-241	14789-14792	249	_	
70-242	14800-14805	0.429	_	
70-243	14814-14822	Duration	_	
70-244	14823-14825	of	_	
70-245	14826-14836	medication	_	
70-246	14839-14840	a	_	
70-247	14843-14844	,	_	
70-248	14845-14850	years	_	
70-249	14857-14861	13.2	_	
70-250	14861-14862	 	_	
70-251	14862-14863	±	_	
70-252	14863-14864	 	_	
70-253	14864-14868	10.2	_	
70-254	14875-14879	14.4	_	
70-255	14879-14880	 	_	
70-256	14880-14881	±	_	
70-257	14881-14882	 	_	
70-258	14882-14886	10.5	_	
70-259	14893-14897	12.2	_	
70-260	14897-14898	 	_	
70-261	14898-14899	±	_	
70-262	14899-14900	 	_	
70-263	14900-14904	10.1	_	
70-264	14911-14915	13.6	_	
70-265	14915-14916	 	_	
70-266	14916-14917	±	_	
70-267	14917-14918	 	_	
70-268	14918-14922	10.1	_	
70-269	14929-14934	0.164	_	
70-270	14941-14943	55	_	
70-271	14950-14955	0.870	_	
70-272	14962-14967	0.233	_	
70-273	14974-14976	36	_	
70-274	14983-14988	0.817	_	
70-275	14995-15000	0.457	_	
70-276	15007-15009	40	_	
70-277	15016-15021	0.650	_	
70-278	15030-15040	Medication	_	
70-279	15041-15045	dose	_	
70-280	15045-15046	,	_	
70-281	15047-15049	mg	_	
70-282	15052-15053	d	_	
70-283	15057-15062	706.9	_	
70-284	15062-15063	 	_	
70-285	15063-15064	±	_	
70-286	15064-15065	 	_	
70-287	15065-15070	606.4	_	
70-288	15077-15082	682.3	_	
70-289	15082-15083	 	_	
70-290	15083-15084	±	_	
70-291	15084-15085	 	_	
70-292	15085-15090	543.7	_	
70-293	15097-15102	726.3	_	
70-294	15102-15103	 	_	
70-295	15103-15104	±	_	
70-296	15104-15105	 	_	
70-297	15105-15110	665.7	_	
70-298	15117-15122	477.3	_	
70-299	15122-15123	 	_	
70-300	15123-15124	±	_	
70-301	15124-15125	 	_	
70-302	15125-15130	434.8	_	
70-303	15137-15142	476.5	_	
70-304	15150-15155	0.164	_	
70-305	15162-15167	212.5	_	
70-306	15175-15180	0.235	_	
70-307	15187-15190	264	_	
70-308	15198-15203	0.249	_	
70-309	15212-15222	Medication	_	
70-310	15223-15227	type	_	
70-311	15227-15228	,	_	
70-312	15229-15236	Typical	_	
70-313	15236-15237	/	_	
70-314	15237-15245	Atypical	_	
70-315	15245-15246	/	_	
70-316	15246-15250	Both	_	
70-317	15250-15251	/	_	
70-318	15251-15254	Non	_	
70-319	15261-15262	2	_	
70-320	15262-15263	/	_	
70-321	15263-15265	18	_	
70-322	15265-15266	/	_	
70-323	15266-15268	13	_	
70-324	15268-15269	/	_	
70-325	15269-15270	1	_	
70-326	15277-15278	1	_	
70-327	15278-15279	/	_	
70-328	15279-15280	5	_	
70-329	15280-15281	/	_	
70-330	15281-15282	8	_	
70-331	15282-15283	/	_	
70-332	15283-15284	1	_	
70-333	15291-15292	1	_	
70-334	15292-15293	/	_	
70-335	15293-15295	13	_	
70-336	15295-15296	/	_	
70-337	15296-15297	5	_	
70-338	15297-15298	/	_	
70-339	15298-15299	1	_	
70-340	15306-15307	2	_	
70-341	15307-15308	/	_	
70-342	15308-15310	12	_	
70-343	15310-15311	/	_	
70-344	15311-15312	4	_	
70-345	15312-15313	/	_	
70-346	15313-15314	5	_	
70-347	15321-15326	7.000	_	
70-348	15333-15334	3	_	
70-349	15341-15346	0.072	_	
70-350	15349-15350	f	_	
70-351	15354-15359	5.883	_	
70-352	15366-15367	3	_	
70-353	15374-15379	0.117	_	
70-354	15382-15383	f	_	
70-355	15387-15392	7.041	_	
70-356	15399-15400	3	_	
70-357	15407-15412	0.071	_	
70-358	15415-15416	f	_	
70-359	15422-15427	PANSS	_	
70-360	15430-15431	e	_	
70-361	15450-15458	Positive	_	
70-362	15465-15469	12.2	_	
70-363	15469-15470	 	_	
70-364	15470-15471	±	_	
70-365	15471-15472	 	_	
70-366	15472-15475	4.8	_	
70-367	15482-15486	14.3	_	
70-368	15486-15487	 	_	
70-369	15487-15488	±	_	
70-370	15488-15489	 	_	
70-371	15489-15492	5.3	_	
70-372	15499-15503	10.5	_	
70-373	15503-15504	 	_	
70-374	15504-15505	±	_	
70-375	15505-15506	 	_	
70-376	15506-15509	3.8	_	
70-377	15516-15519	9.4	_	
70-378	15519-15520	 	_	
70-379	15520-15521	±	_	
70-380	15521-15522	 	_	
70-381	15522-15525	3.6	_	
70-382	15532-15537	2.356	_	
70-383	15544-15546	55	_	
70-384	15553-15558	0.022	_	
70-385	15565-15570	3.445	_	
70-386	15577-15579	36	_	
70-387	15586-15591	0.001	_	
70-388	15598-15603	0.952	_	
70-389	15610-15612	40	_	
70-390	15619-15624	0.347	_	
70-391	15633-15641	Negative	_	
70-392	15648-15652	17.1	_	
70-393	15652-15653	 	_	
70-394	15653-15654	±	_	
70-395	15654-15655	 	_	
70-396	15655-15658	7.0	_	
70-397	15665-15669	19.7	_	
70-398	15669-15670	 	_	
70-399	15670-15671	±	_	
70-400	15671-15672	 	_	
70-401	15672-15675	6.7	_	
70-402	15682-15686	15.0	_	
70-403	15686-15687	 	_	
70-404	15687-15688	±	_	
70-405	15688-15689	 	_	
70-406	15689-15692	6.8	_	
70-407	15699-15703	14.7	_	
70-408	15703-15704	 	_	
70-409	15704-15705	±	_	
70-410	15705-15706	 	_	
70-411	15706-15709	6.2	_	
70-412	15716-15721	1.292	_	
70-413	15728-15730	55	_	
70-414	15737-15742	0.202	_	
70-415	15749-15754	2.344	_	
70-416	15761-15763	36	_	
70-417	15770-15775	0.025	_	
70-418	15782-15787	0.130	_	
70-419	15794-15796	40	_	
70-420	15803-15808	0.897	_	
70-421	15817-15832	Disorganization	_	
70-422	15839-15842	8.4	_	
70-423	15842-15843	 	_	
70-424	15843-15844	±	_	
70-425	15844-15845	 	_	
70-426	15845-15848	3.2	_	
70-427	15855-15858	9.2	_	
70-428	15858-15859	 	_	
70-429	15859-15860	±	_	
70-430	15860-15861	 	_	
70-431	15861-15864	3.4	_	
70-432	15871-15874	7.7	_	
70-433	15874-15875	 	_	
70-434	15875-15876	±	_	
70-435	15876-15877	 	_	
70-436	15877-15880	2.9	_	
70-437	15887-15890	6.8	_	
70-438	15890-15891	 	_	
70-439	15891-15892	±	_	
70-440	15892-15893	 	_	
70-441	15893-15896	3.7	_	
70-442	15903-15908	1.737	_	
70-443	15915-15917	55	_	
70-444	15924-15929	0.088	_	
70-445	15936-15941	2.020	_	
70-446	15948-15950	36	_	
70-447	15957-15962	0.051	_	
70-448	15969-15974	0.910	_	
70-449	15981-15983	40	_	
70-450	15990-15995	0.368	_	
70-451	16004-16014	Depressive	_	
70-452	16021-16024	6.7	_	
70-453	16024-16025	 	_	
70-454	16025-16026	±	_	
70-455	16026-16027	 	_	
70-456	16027-16030	2.6	_	
70-457	16037-16040	7.4	_	
70-458	16040-16041	 	_	
70-459	16041-16042	±	_	
70-460	16042-16043	 	_	
70-461	16043-16046	2.9	_	
70-462	16053-16056	6.1	_	
70-463	16056-16057	 	_	
70-464	16057-16058	±	_	
70-465	16058-16059	 	_	
70-466	16059-16062	2.3	_	
70-467	16069-16072	7.0	_	
70-468	16072-16073	 	_	
70-469	16073-16074	±	_	
70-470	16074-16075	 	_	
70-471	16075-16078	3.2	_	
70-472	16085-16090	0.420	_	
70-473	16097-16099	55	_	
70-474	16106-16111	0.676	_	
70-475	16118-16123	0.395	_	
70-476	16130-16132	36	_	
70-477	16139-16144	0.695	_	
70-478	16151-16156	1.024	_	
70-479	16163-16165	40	_	
70-480	16172-16177	0.312	_	
70-481	16186-16196	Excitement	_	
70-482	16203-16206	8.3	_	
70-483	16206-16207	 	_	
70-484	16207-16208	±	_	
70-485	16208-16209	 	_	
70-486	16209-16212	3.5	_	
70-487	16219-16222	8.4	_	
70-488	16222-16223	 	_	
70-489	16223-16224	±	_	
70-490	16224-16225	 	_	
70-491	16225-16228	3.4	_	
70-492	16235-16238	8.2	_	
70-493	16238-16239	 	_	
70-494	16239-16240	±	_	
70-495	16240-16241	 	_	
70-496	16241-16244	3.8	_	
70-497	16251-16254	6.7	_	
70-498	16254-16255	 	_	
70-499	16255-16256	±	_	
70-500	16256-16257	 	_	
70-501	16257-16260	3.0	_	
70-502	16267-16272	1.775	_	
70-503	16279-16281	55	_	
70-504	16288-16293	0.081	_	
70-505	16300-16305	1.627	_	
70-506	16312-16314	36	_	
70-507	16321-16326	0.112	_	
70-508	16333-16338	1.450	_	
70-509	16345-16347	40	_	
70-510	16354-16359	0.155	_	
70-511	16368-16380	Intracranial	_	
70-512	16381-16387	volume	_	
70-513	16387-16388	,	_	
70-514	16389-16391	ml	_	
70-515	16398-16404	1619.8	_	
70-516	16404-16405	 	_	
70-517	16405-16406	±	_	
70-518	16406-16407	 	_	
70-519	16407-16412	154.2	_	
70-520	16419-16425	1589.4	_	
70-521	16425-16426	 	_	
70-522	16426-16427	±	_	
70-523	16427-16428	 	_	
70-524	16428-16433	173.6	_	
70-525	16440-16446	1643.7	_	
70-526	16446-16447	 	_	
70-527	16447-16448	±	_	
70-528	16448-16449	 	_	
70-529	16449-16454	137.1	_	
70-530	16461-16467	1618.0	_	
70-531	16467-16468	 	_	
70-532	16468-16469	±	_	
70-533	16469-16470	 	_	
70-534	16470-16475	136.8	_	
70-535	16482-16487	0.045	_	
70-536	16494-16496	55	_	
70-537	16503-16508	0.964	_	
70-538	16515-16520	0.565	_	
70-539	16527-16529	36	_	
70-540	16536-16541	0.576	_	
70-541	16548-16553	0.606	_	
70-542	16560-16562	40	_	
70-543	16569-16574	0.548	_	
70-544	16582-16583	a	_	
70-545	16584-16592	Forensic	_	
70-546	16593-16598	group	_	
70-547	16599-16601	vs	_	
70-548	16601-16602	.	_	
70-549	16603-16610	control	_	
70-550	16611-16618	patient	_	
70-551	16619-16624	group	_	
70-552	16627-16628	b	_	
70-553	16629-16641	Premeditated	_	
70-554	16642-16648	action	_	
70-555	16649-16654	group	_	
70-556	16655-16657	vs	_	
70-557	16658-16665	control	_	
70-558	16666-16673	patient	_	
70-559	16674-16679	group	_	
70-560	16682-16683	c	_	
70-561	16684-16693	Impulsive	_	
70-562	16694-16699	group	_	
70-563	16700-16702	vs	_	
70-564	16703-16710	control	_	
70-565	16711-16718	patient	_	
70-566	16719-16724	group	_	
70-567	16727-16728	d	_	
70-568	16729-16743	Chlorpromazine	_	
70-569	16744-16754	equivalent	_	
70-570	16757-16758	e	_	
70-571	16759-16762	The	_	
70-572	16763-16771	Wallwork	_	
70-573	16771-16772	/	_	
70-574	16772-16780	Fortgang	_	
70-575	16781-16792	five-factor	_	
70-576	16793-16798	model	_	
70-577	16799-16802	for	_	
70-578	16803-16808	PANSS	_	
70-579	16811-16812	f	_	
70-580	16813-16823	Likelihood	_	
70-581	16824-16829	ratio	_	
70-582	16830-16834	test	_	
70-583	16836-16847	Demographic	_	
70-584	16848-16852	data	_	
70-585	16853-16856	and	_	
70-586	16857-16865	clinical	_	
70-587	16866-16877	information	_	
70-588	16878-16881	are	_	
70-589	16882-16887	shown	_	
70-590	16888-16890	in	_	
70-591	16891-16896	Table	_	
70-592	16897-16898	1	_	
70-593	16898-16899	.	_	

#Text=This study was approved by the Ethical Review Board of the National Center of Neurology and Psychiatry.
71-1	16901-16905	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
71-2	16906-16911	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
71-3	16912-16915	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
71-4	16916-16924	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
71-5	16925-16927	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
71-6	16928-16931	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
71-7	16932-16939	Ethical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
71-8	16940-16946	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
71-9	16947-16952	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
71-10	16953-16955	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
71-11	16956-16959	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
71-12	16960-16968	National	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
71-13	16969-16975	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
71-14	16976-16978	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
71-15	16979-16988	Neurology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
71-16	16989-16992	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
71-17	16993-17003	Psychiatry	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
71-18	17003-17004	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	

#Text=All participants were given a complete description of the study and provided written informed consent to participate.
72-1	17005-17008	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
72-2	17009-17021	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
72-3	17022-17026	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
72-4	17027-17032	given	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
72-5	17033-17034	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
72-6	17035-17043	complete	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
72-7	17044-17055	description	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
72-8	17056-17058	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
72-9	17059-17062	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
72-10	17063-17068	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
72-11	17069-17072	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
72-12	17073-17081	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
72-13	17082-17089	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
72-14	17090-17098	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
72-15	17099-17106	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
72-16	17107-17109	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
72-17	17110-17121	participate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
72-18	17121-17122	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	

#Text=MRI acquisition and processing
#Text=Experiments were performed on a 3-tesla (3T) MRI system (Philips Medical Systems, Best, the Netherlands).
73-1	17123-17126	MRI	_	
73-2	17127-17138	acquisition	_	
73-3	17139-17142	and	_	
73-4	17143-17153	processing	_	
73-5	17154-17165	Experiments	_	
73-6	17166-17170	were	_	
73-7	17171-17180	performed	_	
73-8	17181-17183	on	_	
73-9	17184-17185	a	_	
73-10	17186-17187	3	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[26]	
73-11	17187-17188	-	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[26]	
73-12	17188-17193	tesla	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[26]	
73-13	17194-17195	(	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[26]	
73-14	17195-17197	3T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[26]	
73-15	17197-17198	)	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[26]	
73-16	17199-17202	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[26]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[27]	
73-17	17203-17209	system	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[26]	
73-18	17210-17211	(	_	
73-19	17211-17218	Philips	_	
73-20	17219-17226	Medical	_	
73-21	17227-17234	Systems	_	
73-22	17234-17235	,	_	
73-23	17236-17240	Best	_	
73-24	17240-17241	,	_	
73-25	17242-17245	the	_	
73-26	17246-17257	Netherlands	_	
73-27	17257-17258	)	_	
73-28	17258-17259	.	_	

#Text=High spatial resolution, 3-dimensional (3D) T1-weighted images were used for morphometric study. 3D T1-weighted images were acquired in the sagittal plane (repetition time (TR)/echo time (TE), 7.18/3.46 ms; flip angle, 10°; effective section thickness, 0.6 mm; slab thickness, 180 mm; matrix, 384 × 384; field of view (FOV), 261 × 261 mm; number of signals acquired, 1), yielding 300 contiguous slices through the brain.
74-1	17260-17264	High	_	
74-2	17265-17272	spatial	_	
74-3	17273-17283	resolution	_	
74-4	17283-17284	,	_	
74-5	17285-17286	3	_	
74-6	17286-17287	-	_	
74-7	17287-17298	dimensional	_	
74-8	17299-17300	(	_	
74-9	17300-17302	3D	_	
74-10	17302-17303	)	_	
74-11	17304-17306	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[28]	
74-12	17306-17307	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[28]	
74-13	17307-17315	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[28]	
74-14	17316-17322	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[28]	
74-15	17323-17327	were	_	
74-16	17328-17332	used	_	
74-17	17333-17336	for	_	
74-18	17337-17349	morphometric	_	
74-19	17350-17355	study	_	
74-20	17355-17356	.	_	
74-21	17357-17359	3D	_	
74-22	17360-17362	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[29]	
74-23	17362-17363	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[29]	
74-24	17363-17371	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[29]	
74-25	17372-17378	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[29]	
74-26	17379-17383	were	_	
74-27	17384-17392	acquired	_	
74-28	17393-17395	in	_	
74-29	17396-17399	the	_	
74-30	17400-17408	sagittal	_	
74-31	17409-17414	plane	_	
74-32	17415-17416	(	_	
74-33	17416-17426	repetition	_	
74-34	17427-17431	time	_	
74-35	17432-17433	(	_	
74-36	17433-17435	TR	_	
74-37	17435-17436	)	_	
74-38	17436-17437	/	_	
74-39	17437-17441	echo	_	
74-40	17442-17446	time	_	
74-41	17447-17448	(	_	
74-42	17448-17450	TE	_	
74-43	17450-17451	)	_	
74-44	17451-17452	,	_	
74-45	17453-17457	7.18	_	
74-46	17457-17458	/	_	
74-47	17458-17462	3.46	_	
74-48	17462-17463	 	_	
74-49	17463-17465	ms	_	
74-50	17465-17466	;	_	
74-51	17467-17471	flip	_	
74-52	17472-17477	angle	_	
74-53	17477-17478	,	_	
74-54	17479-17481	10	_	
74-55	17481-17482	°	_	
74-56	17482-17483	;	_	
74-57	17484-17493	effective	_	
74-58	17494-17501	section	_	
74-59	17502-17511	thickness	_	
74-60	17511-17512	,	_	
74-61	17513-17516	0.6	_	
74-62	17516-17517	 	_	
74-63	17517-17519	mm	_	
74-64	17519-17520	;	_	
74-65	17521-17525	slab	_	
74-66	17526-17535	thickness	_	
74-67	17535-17536	,	_	
74-68	17537-17540	180	_	
74-69	17540-17541	 	_	
74-70	17541-17543	mm	_	
74-71	17543-17544	;	_	
74-72	17545-17551	matrix	_	
74-73	17551-17552	,	_	
74-74	17553-17556	384	_	
74-75	17556-17557	 	_	
74-76	17557-17558	×	_	
74-77	17558-17559	 	_	
74-78	17559-17562	384	_	
74-79	17562-17563	;	_	
74-80	17564-17569	field	_	
74-81	17570-17572	of	_	
74-82	17573-17577	view	_	
74-83	17578-17579	(	_	
74-84	17579-17582	FOV	_	
74-85	17582-17583	)	_	
74-86	17583-17584	,	_	
74-87	17585-17588	261	_	
74-88	17588-17589	 	_	
74-89	17589-17590	×	_	
74-90	17590-17591	 	_	
74-91	17591-17594	261	_	
74-92	17594-17595	 	_	
74-93	17595-17597	mm	_	
74-94	17597-17598	;	_	
74-95	17599-17605	number	_	
74-96	17606-17608	of	_	
74-97	17609-17616	signals	_	
74-98	17617-17625	acquired	_	
74-99	17625-17626	,	_	
74-100	17627-17628	1	_	
74-101	17628-17629	)	_	
74-102	17629-17630	,	_	
74-103	17631-17639	yielding	_	
74-104	17640-17643	300	_	
74-105	17644-17654	contiguous	_	
74-106	17655-17661	slices	_	
74-107	17662-17669	through	_	
74-108	17670-17673	the	_	
74-109	17674-17679	brain	_	
74-110	17679-17680	.	_	

#Text=Voxel-based morphometry analysis was performed using SPM12 (Statistical Parametric Mapping, Functional Imaging Laboratory (FIL), the Wellcome Trust Centre for NeuroImaging, Institute of Neurology at University College London (UCL), UK) under Matlab 7.14.0 (MathWorks, Natick, MA, USA).
75-1	17681-17692	Voxel-based	_	
75-2	17693-17704	morphometry	_	
75-3	17705-17713	analysis	_	
75-4	17714-17717	was	_	
75-5	17718-17727	performed	_	
75-6	17728-17733	using	_	
75-7	17734-17739	SPM12	_	
75-8	17740-17741	(	_	
75-9	17741-17752	Statistical	_	
75-10	17753-17763	Parametric	_	
75-11	17764-17771	Mapping	_	
75-12	17771-17772	,	_	
75-13	17773-17783	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[30]	
75-14	17784-17791	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[30]	
75-15	17792-17802	Laboratory	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[30]	
75-16	17803-17804	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[30]	
75-17	17804-17807	FIL	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[30]	
75-18	17807-17808	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[30]	
75-19	17808-17809	,	_	
75-20	17810-17813	the	_	
75-21	17814-17822	Wellcome	_	
75-22	17823-17828	Trust	_	
75-23	17829-17835	Centre	_	
75-24	17836-17839	for	_	
75-25	17840-17852	NeuroImaging	_	
75-26	17852-17853	,	_	
75-27	17854-17863	Institute	_	
75-28	17864-17866	of	_	
75-29	17867-17876	Neurology	_	
75-30	17877-17879	at	_	
75-31	17880-17890	University	_	
75-32	17891-17898	College	_	
75-33	17899-17905	London	_	
75-34	17906-17907	(	_	
75-35	17907-17910	UCL	_	
75-36	17910-17911	)	_	
75-37	17911-17912	,	_	
75-38	17913-17915	UK	_	
75-39	17915-17916	)	_	
75-40	17917-17922	under	_	
75-41	17923-17929	Matlab	_	
75-42	17930-17936	7.14.0	_	
75-43	17937-17938	(	_	
75-44	17938-17947	MathWorks	_	
75-45	17947-17948	,	_	
75-46	17949-17955	Natick	_	
75-47	17955-17956	,	_	
75-48	17957-17959	MA	_	
75-49	17959-17960	,	_	
75-50	17961-17964	USA	_	
75-51	17964-17965	)	_	
75-52	17965-17966	.	_	

#Text=Structural T1-weighted MR images were segmented into gray matter, white matter, cerebrospinal fluid, bone, soft tissue, and air/background after bias regularization.
76-1	17967-17977	Structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[31]	
76-2	17978-17980	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[31]	
76-3	17980-17981	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[31]	
76-4	17981-17989	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[31]	
76-5	17990-17992	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
76-6	17993-17999	images	_	
76-7	18000-18004	were	_	
76-8	18005-18014	segmented	_	
76-9	18015-18019	into	_	
76-10	18020-18024	gray	_	
76-11	18025-18031	matter	_	
76-12	18031-18032	,	_	
76-13	18033-18038	white	_	
76-14	18039-18045	matter	_	
76-15	18045-18046	,	_	
76-16	18047-18060	cerebrospinal	_	
76-17	18061-18066	fluid	_	
76-18	18066-18067	,	_	
76-19	18068-18072	bone	_	
76-20	18072-18073	,	_	
76-21	18074-18078	soft	_	
76-22	18079-18085	tissue	_	
76-23	18085-18086	,	_	
76-24	18087-18090	and	_	
76-25	18091-18094	air	_	
76-26	18094-18095	/	_	
76-27	18095-18105	background	_	
76-28	18106-18111	after	_	
76-29	18112-18116	bias	_	
76-30	18117-18131	regularization	_	
76-31	18131-18132	.	_	

#Text=Images of gray matter and white matter were spatially normalized to the Montreal Neurological Institute (MNI) space through Diffeomorphic Anatomic Registration using the Exponentiated Lie Algebra (DARTEL) algorithm.
77-1	18133-18139	Images	_	
77-2	18140-18142	of	_	
77-3	18143-18147	gray	_	
77-4	18148-18154	matter	_	
77-5	18155-18158	and	_	
77-6	18159-18164	white	_	
77-7	18165-18171	matter	_	
77-8	18172-18176	were	_	
77-9	18177-18186	spatially	_	
77-10	18187-18197	normalized	_	
77-11	18198-18200	to	_	
77-12	18201-18204	the	_	
77-13	18205-18213	Montreal	_	
77-14	18214-18226	Neurological	_	
77-15	18227-18236	Institute	_	
77-16	18237-18238	(	_	
77-17	18238-18241	MNI	_	
77-18	18241-18242	)	_	
77-19	18243-18248	space	_	
77-20	18249-18256	through	_	
77-21	18257-18270	Diffeomorphic	_	
77-22	18271-18279	Anatomic	_	
77-23	18280-18292	Registration	_	
77-24	18293-18298	using	_	
77-25	18299-18302	the	_	
77-26	18303-18316	Exponentiated	_	
77-27	18317-18320	Lie	_	
77-28	18321-18328	Algebra	_	
77-29	18329-18330	(	_	
77-30	18330-18336	DARTEL	_	
77-31	18336-18337	)	_	
77-32	18338-18347	algorithm	_	
77-33	18347-18348	.	_	

#Text=We modulated the images by the Jacobean determinants derived from the spatial normalization to MNI space using DARTEL to preserve volume information.
78-1	18349-18351	We	_	
78-2	18352-18361	modulated	_	
78-3	18362-18365	the	_	
78-4	18366-18372	images	_	
78-5	18373-18375	by	_	
78-6	18376-18379	the	_	
78-7	18380-18388	Jacobean	_	
78-8	18389-18401	determinants	_	
78-9	18402-18409	derived	_	
78-10	18410-18414	from	_	
78-11	18415-18418	the	_	
78-12	18419-18426	spatial	_	
78-13	18427-18440	normalization	_	
78-14	18441-18443	to	_	
78-15	18444-18447	MNI	_	
78-16	18448-18453	space	_	
78-17	18454-18459	using	_	
78-18	18460-18466	DARTEL	_	
78-19	18467-18469	to	_	
78-20	18470-18478	preserve	_	
78-21	18479-18485	volume	_	
78-22	18486-18497	information	_	
78-23	18497-18498	.	_	

#Text=Images were smoothed with an 8-mm, full width at half maximum Gaussian kernel.
79-1	18499-18505	Images	_	
79-2	18506-18510	were	_	
79-3	18511-18519	smoothed	_	
79-4	18520-18524	with	_	
79-5	18525-18527	an	_	
79-6	18528-18529	8	_	
79-7	18529-18530	-	_	
79-8	18530-18532	mm	_	
79-9	18532-18533	,	_	
79-10	18534-18538	full	_	
79-11	18539-18544	width	_	
79-12	18545-18547	at	_	
79-13	18548-18552	half	_	
79-14	18553-18560	maximum	_	
79-15	18561-18569	Gaussian	_	
79-16	18570-18576	kernel	_	
79-17	18576-18577	.	_	

#Text=Statistical analysis
#Text=Independent samples t-tests or Mann-Whitney’s U tests were performed to assess differences between the forensic and the control groups in terms of age at scan, duration of education, age at onset, duration of illness, duration of medication, duration of untreated psychosis, medication dosage converted to chlorpromazine equivalents, composite scores for five factors of PANSS (e.g., positive symptoms, negative symptoms, disorganization/concrete symptoms, depressive symptoms, and excitement symptoms), and intracranial volumes (e.g., total gray matter volume (GMV) + total white matter volume + total cerebrospinal fluid volume; ICV).
80-1	18578-18589	Statistical	_	
80-2	18590-18598	analysis	_	
80-3	18599-18610	Independent	_	
80-4	18611-18618	samples	_	
80-5	18619-18626	t-tests	_	
80-6	18627-18629	or	_	
80-7	18630-18642	Mann-Whitney	_	
80-8	18642-18643	’	_	
80-9	18643-18644	s	_	
80-10	18645-18646	U	_	
80-11	18647-18652	tests	_	
80-12	18653-18657	were	_	
80-13	18658-18667	performed	_	
80-14	18668-18670	to	_	
80-15	18671-18677	assess	_	
80-16	18678-18689	differences	_	
80-17	18690-18697	between	_	
80-18	18698-18701	the	_	
80-19	18702-18710	forensic	_	
80-20	18711-18714	and	_	
80-21	18715-18718	the	_	
80-22	18719-18726	control	_	
80-23	18727-18733	groups	_	
80-24	18734-18736	in	_	
80-25	18737-18742	terms	_	
80-26	18743-18745	of	_	
80-27	18746-18749	age	_	
80-28	18750-18752	at	_	
80-29	18753-18757	scan	_	
80-30	18757-18758	,	_	
80-31	18759-18767	duration	_	
80-32	18768-18770	of	_	
80-33	18771-18780	education	_	
80-34	18780-18781	,	_	
80-35	18782-18785	age	_	
80-36	18786-18788	at	_	
80-37	18789-18794	onset	_	
80-38	18794-18795	,	_	
80-39	18796-18804	duration	_	
80-40	18805-18807	of	_	
80-41	18808-18815	illness	_	
80-42	18815-18816	,	_	
80-43	18817-18825	duration	_	
80-44	18826-18828	of	_	
80-45	18829-18839	medication	_	
80-46	18839-18840	,	_	
80-47	18841-18849	duration	_	
80-48	18850-18852	of	_	
80-49	18853-18862	untreated	_	
80-50	18863-18872	psychosis	_	
80-51	18872-18873	,	_	
80-52	18874-18884	medication	_	
80-53	18885-18891	dosage	_	
80-54	18892-18901	converted	_	
80-55	18902-18904	to	_	
80-56	18905-18919	chlorpromazine	_	
80-57	18920-18931	equivalents	_	
80-58	18931-18932	,	_	
80-59	18933-18942	composite	_	
80-60	18943-18949	scores	_	
80-61	18950-18953	for	_	
80-62	18954-18958	five	_	
80-63	18959-18966	factors	_	
80-64	18967-18969	of	_	
80-65	18970-18975	PANSS	_	
80-66	18976-18977	(	_	
80-67	18977-18980	e.g	_	
80-68	18980-18981	.	_	
80-69	18981-18982	,	_	
80-70	18983-18991	positive	_	
80-71	18992-19000	symptoms	_	
80-72	19000-19001	,	_	
80-73	19002-19010	negative	_	
80-74	19011-19019	symptoms	_	
80-75	19019-19020	,	_	
80-76	19021-19036	disorganization	_	
80-77	19036-19037	/	_	
80-78	19037-19045	concrete	_	
80-79	19046-19054	symptoms	_	
80-80	19054-19055	,	_	
80-81	19056-19066	depressive	_	
80-82	19067-19075	symptoms	_	
80-83	19075-19076	,	_	
80-84	19077-19080	and	_	
80-85	19081-19091	excitement	_	
80-86	19092-19100	symptoms	_	
80-87	19100-19101	)	_	
80-88	19101-19102	,	_	
80-89	19103-19106	and	_	
80-90	19107-19119	intracranial	_	
80-91	19120-19127	volumes	_	
80-92	19128-19129	(	_	
80-93	19129-19132	e.g	_	
80-94	19132-19133	.	_	
80-95	19133-19134	,	_	
80-96	19135-19140	total	_	
80-97	19141-19145	gray	_	
80-98	19146-19152	matter	_	
80-99	19153-19159	volume	_	
80-100	19160-19161	(	_	
80-101	19161-19164	GMV	_	
80-102	19164-19165	)	_	
80-103	19165-19166	 	_	
80-104	19166-19167	+	_	
80-105	19167-19168	 	_	
80-106	19168-19173	total	_	
80-107	19174-19179	white	_	
80-108	19180-19186	matter	_	
80-109	19187-19193	volume	_	
80-110	19193-19194	 	_	
80-111	19194-19195	+	_	
80-112	19195-19196	 	_	
80-113	19196-19201	total	_	
80-114	19202-19215	cerebrospinal	_	
80-115	19216-19221	fluid	_	
80-116	19222-19228	volume	_	
80-117	19228-19229	;	_	
80-118	19230-19233	ICV	_	
80-119	19233-19234	)	_	
80-120	19234-19235	.	_	

#Text=T-tests were performed when variables were normally distributed according to Shapiro-Wilk tests; otherwise, Mann-Whitney’s U tests were performed.
81-1	19236-19243	T-tests	_	
81-2	19244-19248	were	_	
81-3	19249-19258	performed	_	
81-4	19259-19263	when	_	
81-5	19264-19273	variables	_	
81-6	19274-19278	were	_	
81-7	19279-19287	normally	_	
81-8	19288-19299	distributed	_	
81-9	19300-19309	according	_	
81-10	19310-19312	to	_	
81-11	19313-19325	Shapiro-Wilk	_	
81-12	19326-19331	tests	_	
81-13	19331-19332	;	_	
81-14	19333-19342	otherwise	_	
81-15	19342-19343	,	_	
81-16	19344-19356	Mann-Whitney	_	
81-17	19356-19357	’	_	
81-18	19357-19358	s	_	
81-19	19359-19360	U	_	
81-20	19361-19366	tests	_	
81-21	19367-19371	were	_	
81-22	19372-19381	performed	_	
81-23	19381-19382	.	_	

#Text=The likelihood ratio test was performed for comparison of medication type (i.e., only typical/only atypical/both types/no medication) between two groups.
82-1	19383-19386	The	_	
82-2	19387-19397	likelihood	_	
82-3	19398-19403	ratio	_	
82-4	19404-19408	test	_	
82-5	19409-19412	was	_	
82-6	19413-19422	performed	_	
82-7	19423-19426	for	_	
82-8	19427-19437	comparison	_	
82-9	19438-19440	of	_	
82-10	19441-19451	medication	_	
82-11	19452-19456	type	_	
82-12	19457-19458	(	_	
82-13	19458-19461	i.e	_	
82-14	19461-19462	.	_	
82-15	19462-19463	,	_	
82-16	19464-19468	only	_	
82-17	19469-19476	typical	_	
82-18	19476-19477	/	_	
82-19	19477-19481	only	_	
82-20	19482-19490	atypical	_	
82-21	19490-19491	/	_	
82-22	19491-19495	both	_	
82-23	19496-19501	types	_	
82-24	19501-19502	/	_	
82-25	19502-19504	no	_	
82-26	19505-19515	medication	_	
82-27	19515-19516	)	_	
82-28	19517-19524	between	_	
82-29	19525-19528	two	_	
82-30	19529-19535	groups	_	
82-31	19535-19536	.	_	

#Text=Similarly, independent samples t-tests or Mann-Whitney’s U tests for these clinical variables were performed between the premeditated action group and the control patient group, as well as between the impulsive group and the control patient group.
83-1	19537-19546	Similarly	_	
83-2	19546-19547	,	_	
83-3	19548-19559	independent	_	
83-4	19560-19567	samples	_	
83-5	19568-19575	t-tests	_	
83-6	19576-19578	or	_	
83-7	19579-19591	Mann-Whitney	_	
83-8	19591-19592	’	_	
83-9	19592-19593	s	_	
83-10	19594-19595	U	_	
83-11	19596-19601	tests	_	
83-12	19602-19605	for	_	
83-13	19606-19611	these	_	
83-14	19612-19620	clinical	_	
83-15	19621-19630	variables	_	
83-16	19631-19635	were	_	
83-17	19636-19645	performed	_	
83-18	19646-19653	between	_	
83-19	19654-19657	the	_	
83-20	19658-19670	premeditated	_	
83-21	19671-19677	action	_	
83-22	19678-19683	group	_	
83-23	19684-19687	and	_	
83-24	19688-19691	the	_	
83-25	19692-19699	control	_	
83-26	19700-19707	patient	_	
83-27	19708-19713	group	_	
83-28	19713-19714	,	_	
83-29	19715-19717	as	_	
83-30	19718-19722	well	_	
83-31	19723-19725	as	_	
83-32	19726-19733	between	_	
83-33	19734-19737	the	_	
83-34	19738-19747	impulsive	_	
83-35	19748-19753	group	_	
83-36	19754-19757	and	_	
83-37	19758-19761	the	_	
83-38	19762-19769	control	_	
83-39	19770-19777	patient	_	
83-40	19778-19783	group	_	
83-41	19783-19784	.	_	

#Text=We performed voxel-level comparison of GMV scaled by ICV between the forensic group and control group of patients with schizophrenia, using a two-sample t-test while considering other clinical factors when the significant group differences were identified as covariates.
84-1	19785-19787	We	_	
84-2	19788-19797	performed	_	
84-3	19798-19809	voxel-level	_	
84-4	19810-19820	comparison	_	
84-5	19821-19823	of	_	
84-6	19824-19827	GMV	_	
84-7	19828-19834	scaled	_	
84-8	19835-19837	by	_	
84-9	19838-19841	ICV	_	
84-10	19842-19849	between	_	
84-11	19850-19853	the	_	
84-12	19854-19862	forensic	_	
84-13	19863-19868	group	_	
84-14	19869-19872	and	_	
84-15	19873-19880	control	_	
84-16	19881-19886	group	_	
84-17	19887-19889	of	_	
84-18	19890-19898	patients	_	
84-19	19899-19903	with	_	
84-20	19904-19917	schizophrenia	_	
84-21	19917-19918	,	_	
84-22	19919-19924	using	_	
84-23	19925-19926	a	_	
84-24	19927-19937	two-sample	_	
84-25	19938-19944	t-test	_	
84-26	19945-19950	while	_	
84-27	19951-19962	considering	_	
84-28	19963-19968	other	_	
84-29	19969-19977	clinical	_	
84-30	19978-19985	factors	_	
84-31	19986-19990	when	_	
84-32	19991-19994	the	_	
84-33	19995-20006	significant	_	
84-34	20007-20012	group	_	
84-35	20013-20024	differences	_	
84-36	20025-20029	were	_	
84-37	20030-20040	identified	_	
84-38	20041-20043	as	_	
84-39	20044-20054	covariates	_	
84-40	20054-20055	.	_	

#Text=Group comparisons were assessed using the cluster-level family-wise error (FWE) correction for multiple comparisons, where the initial voxel threshold was set to uncorrected p = 0.001 and clusters were considered significant when falling below a cluster-corrected p(FWE) = 0.05.
85-1	20056-20061	Group	_	
85-2	20062-20073	comparisons	_	
85-3	20074-20078	were	_	
85-4	20079-20087	assessed	_	
85-5	20088-20093	using	_	
85-6	20094-20097	the	_	
85-7	20098-20111	cluster-level	_	
85-8	20112-20123	family-wise	_	
85-9	20124-20129	error	_	
85-10	20130-20131	(	_	
85-11	20131-20134	FWE	_	
85-12	20134-20135	)	_	
85-13	20136-20146	correction	_	
85-14	20147-20150	for	_	
85-15	20151-20159	multiple	_	
85-16	20160-20171	comparisons	_	
85-17	20171-20172	,	_	
85-18	20173-20178	where	_	
85-19	20179-20182	the	_	
85-20	20183-20190	initial	_	
85-21	20191-20196	voxel	_	
85-22	20197-20206	threshold	_	
85-23	20207-20210	was	_	
85-24	20211-20214	set	_	
85-25	20215-20217	to	_	
85-26	20218-20229	uncorrected	_	
85-27	20230-20231	p	_	
85-28	20231-20232	 	_	
85-29	20232-20233	=	_	
85-30	20233-20234	 	_	
85-31	20234-20239	0.001	_	
85-32	20240-20243	and	_	
85-33	20244-20252	clusters	_	
85-34	20253-20257	were	_	
85-35	20258-20268	considered	_	
85-36	20269-20280	significant	_	
85-37	20281-20285	when	_	
85-38	20286-20293	falling	_	
85-39	20294-20299	below	_	
85-40	20300-20301	a	_	
85-41	20302-20319	cluster-corrected	_	
85-42	20320-20321	p	_	
85-43	20321-20322	(	_	
85-44	20322-20325	FWE	_	
85-45	20325-20326	)	_	
85-46	20326-20327	 	_	
85-47	20327-20328	=	_	
85-48	20328-20329	 	_	
85-49	20329-20333	0.05	_	
85-50	20333-20334	.	_	

#Text=Prior to the comparison, we applied masking voxels in order to exclude non-brain voxels.
86-1	20335-20340	Prior	_	
86-2	20341-20343	to	_	
86-3	20344-20347	the	_	
86-4	20348-20358	comparison	_	
86-5	20358-20359	,	_	
86-6	20360-20362	we	_	
86-7	20363-20370	applied	_	
86-8	20371-20378	masking	_	
86-9	20379-20385	voxels	_	
86-10	20386-20388	in	_	
86-11	20389-20394	order	_	
86-12	20395-20397	to	_	
86-13	20398-20405	exclude	_	
86-14	20406-20415	non-brain	_	
86-15	20416-20422	voxels	_	
86-16	20422-20423	.	_	

#Text=A history of substance abuse can affect brain morphometry, and previously shown to be associated with violence risk.
87-1	20424-20425	A	_	
87-2	20426-20433	history	_	
87-3	20434-20436	of	_	
87-4	20437-20446	substance	_	
87-5	20447-20452	abuse	_	
87-6	20453-20456	can	_	
87-7	20457-20463	affect	_	
87-8	20464-20469	brain	_	
87-9	20470-20481	morphometry	_	
87-10	20481-20482	,	_	
87-11	20483-20486	and	_	
87-12	20487-20497	previously	_	
87-13	20498-20503	shown	_	
87-14	20504-20506	to	_	
87-15	20507-20509	be	_	
87-16	20510-20520	associated	_	
87-17	20521-20525	with	_	
87-18	20526-20534	violence	_	
87-19	20535-20539	risk	_	
87-20	20539-20540	.	_	

#Text=To eliminate the influence of substance abuse, a similar voxel-level comparison of GMV between the forensic group without patients with a history of substance abuse and the control patient group was performed, as no patients had a history of substance abuse in the control patient group.
88-1	20541-20543	To	_	
88-2	20544-20553	eliminate	_	
88-3	20554-20557	the	_	
88-4	20558-20567	influence	_	
88-5	20568-20570	of	_	
88-6	20571-20580	substance	_	
88-7	20581-20586	abuse	_	
88-8	20586-20587	,	_	
88-9	20588-20589	a	_	
88-10	20590-20597	similar	_	
88-11	20598-20609	voxel-level	_	
88-12	20610-20620	comparison	_	
88-13	20621-20623	of	_	
88-14	20624-20627	GMV	_	
88-15	20628-20635	between	_	
88-16	20636-20639	the	_	
88-17	20640-20648	forensic	_	
88-18	20649-20654	group	_	
88-19	20655-20662	without	_	
88-20	20663-20671	patients	_	
88-21	20672-20676	with	_	
88-22	20677-20678	a	_	
88-23	20679-20686	history	_	
88-24	20687-20689	of	_	
88-25	20690-20699	substance	_	
88-26	20700-20705	abuse	_	
88-27	20706-20709	and	_	
88-28	20710-20713	the	_	
88-29	20714-20721	control	_	
88-30	20722-20729	patient	_	
88-31	20730-20735	group	_	
88-32	20736-20739	was	_	
88-33	20740-20749	performed	_	
88-34	20749-20750	,	_	
88-35	20751-20753	as	_	
88-36	20754-20756	no	_	
88-37	20757-20765	patients	_	
88-38	20766-20769	had	_	
88-39	20770-20771	a	_	
88-40	20772-20779	history	_	
88-41	20780-20782	of	_	
88-42	20783-20792	substance	_	
88-43	20793-20798	abuse	_	
88-44	20799-20801	in	_	
88-45	20802-20805	the	_	
88-46	20806-20813	control	_	
88-47	20814-20821	patient	_	
88-48	20822-20827	group	_	
88-49	20827-20828	.	_	

#Text=We performed similar voxel-level comparison of GMV between the premeditated action group and the control patient group, as well as between the impulsive group and the control patient group.
89-1	20829-20831	We	_	
89-2	20832-20841	performed	_	
89-3	20842-20849	similar	_	
89-4	20850-20861	voxel-level	_	
89-5	20862-20872	comparison	_	
89-6	20873-20875	of	_	
89-7	20876-20879	GMV	_	
89-8	20880-20887	between	_	
89-9	20888-20891	the	_	
89-10	20892-20904	premeditated	_	
89-11	20905-20911	action	_	
89-12	20912-20917	group	_	
89-13	20918-20921	and	_	
89-14	20922-20925	the	_	
89-15	20926-20933	control	_	
89-16	20934-20941	patient	_	
89-17	20942-20947	group	_	
89-18	20947-20948	,	_	
89-19	20949-20951	as	_	
89-20	20952-20956	well	_	
89-21	20957-20959	as	_	
89-22	20960-20967	between	_	
89-23	20968-20971	the	_	
89-24	20972-20981	impulsive	_	
89-25	20982-20987	group	_	
89-26	20988-20991	and	_	
89-27	20992-20995	the	_	
89-28	20996-21003	control	_	
89-29	21004-21011	patient	_	
89-30	21012-21017	group	_	
89-31	21017-21018	.	_	

#Text=Results
#Text=No significant differences between the forensic group and the control patient group were identified in terms of age at scan, age at first episode, duration of illness, duration of untreated psychosis, duration of medications, and doses of antipsychotics.
90-1	21019-21026	Results	_	
90-2	21027-21029	No	_	
90-3	21030-21041	significant	_	
90-4	21042-21053	differences	_	
90-5	21054-21061	between	_	
90-6	21062-21065	the	_	
90-7	21066-21074	forensic	_	
90-8	21075-21080	group	_	
90-9	21081-21084	and	_	
90-10	21085-21088	the	_	
90-11	21089-21096	control	_	
90-12	21097-21104	patient	_	
90-13	21105-21110	group	_	
90-14	21111-21115	were	_	
90-15	21116-21126	identified	_	
90-16	21127-21129	in	_	
90-17	21130-21135	terms	_	
90-18	21136-21138	of	_	
90-19	21139-21142	age	_	
90-20	21143-21145	at	_	
90-21	21146-21150	scan	_	
90-22	21150-21151	,	_	
90-23	21152-21155	age	_	
90-24	21156-21158	at	_	
90-25	21159-21164	first	_	
90-26	21165-21172	episode	_	
90-27	21172-21173	,	_	
90-28	21174-21182	duration	_	
90-29	21183-21185	of	_	
90-30	21186-21193	illness	_	
90-31	21193-21194	,	_	
90-32	21195-21203	duration	_	
90-33	21204-21206	of	_	
90-34	21207-21216	untreated	_	
90-35	21217-21226	psychosis	_	
90-36	21226-21227	,	_	
90-37	21228-21236	duration	_	
90-38	21237-21239	of	_	
90-39	21240-21251	medications	_	
90-40	21251-21252	,	_	
90-41	21253-21256	and	_	
90-42	21257-21262	doses	_	
90-43	21263-21265	of	_	
90-44	21266-21280	antipsychotics	_	
90-45	21280-21281	.	_	

#Text=The forensic group showed a significantly lower duration of education compared to the control patient group.
91-1	21282-21285	The	_	
91-2	21286-21294	forensic	_	
91-3	21295-21300	group	_	
91-4	21301-21307	showed	_	
91-5	21308-21309	a	_	
91-6	21310-21323	significantly	_	
91-7	21324-21329	lower	_	
91-8	21330-21338	duration	_	
91-9	21339-21341	of	_	
91-10	21342-21351	education	_	
91-11	21352-21360	compared	_	
91-12	21361-21363	to	_	
91-13	21364-21367	the	_	
91-14	21368-21375	control	_	
91-15	21376-21383	patient	_	
91-16	21384-21389	group	_	
91-17	21389-21390	.	_	

#Text=The forensic group also showed significantly higher composite score on positive symptoms compared to the control patient group.
92-1	21391-21394	The	_	
92-2	21395-21403	forensic	_	
92-3	21404-21409	group	_	
92-4	21410-21414	also	_	
92-5	21415-21421	showed	_	
92-6	21422-21435	significantly	_	
92-7	21436-21442	higher	_	
92-8	21443-21452	composite	_	
92-9	21453-21458	score	_	
92-10	21459-21461	on	_	
92-11	21462-21470	positive	_	
92-12	21471-21479	symptoms	_	
92-13	21480-21488	compared	_	
92-14	21489-21491	to	_	
92-15	21492-21495	the	_	
92-16	21496-21503	control	_	
92-17	21504-21511	patient	_	
92-18	21512-21517	group	_	
92-19	21517-21518	.	_	

#Text=No significant differences were found for the other components of the PANSS.
93-1	21519-21521	No	_	
93-2	21522-21533	significant	_	
93-3	21534-21545	differences	_	
93-4	21546-21550	were	_	
93-5	21551-21556	found	_	
93-6	21557-21560	for	_	
93-7	21561-21564	the	_	
93-8	21565-21570	other	_	
93-9	21571-21581	components	_	
93-10	21582-21584	of	_	
93-11	21585-21588	the	_	
93-12	21589-21594	PANSS	_	
93-13	21594-21595	.	_	

#Text=Duration of education and scores of positive symptoms were used as covariates for further voxel-level comparisons.
94-1	21596-21604	Duration	_	
94-2	21605-21607	of	_	
94-3	21608-21617	education	_	
94-4	21618-21621	and	_	
94-5	21622-21628	scores	_	
94-6	21629-21631	of	_	
94-7	21632-21640	positive	_	
94-8	21641-21649	symptoms	_	
94-9	21650-21654	were	_	
94-10	21655-21659	used	_	
94-11	21660-21662	as	_	
94-12	21663-21673	covariates	_	
94-13	21674-21677	for	_	
94-14	21678-21685	further	_	
94-15	21686-21697	voxel-level	_	
94-16	21698-21709	comparisons	_	
94-17	21709-21710	.	_	

#Text=No significant differences were found in ICV.
95-1	21711-21713	No	_	
95-2	21714-21725	significant	_	
95-3	21726-21737	differences	_	
95-4	21738-21742	were	_	
95-5	21743-21748	found	_	
95-6	21749-21751	in	_	
95-7	21752-21755	ICV	_	
95-8	21755-21756	.	_	

#Text=Regarding comparisons between the premeditated action group and the control patient group, and between the impulsive group and the control patient group, the premeditated action group showed a significantly lower duration of education and higher scores of positive symptoms compared to the control patient group, while no significant differences were found in these variables between the impulsive group and the control patient group.
96-1	21757-21766	Regarding	_	
96-2	21767-21778	comparisons	_	
96-3	21779-21786	between	_	
96-4	21787-21790	the	_	
96-5	21791-21803	premeditated	_	
96-6	21804-21810	action	_	
96-7	21811-21816	group	_	
96-8	21817-21820	and	_	
96-9	21821-21824	the	_	
96-10	21825-21832	control	_	
96-11	21833-21840	patient	_	
96-12	21841-21846	group	_	
96-13	21846-21847	,	_	
96-14	21848-21851	and	_	
96-15	21852-21859	between	_	
96-16	21860-21863	the	_	
96-17	21864-21873	impulsive	_	
96-18	21874-21879	group	_	
96-19	21880-21883	and	_	
96-20	21884-21887	the	_	
96-21	21888-21895	control	_	
96-22	21896-21903	patient	_	
96-23	21904-21909	group	_	
96-24	21909-21910	,	_	
96-25	21911-21914	the	_	
96-26	21915-21927	premeditated	_	
96-27	21928-21934	action	_	
96-28	21935-21940	group	_	
96-29	21941-21947	showed	_	
96-30	21948-21949	a	_	
96-31	21950-21963	significantly	_	
96-32	21964-21969	lower	_	
96-33	21970-21978	duration	_	
96-34	21979-21981	of	_	
96-35	21982-21991	education	_	
96-36	21992-21995	and	_	
96-37	21996-22002	higher	_	
96-38	22003-22009	scores	_	
96-39	22010-22012	of	_	
96-40	22013-22021	positive	_	
96-41	22022-22030	symptoms	_	
96-42	22031-22039	compared	_	
96-43	22040-22042	to	_	
96-44	22043-22046	the	_	
96-45	22047-22054	control	_	
96-46	22055-22062	patient	_	
96-47	22063-22068	group	_	
96-48	22068-22069	,	_	
96-49	22070-22075	while	_	
96-50	22076-22078	no	_	
96-51	22079-22090	significant	_	
96-52	22091-22102	differences	_	
96-53	22103-22107	were	_	
96-54	22108-22113	found	_	
96-55	22114-22116	in	_	
96-56	22117-22122	these	_	
96-57	22123-22132	variables	_	
96-58	22133-22140	between	_	
96-59	22141-22144	the	_	
96-60	22145-22154	impulsive	_	
96-61	22155-22160	group	_	
96-62	22161-22164	and	_	
96-63	22165-22168	the	_	
96-64	22169-22176	control	_	
96-65	22177-22184	patient	_	
96-66	22185-22190	group	_	
96-67	22190-22191	.	_	

#Text=There were also no significant differences in the other variables between the impulsive group and the control patient group.
97-1	22192-22197	There	_	
97-2	22198-22202	were	_	
97-3	22203-22207	also	_	
97-4	22208-22210	no	_	
97-5	22211-22222	significant	_	
97-6	22223-22234	differences	_	
97-7	22235-22237	in	_	
97-8	22238-22241	the	_	
97-9	22242-22247	other	_	
97-10	22248-22257	variables	_	
97-11	22258-22265	between	_	
97-12	22266-22269	the	_	
97-13	22270-22279	impulsive	_	
97-14	22280-22285	group	_	
97-15	22286-22289	and	_	
97-16	22290-22293	the	_	
97-17	22294-22301	control	_	
97-18	22302-22309	patient	_	
97-19	22310-22315	group	_	
97-20	22315-22316	.	_	

#Text=However, significant differences were found in terms of age at scan and scores of negative symptoms between the premeditated action group and the control patient group.
98-1	22317-22324	However	_	
98-2	22324-22325	,	_	
98-3	22326-22337	significant	_	
98-4	22338-22349	differences	_	
98-5	22350-22354	were	_	
98-6	22355-22360	found	_	
98-7	22361-22363	in	_	
98-8	22364-22369	terms	_	
98-9	22370-22372	of	_	
98-10	22373-22376	age	_	
98-11	22377-22379	at	_	
98-12	22380-22384	scan	_	
98-13	22385-22388	and	_	
98-14	22389-22395	scores	_	
98-15	22396-22398	of	_	
98-16	22399-22407	negative	_	
98-17	22408-22416	symptoms	_	
98-18	22417-22424	between	_	
98-19	22425-22428	the	_	
98-20	22429-22441	premeditated	_	
98-21	22442-22448	action	_	
98-22	22449-22454	group	_	
98-23	22455-22458	and	_	
98-24	22459-22462	the	_	
98-25	22463-22470	control	_	
98-26	22471-22478	patient	_	
98-27	22479-22484	group	_	
98-28	22484-22485	.	_	

#Text=Gray matter volume reduction in patients with a history of serious violence relative to control patients
#Text=
#Text=Cluster\tCluster-level p value (FWE-corrected)\tNumber of voxels\tArea\tPeak coordinatea\t \t\t\t\t\tx\ty\tz\t \tForensic group (n = 34) vs.
99-1	22487-22491	Gray	_	
99-2	22492-22498	matter	_	
99-3	22499-22505	volume	_	
99-4	22506-22515	reduction	_	
99-5	22516-22518	in	_	
99-6	22519-22527	patients	_	
99-7	22528-22532	with	_	
99-8	22533-22534	a	_	
99-9	22535-22542	history	_	
99-10	22543-22545	of	_	
99-11	22546-22553	serious	_	
99-12	22554-22562	violence	_	
99-13	22563-22571	relative	_	
99-14	22572-22574	to	_	
99-15	22575-22582	control	_	
99-16	22583-22591	patients	_	
99-17	22593-22600	Cluster	_	
99-18	22601-22614	Cluster-level	_	
99-19	22615-22616	p	_	
99-20	22617-22622	value	_	
99-21	22623-22624	(	_	
99-22	22624-22637	FWE-corrected	_	
99-23	22637-22638	)	_	
99-24	22639-22645	Number	_	
99-25	22646-22648	of	_	
99-26	22649-22655	voxels	_	
99-27	22656-22660	Area	_	
99-28	22661-22665	Peak	_	
99-29	22666-22677	coordinatea	_	
99-30	22684-22685	x	_	
99-31	22686-22687	y	_	
99-32	22688-22689	z	_	
99-33	22692-22700	Forensic	_	
99-34	22701-22706	group	_	
99-35	22707-22708	(	_	
99-36	22708-22709	n	_	
99-37	22709-22710	 	_	
99-38	22710-22711	=	_	
99-39	22711-22712	 	_	
99-40	22712-22714	34	_	
99-41	22714-22715	)	_	
99-42	22716-22718	vs	_	
99-43	22718-22719	.	_	

#Text=Control patient group (n = 23)\t \t For-1\t0.001\t3336\tRight ITG, Right TP, Right MTG\t44\t0\t-42\t \t\t\t\t\t46\t-6\t-50\t \t\t\t\t\t57\t-6\t-33\t \t For-2\t0.003\t2369\tRight PINS, Right AINS, Right VD\t38\t-6\t-16\t \t\t\t\t\t40\t3\t-9\t \t\t\t\t\t20\t-10\t-10\t \tForensic group excluded subjects with a history of substance abuse (n = 24) vs.
100-1	22720-22727	Control	_	
100-2	22728-22735	patient	_	
100-3	22736-22741	group	_	
100-4	22742-22743	(	_	
100-5	22743-22744	n	_	
100-6	22744-22745	 	_	
100-7	22745-22746	=	_	
100-8	22746-22747	 	_	
100-9	22747-22749	23	_	
100-10	22749-22750	)	_	
100-11	22754-22757	For	_	
100-12	22757-22758	-	_	
100-13	22758-22759	1	_	
100-14	22760-22765	0.001	_	
100-15	22766-22770	3336	_	
100-16	22771-22776	Right	_	
100-17	22777-22780	ITG	_	
100-18	22780-22781	,	_	
100-19	22782-22787	Right	_	
100-20	22788-22790	TP	_	
100-21	22790-22791	,	_	
100-22	22792-22797	Right	_	
100-23	22798-22801	MTG	_	
100-24	22802-22804	44	_	
100-25	22805-22806	0	_	
100-26	22807-22808	-	_	
100-27	22808-22810	42	_	
100-28	22817-22819	46	_	
100-29	22820-22821	-	_	
100-30	22821-22822	6	_	
100-31	22823-22824	-	_	
100-32	22824-22826	50	_	
100-33	22833-22835	57	_	
100-34	22836-22837	-	_	
100-35	22837-22838	6	_	
100-36	22839-22840	-	_	
100-37	22840-22842	33	_	
100-38	22846-22849	For	_	
100-39	22849-22850	-	_	
100-40	22850-22851	2	_	
100-41	22852-22857	0.003	_	
100-42	22858-22862	2369	_	
100-43	22863-22868	Right	_	
100-44	22869-22873	PINS	_	
100-45	22873-22874	,	_	
100-46	22875-22880	Right	_	
100-47	22881-22885	AINS	_	
100-48	22885-22886	,	_	
100-49	22887-22892	Right	_	
100-50	22893-22895	VD	_	
100-51	22896-22898	38	_	
100-52	22899-22900	-	_	
100-53	22900-22901	6	_	
100-54	22902-22903	-	_	
100-55	22903-22905	16	_	
100-56	22912-22914	40	_	
100-57	22915-22916	3	_	
100-58	22917-22918	-	_	
100-59	22918-22919	9	_	
100-60	22926-22928	20	_	
100-61	22929-22930	-	_	
100-62	22930-22932	10	_	
100-63	22933-22934	-	_	
100-64	22934-22936	10	_	
100-65	22939-22947	Forensic	_	
100-66	22948-22953	group	_	
100-67	22954-22962	excluded	_	
100-68	22963-22971	subjects	_	
100-69	22972-22976	with	_	
100-70	22977-22978	a	_	
100-71	22979-22986	history	_	
100-72	22987-22989	of	_	
100-73	22990-22999	substance	_	
100-74	23000-23005	abuse	_	
100-75	23006-23007	(	_	
100-76	23007-23008	n	_	
100-77	23008-23009	 	_	
100-78	23009-23010	=	_	
100-79	23010-23011	 	_	
100-80	23011-23013	24	_	
100-81	23013-23014	)	_	
100-82	23015-23017	vs	_	
100-83	23017-23018	.	_	

#Text=Control patient group (n = 23)\t \t For(noS)-1\t0.043\t1194\tRight ITG, Right TP\t45\t0\t-40\t \t\t\t\t\t48\t-6\t-50\t \t\t\t\t\t42\t9\t-42\t \t
#Text=
#Text=ITG inferior temporal gyrus, MTG middle temporal gyrus, TP temporal pole, AINS anterior insula, PINS posterior insula, VD ventral diencephalon
#Text=
#Text=aMNI space.
101-1	23019-23026	Control	_	
101-2	23027-23034	patient	_	
101-3	23035-23040	group	_	
101-4	23041-23042	(	_	
101-5	23042-23043	n	_	
101-6	23043-23044	 	_	
101-7	23044-23045	=	_	
101-8	23045-23046	 	_	
101-9	23046-23048	23	_	
101-10	23048-23049	)	_	
101-11	23053-23056	For	_	
101-12	23056-23057	(	_	
101-13	23057-23060	noS	_	
101-14	23060-23061	)	_	
101-15	23061-23062	-	_	
101-16	23062-23063	1	_	
101-17	23064-23069	0.043	_	
101-18	23070-23074	1194	_	
101-19	23075-23080	Right	_	
101-20	23081-23084	ITG	_	
101-21	23084-23085	,	_	
101-22	23086-23091	Right	_	
101-23	23092-23094	TP	_	
101-24	23095-23097	45	_	
101-25	23098-23099	0	_	
101-26	23100-23101	-	_	
101-27	23101-23103	40	_	
101-28	23110-23112	48	_	
101-29	23113-23114	-	_	
101-30	23114-23115	6	_	
101-31	23116-23117	-	_	
101-32	23117-23119	50	_	
101-33	23126-23128	42	_	
101-34	23129-23130	9	_	
101-35	23131-23132	-	_	
101-36	23132-23134	42	_	
101-37	23139-23142	ITG	_	
101-38	23143-23151	inferior	_	
101-39	23152-23160	temporal	_	
101-40	23161-23166	gyrus	_	
101-41	23166-23167	,	_	
101-42	23168-23171	MTG	_	
101-43	23172-23178	middle	_	
101-44	23179-23187	temporal	_	
101-45	23188-23193	gyrus	_	
101-46	23193-23194	,	_	
101-47	23195-23197	TP	_	
101-48	23198-23206	temporal	_	
101-49	23207-23211	pole	_	
101-50	23211-23212	,	_	
101-51	23213-23217	AINS	_	
101-52	23218-23226	anterior	_	
101-53	23227-23233	insula	_	
101-54	23233-23234	,	_	
101-55	23235-23239	PINS	_	
101-56	23240-23249	posterior	_	
101-57	23250-23256	insula	_	
101-58	23256-23257	,	_	
101-59	23258-23260	VD	_	
101-60	23261-23268	ventral	_	
101-61	23269-23281	diencephalon	_	
101-62	23283-23287	aMNI	_	
101-63	23288-23293	space	_	
101-64	23293-23294	.	_	

#Text=Top 3 separate (>8 mm apart) maxima within a cluster
#Text=
#Text=Brain regions with low gray matter volume in the forensic group.
102-1	23295-23298	Top	_	
102-2	23299-23300	3	_	
102-3	23301-23309	separate	_	
102-4	23310-23311	(	_	
102-5	23311-23312	>	_	
102-6	23312-23313	8	_	
102-7	23313-23314	 	_	
102-8	23314-23316	mm	_	
102-9	23317-23322	apart	_	
102-10	23322-23323	)	_	
102-11	23324-23330	maxima	_	
102-12	23331-23337	within	_	
102-13	23338-23339	a	_	
102-14	23340-23347	cluster	_	
102-15	23349-23354	Brain	_	
102-16	23355-23362	regions	_	
102-17	23363-23367	with	_	
102-18	23368-23371	low	_	
102-19	23372-23376	gray	_	
102-20	23377-23383	matter	_	
102-21	23384-23390	volume	_	
102-22	23391-23393	in	_	
102-23	23394-23397	the	_	
102-24	23398-23406	forensic	_	
102-25	23407-23412	group	_	
102-26	23412-23413	.	_	

#Text=The initial voxel threshold: uncorrected
#Text=p = 0.001, the cluster-level FWE correction, and a cluster-corrected p(FWE) < 0.05.
103-1	23414-23417	The	_	
103-2	23418-23425	initial	_	
103-3	23426-23431	voxel	_	
103-4	23432-23441	threshold	_	
103-5	23441-23442	:	_	
103-6	23443-23454	uncorrected	_	
103-7	23455-23456	p	_	
103-8	23456-23457	 	_	
103-9	23457-23458	=	_	
103-10	23458-23459	 	_	
103-11	23459-23464	0.001	_	
103-12	23464-23465	,	_	
103-13	23466-23469	the	_	
103-14	23470-23483	cluster-level	_	
103-15	23484-23487	FWE	_	
103-16	23488-23498	correction	_	
103-17	23498-23499	,	_	
103-18	23500-23503	and	_	
103-19	23504-23505	a	_	
103-20	23506-23523	cluster-corrected	_	
103-21	23524-23525	p	_	
103-22	23525-23526	(	_	
103-23	23526-23529	FWE	_	
103-24	23529-23530	)	_	
103-25	23530-23531	 	_	
103-26	23531-23532	<	_	
103-27	23532-23533	 	_	
103-28	23533-23537	0.05	_	
103-29	23537-23538	.	_	

#Text=Left column
#Text=: Low gray matter volume in the forensic group (
#Text=n = 34) compared with the control patient group (
#Text=n = 23).
104-1	23539-23543	Left	_	
104-2	23544-23550	column	_	
104-3	23551-23552	:	_	
104-4	23553-23556	Low	_	
104-5	23557-23561	gray	_	
104-6	23562-23568	matter	_	
104-7	23569-23575	volume	_	
104-8	23576-23578	in	_	
104-9	23579-23582	the	_	
104-10	23583-23591	forensic	_	
104-11	23592-23597	group	_	
104-12	23598-23599	(	_	
104-13	23600-23601	n	_	
104-14	23601-23602	 	_	
104-15	23602-23603	=	_	
104-16	23603-23604	 	_	
104-17	23604-23606	34	_	
104-18	23606-23607	)	_	
104-19	23608-23616	compared	_	
104-20	23617-23621	with	_	
104-21	23622-23625	the	_	
104-22	23626-23633	control	_	
104-23	23634-23641	patient	_	
104-24	23642-23647	group	_	
104-25	23648-23649	(	_	
104-26	23650-23651	n	_	
104-27	23651-23652	 	_	
104-28	23652-23653	=	_	
104-29	23653-23654	 	_	
104-30	23654-23656	23	_	
104-31	23656-23657	)	_	
104-32	23657-23658	.	_	

#Text=Cluster For-1 (Table 2
#Text=): The anterior part of the right inferior temporal gyrus expanded to the fusiform gyrus, the middle temporal gyrus, and the temporal pole.
105-1	23659-23666	Cluster	_	
105-2	23667-23670	For	_	
105-3	23670-23671	-	_	
105-4	23671-23672	1	_	
105-5	23673-23674	(	_	
105-6	23674-23679	Table	_	
105-7	23680-23681	2	_	
105-8	23682-23683	)	_	
105-9	23683-23684	:	_	
105-10	23685-23688	The	_	
105-11	23689-23697	anterior	_	
105-12	23698-23702	part	_	
105-13	23703-23705	of	_	
105-14	23706-23709	the	_	
105-15	23710-23715	right	_	
105-16	23716-23724	inferior	_	
105-17	23725-23733	temporal	_	
105-18	23734-23739	gyrus	_	
105-19	23740-23748	expanded	_	
105-20	23749-23751	to	_	
105-21	23752-23755	the	_	
105-22	23756-23764	fusiform	_	
105-23	23765-23770	gyrus	_	
105-24	23770-23771	,	_	
105-25	23772-23775	the	_	
105-26	23776-23782	middle	_	
105-27	23783-23791	temporal	_	
105-28	23792-23797	gyrus	_	
105-29	23797-23798	,	_	
105-30	23799-23802	and	_	
105-31	23803-23806	the	_	
105-32	23807-23815	temporal	_	
105-33	23816-23820	pole	_	
105-34	23820-23821	.	_	

#Text=Cluster For-2 (Table 2
#Text=): The right insula expanded to the ventral diencephalon.
106-1	23822-23829	Cluster	_	
106-2	23830-23833	For	_	
106-3	23833-23834	-	_	
106-4	23834-23835	2	_	
106-5	23836-23837	(	_	
106-6	23837-23842	Table	_	
106-7	23843-23844	2	_	
106-8	23845-23846	)	_	
106-9	23846-23847	:	_	
106-10	23848-23851	The	_	
106-11	23852-23857	right	_	
106-12	23858-23864	insula	_	
106-13	23865-23873	expanded	_	
106-14	23874-23876	to	_	
106-15	23877-23880	the	_	
106-16	23881-23888	ventral	_	
106-17	23889-23901	diencephalon	_	
106-18	23901-23902	.	_	

#Text=Right column
#Text=: Low gray matter volume in the forensic group not including subjects with a history of substance abuse (
#Text=n = 24) compared with the control patient group (
#Text=n = 23).
107-1	23903-23908	Right	_	
107-2	23909-23915	column	_	
107-3	23916-23917	:	_	
107-4	23918-23921	Low	_	
107-5	23922-23926	gray	_	
107-6	23927-23933	matter	_	
107-7	23934-23940	volume	_	
107-8	23941-23943	in	_	
107-9	23944-23947	the	_	
107-10	23948-23956	forensic	_	
107-11	23957-23962	group	_	
107-12	23963-23966	not	_	
107-13	23967-23976	including	_	
107-14	23977-23985	subjects	_	
107-15	23986-23990	with	_	
107-16	23991-23992	a	_	
107-17	23993-24000	history	_	
107-18	24001-24003	of	_	
107-19	24004-24013	substance	_	
107-20	24014-24019	abuse	_	
107-21	24020-24021	(	_	
107-22	24022-24023	n	_	
107-23	24023-24024	 	_	
107-24	24024-24025	=	_	
107-25	24025-24026	 	_	
107-26	24026-24028	24	_	
107-27	24028-24029	)	_	
107-28	24030-24038	compared	_	
107-29	24039-24043	with	_	
107-30	24044-24047	the	_	
107-31	24048-24055	control	_	
107-32	24056-24063	patient	_	
107-33	24064-24069	group	_	
107-34	24070-24071	(	_	
107-35	24072-24073	n	_	
107-36	24073-24074	 	_	
107-37	24074-24075	=	_	
107-38	24075-24076	 	_	
107-39	24076-24078	23	_	
107-40	24078-24079	)	_	
107-41	24079-24080	.	_	

#Text=Cluster For(noS)-1 (Table 2
#Text=): The anterior part of the right inferior temporal gyrus expanded to the temporal pole.
#Text=a Montage of coronal slices y = −27 to 24 (MNI space).
108-1	24081-24088	Cluster	_	
108-2	24089-24092	For	_	
108-3	24092-24093	(	_	
108-4	24093-24096	noS	_	
108-5	24096-24097	)	_	
108-6	24097-24098	-	_	
108-7	24098-24099	1	_	
108-8	24100-24101	(	_	
108-9	24101-24106	Table	_	
108-10	24107-24108	2	_	
108-11	24109-24110	)	_	
108-12	24110-24111	:	_	
108-13	24112-24115	The	_	
108-14	24116-24124	anterior	_	
108-15	24125-24129	part	_	
108-16	24130-24132	of	_	
108-17	24133-24136	the	_	
108-18	24137-24142	right	_	
108-19	24143-24151	inferior	_	
108-20	24152-24160	temporal	_	
108-21	24161-24166	gyrus	_	
108-22	24167-24175	expanded	_	
108-23	24176-24178	to	_	
108-24	24179-24182	the	_	
108-25	24183-24191	temporal	_	
108-26	24192-24196	pole	_	
108-27	24196-24197	.	_	
108-28	24198-24199	a	_	
108-29	24200-24207	Montage	_	
108-30	24208-24210	of	_	
108-31	24211-24218	coronal	_	
108-32	24219-24225	slices	_	
108-33	24226-24227	y	_	
108-34	24227-24228	 	_	
108-35	24228-24229	=	_	
108-36	24229-24230	 	_	
108-37	24230-24231	−	_	
108-38	24231-24233	27	_	
108-39	24234-24236	to	_	
108-40	24237-24239	24	_	
108-41	24240-24241	(	_	
108-42	24241-24244	MNI	_	
108-43	24245-24250	space	_	
108-44	24250-24251	)	_	
108-45	24251-24252	.	_	

#Text=The maps were overlaid on the images of a single subject provided in SPM12.
109-1	24253-24256	The	_	
109-2	24257-24261	maps	_	
109-3	24262-24266	were	_	
109-4	24267-24275	overlaid	_	
109-5	24276-24278	on	_	
109-6	24279-24282	the	_	
109-7	24283-24289	images	_	
109-8	24290-24292	of	_	
109-9	24293-24294	a	_	
109-10	24295-24301	single	_	
109-11	24302-24309	subject	_	
109-12	24310-24318	provided	_	
109-13	24319-24321	in	_	
109-14	24322-24327	SPM12	_	
109-15	24327-24328	.	_	

#Text=Right is right. b The maps rendered on the brain surface provided in SPM12
#Text=Statistical analysis showed that the forensic group had significantly lower GMV in the anterior part of the right inferior temporal gyrus expanded to the middle temporal gyrus, the temporal pole, and the fusiform gyrus (Table 2 cluster For-1, Fig. 1a, b left), as well as the right insula expanded to the ventral diencephalon (Table 2 cluster For-2, Fig. 1a left), compared to the control patient group.
110-1	24329-24334	Right	_	
110-2	24335-24337	is	_	
110-3	24338-24343	right	_	
110-4	24343-24344	.	_	
110-5	24345-24346	b	_	
110-6	24347-24350	The	_	
110-7	24351-24355	maps	_	
110-8	24356-24364	rendered	_	
110-9	24365-24367	on	_	
110-10	24368-24371	the	_	
110-11	24372-24377	brain	_	
110-12	24378-24385	surface	_	
110-13	24386-24394	provided	_	
110-14	24395-24397	in	_	
110-15	24398-24403	SPM12	_	
110-16	24404-24415	Statistical	_	
110-17	24416-24424	analysis	_	
110-18	24425-24431	showed	_	
110-19	24432-24436	that	_	
110-20	24437-24440	the	_	
110-21	24441-24449	forensic	_	
110-22	24450-24455	group	_	
110-23	24456-24459	had	_	
110-24	24460-24473	significantly	_	
110-25	24474-24479	lower	_	
110-26	24480-24483	GMV	_	
110-27	24484-24486	in	_	
110-28	24487-24490	the	_	
110-29	24491-24499	anterior	_	
110-30	24500-24504	part	_	
110-31	24505-24507	of	_	
110-32	24508-24511	the	_	
110-33	24512-24517	right	_	
110-34	24518-24526	inferior	_	
110-35	24527-24535	temporal	_	
110-36	24536-24541	gyrus	_	
110-37	24542-24550	expanded	_	
110-38	24551-24553	to	_	
110-39	24554-24557	the	_	
110-40	24558-24564	middle	_	
110-41	24565-24573	temporal	_	
110-42	24574-24579	gyrus	_	
110-43	24579-24580	,	_	
110-44	24581-24584	the	_	
110-45	24585-24593	temporal	_	
110-46	24594-24598	pole	_	
110-47	24598-24599	,	_	
110-48	24600-24603	and	_	
110-49	24604-24607	the	_	
110-50	24608-24616	fusiform	_	
110-51	24617-24622	gyrus	_	
110-52	24623-24624	(	_	
110-53	24624-24629	Table	_	
110-54	24630-24631	2	_	
110-55	24632-24639	cluster	_	
110-56	24640-24643	For	_	
110-57	24643-24644	-	_	
110-58	24644-24645	1	_	
110-59	24645-24646	,	_	
110-60	24647-24650	Fig	_	
110-61	24650-24651	.	_	
110-62	24652-24654	1a	_	
110-63	24654-24655	,	_	
110-64	24656-24657	b	_	
110-65	24658-24662	left	_	
110-66	24662-24663	)	_	
110-67	24663-24664	,	_	
110-68	24665-24667	as	_	
110-69	24668-24672	well	_	
110-70	24673-24675	as	_	
110-71	24676-24679	the	_	
110-72	24680-24685	right	_	
110-73	24686-24692	insula	_	
110-74	24693-24701	expanded	_	
110-75	24702-24704	to	_	
110-76	24705-24708	the	_	
110-77	24709-24716	ventral	_	
110-78	24717-24729	diencephalon	_	
110-79	24730-24731	(	_	
110-80	24731-24736	Table	_	
110-81	24737-24738	2	_	
110-82	24739-24746	cluster	_	
110-83	24747-24750	For	_	
110-84	24750-24751	-	_	
110-85	24751-24752	2	_	
110-86	24752-24753	,	_	
110-87	24754-24757	Fig	_	
110-88	24757-24758	.	_	
110-89	24759-24761	1a	_	
110-90	24762-24766	left	_	
110-91	24766-24767	)	_	
110-92	24767-24768	,	_	
110-93	24769-24777	compared	_	
110-94	24778-24780	to	_	
110-95	24781-24784	the	_	
110-96	24785-24792	control	_	
110-97	24793-24800	patient	_	
110-98	24801-24806	group	_	
110-99	24806-24807	.	_	

#Text=After excluding cases with a history of substance abuse, statistical significance remained for the right inferior temporal area expanded to the right temporal pole (Table 2 cluster For(noS)-1, Fig. 1a, b right).
111-1	24808-24813	After	_	
111-2	24814-24823	excluding	_	
111-3	24824-24829	cases	_	
111-4	24830-24834	with	_	
111-5	24835-24836	a	_	
111-6	24837-24844	history	_	
111-7	24845-24847	of	_	
111-8	24848-24857	substance	_	
111-9	24858-24863	abuse	_	
111-10	24863-24864	,	_	
111-11	24865-24876	statistical	_	
111-12	24877-24889	significance	_	
111-13	24890-24898	remained	_	
111-14	24899-24902	for	_	
111-15	24903-24906	the	_	
111-16	24907-24912	right	_	
111-17	24913-24921	inferior	_	
111-18	24922-24930	temporal	_	
111-19	24931-24935	area	_	
111-20	24936-24944	expanded	_	
111-21	24945-24947	to	_	
111-22	24948-24951	the	_	
111-23	24952-24957	right	_	
111-24	24958-24966	temporal	_	
111-25	24967-24971	pole	_	
111-26	24972-24973	(	_	
111-27	24973-24978	Table	_	
111-28	24979-24980	2	_	
111-29	24981-24988	cluster	_	
111-30	24989-24992	For	_	
111-31	24992-24993	(	_	
111-32	24993-24996	noS	_	
111-33	24996-24997	)	_	
111-34	24997-24998	-	_	
111-35	24998-24999	1	_	
111-36	24999-25000	,	_	
111-37	25001-25004	Fig	_	
111-38	25004-25005	.	_	
111-39	25006-25008	1a	_	
111-40	25008-25009	,	_	
111-41	25010-25011	b	_	
111-42	25012-25017	right	_	
111-43	25017-25018	)	_	
111-44	25018-25019	.	_	

#Text=Gray matter volume redunction in the impulsive group and the premeditated action group, compared with the control group
#Text=Cluster\tCluster-level p value (FWE-corrected)\tNumber of voxels\tArea\tPeak coordinatea\t \t\t\t\t\tx\ty\tz\t \tPremeditated action group (n = 15) vs control group (n = 23)\t \t Prem-1\t<0.001\t6836\tRight VD, Right AINS, Right PINS\t20\t-10\t-10\t \t\t\t\t\t42\t4\t-9\t \t\t\t\t\t38\t-4\t-16\t \t Prem-2\t0.009\t1789\tLeft PP, Left PINS, Left AINS\t-45\t-8\t-4\t \t\t\t\t\t-42\t-2\t-9\t \t\t\t\t\t-33\t-6\t-22\t \t Prem-3\t0.005\t2109\tLeft PCu, Right PCu, Left PCgG\t0\t-50\t36\t \t\t\t\t\t6\t-62\t22\t \t\t\t\t\t-9\t-44\t28\t \tImpulsive group (n = 19) vs control group (n = 23)\t\t \t Imp-1\t0.02\t1456\tRight ITG, Right TP\t45\t0\t-40\t \t\t\t\t\t46\t-6\t-50\t \t\t\t\t\t42\t8\t-44\t \t
#Text=
#Text=ITG inferior temporal gyrus, TP temporal pole, VD ventral diencephalon, AINS anterior insula, PINS posterior insula, PP planum polare, PCu precuneus, PCgG posterior cingulate gyrus
#Text=
#Text=aMNI space.
112-1	25022-25026	Gray	_	
112-2	25027-25033	matter	_	
112-3	25034-25040	volume	_	
112-4	25041-25051	redunction	_	
112-5	25052-25054	in	_	
112-6	25055-25058	the	_	
112-7	25059-25068	impulsive	_	
112-8	25069-25074	group	_	
112-9	25075-25078	and	_	
112-10	25079-25082	the	_	
112-11	25083-25095	premeditated	_	
112-12	25096-25102	action	_	
112-13	25103-25108	group	_	
112-14	25108-25109	,	_	
112-15	25110-25118	compared	_	
112-16	25119-25123	with	_	
112-17	25124-25127	the	_	
112-18	25128-25135	control	_	
112-19	25136-25141	group	_	
112-20	25142-25149	Cluster	_	
112-21	25150-25163	Cluster-level	_	
112-22	25164-25165	p	_	
112-23	25166-25171	value	_	
112-24	25172-25173	(	_	
112-25	25173-25186	FWE-corrected	_	
112-26	25186-25187	)	_	
112-27	25188-25194	Number	_	
112-28	25195-25197	of	_	
112-29	25198-25204	voxels	_	
112-30	25205-25209	Area	_	
112-31	25210-25214	Peak	_	
112-32	25215-25226	coordinatea	_	
112-33	25233-25234	x	_	
112-34	25235-25236	y	_	
112-35	25237-25238	z	_	
112-36	25241-25253	Premeditated	_	
112-37	25254-25260	action	_	
112-38	25261-25266	group	_	
112-39	25267-25268	(	_	
112-40	25268-25269	n	_	
112-41	25269-25270	 	_	
112-42	25270-25271	=	_	
112-43	25271-25272	 	_	
112-44	25272-25274	15	_	
112-45	25274-25275	)	_	
112-46	25276-25278	vs	_	
112-47	25279-25286	control	_	
112-48	25287-25292	group	_	
112-49	25293-25294	(	_	
112-50	25294-25295	n	_	
112-51	25295-25296	 	_	
112-52	25296-25297	=	_	
112-53	25297-25298	 	_	
112-54	25298-25300	23	_	
112-55	25300-25301	)	_	
112-56	25305-25309	Prem	_	
112-57	25309-25310	-	_	
112-58	25310-25311	1	_	
112-59	25312-25313	<	_	
112-60	25313-25318	0.001	_	
112-61	25319-25323	6836	_	
112-62	25324-25329	Right	_	
112-63	25330-25332	VD	_	
112-64	25332-25333	,	_	
112-65	25334-25339	Right	_	
112-66	25340-25344	AINS	_	
112-67	25344-25345	,	_	
112-68	25346-25351	Right	_	
112-69	25352-25356	PINS	_	
112-70	25357-25359	20	_	
112-71	25360-25361	-	_	
112-72	25361-25363	10	_	
112-73	25364-25365	-	_	
112-74	25365-25367	10	_	
112-75	25374-25376	42	_	
112-76	25377-25378	4	_	
112-77	25379-25380	-	_	
112-78	25380-25381	9	_	
112-79	25388-25390	38	_	
112-80	25391-25392	-	_	
112-81	25392-25393	4	_	
112-82	25394-25395	-	_	
112-83	25395-25397	16	_	
112-84	25401-25405	Prem	_	
112-85	25405-25406	-	_	
112-86	25406-25407	2	_	
112-87	25408-25413	0.009	_	
112-88	25414-25418	1789	_	
112-89	25419-25423	Left	_	
112-90	25424-25426	PP	_	
112-91	25426-25427	,	_	
112-92	25428-25432	Left	_	
112-93	25433-25437	PINS	_	
112-94	25437-25438	,	_	
112-95	25439-25443	Left	_	
112-96	25444-25448	AINS	_	
112-97	25449-25450	-	_	
112-98	25450-25452	45	_	
112-99	25453-25454	-	_	
112-100	25454-25455	8	_	
112-101	25456-25457	-	_	
112-102	25457-25458	4	_	
112-103	25465-25466	-	_	
112-104	25466-25468	42	_	
112-105	25469-25470	-	_	
112-106	25470-25471	2	_	
112-107	25472-25473	-	_	
112-108	25473-25474	9	_	
112-109	25481-25482	-	_	
112-110	25482-25484	33	_	
112-111	25485-25486	-	_	
112-112	25486-25487	6	_	
112-113	25488-25489	-	_	
112-114	25489-25491	22	_	
112-115	25495-25499	Prem	_	
112-116	25499-25500	-	_	
112-117	25500-25501	3	_	
112-118	25502-25507	0.005	_	
112-119	25508-25512	2109	_	
112-120	25513-25517	Left	_	
112-121	25518-25521	PCu	_	
112-122	25521-25522	,	_	
112-123	25523-25528	Right	_	
112-124	25529-25532	PCu	_	
112-125	25532-25533	,	_	
112-126	25534-25538	Left	_	
112-127	25539-25543	PCgG	_	
112-128	25544-25545	0	_	
112-129	25546-25547	-	_	
112-130	25547-25549	50	_	
112-131	25550-25552	36	_	
112-132	25559-25560	6	_	
112-133	25561-25562	-	_	
112-134	25562-25564	62	_	
112-135	25565-25567	22	_	
112-136	25574-25575	-	_	
112-137	25575-25576	9	_	
112-138	25577-25578	-	_	
112-139	25578-25580	44	_	
112-140	25581-25583	28	_	
112-141	25586-25595	Impulsive	_	
112-142	25596-25601	group	_	
112-143	25602-25603	(	_	
112-144	25603-25604	n	_	
112-145	25604-25605	 	_	
112-146	25605-25606	=	_	
112-147	25606-25607	 	_	
112-148	25607-25609	19	_	
112-149	25609-25610	)	_	
112-150	25611-25613	vs	_	
112-151	25614-25621	control	_	
112-152	25622-25627	group	_	
112-153	25628-25629	(	_	
112-154	25629-25630	n	_	
112-155	25630-25631	 	_	
112-156	25631-25632	=	_	
112-157	25632-25633	 	_	
112-158	25633-25635	23	_	
112-159	25635-25636	)	_	
112-160	25641-25644	Imp	_	
112-161	25644-25645	-	_	
112-162	25645-25646	1	_	
112-163	25647-25651	0.02	_	
112-164	25652-25656	1456	_	
112-165	25657-25662	Right	_	
112-166	25663-25666	ITG	_	
112-167	25666-25667	,	_	
112-168	25668-25673	Right	_	
112-169	25674-25676	TP	_	
112-170	25677-25679	45	_	
112-171	25680-25681	0	_	
112-172	25682-25683	-	_	
112-173	25683-25685	40	_	
112-174	25692-25694	46	_	
112-175	25695-25696	-	_	
112-176	25696-25697	6	_	
112-177	25698-25699	-	_	
112-178	25699-25701	50	_	
112-179	25708-25710	42	_	
112-180	25711-25712	8	_	
112-181	25713-25714	-	_	
112-182	25714-25716	44	_	
112-183	25721-25724	ITG	_	
112-184	25725-25733	inferior	_	
112-185	25734-25742	temporal	_	
112-186	25743-25748	gyrus	_	
112-187	25748-25749	,	_	
112-188	25750-25752	TP	_	
112-189	25753-25761	temporal	_	
112-190	25762-25766	pole	_	
112-191	25766-25767	,	_	
112-192	25768-25770	VD	_	
112-193	25771-25778	ventral	_	
112-194	25779-25791	diencephalon	_	
112-195	25791-25792	,	_	
112-196	25793-25797	AINS	_	
112-197	25798-25806	anterior	_	
112-198	25807-25813	insula	_	
112-199	25813-25814	,	_	
112-200	25815-25819	PINS	_	
112-201	25820-25829	posterior	_	
112-202	25830-25836	insula	_	
112-203	25836-25837	,	_	
112-204	25838-25840	PP	_	
112-205	25841-25847	planum	_	
112-206	25848-25854	polare	_	
112-207	25854-25855	,	_	
112-208	25856-25859	PCu	_	
112-209	25860-25869	precuneus	_	
112-210	25869-25870	,	_	
112-211	25871-25875	PCgG	_	
112-212	25876-25885	posterior	_	
112-213	25886-25895	cingulate	_	
112-214	25896-25901	gyrus	_	
112-215	25903-25907	aMNI	_	
112-216	25908-25913	space	_	
112-217	25913-25914	.	_	

#Text=Top 3 separate (>8 mm apart) maxima within a cluster
#Text=
#Text=Brain regions with low gray matter volume in the premeditated action group.
113-1	25915-25918	Top	_	
113-2	25919-25920	3	_	
113-3	25921-25929	separate	_	
113-4	25930-25931	(	_	
113-5	25931-25932	>	_	
113-6	25932-25933	8	_	
113-7	25933-25934	 	_	
113-8	25934-25936	mm	_	
113-9	25937-25942	apart	_	
113-10	25942-25943	)	_	
113-11	25944-25950	maxima	_	
113-12	25951-25957	within	_	
113-13	25958-25959	a	_	
113-14	25960-25967	cluster	_	
113-15	25969-25974	Brain	_	
113-16	25975-25982	regions	_	
113-17	25983-25987	with	_	
113-18	25988-25991	low	_	
113-19	25992-25996	gray	_	
113-20	25997-26003	matter	_	
113-21	26004-26010	volume	_	
113-22	26011-26013	in	_	
113-23	26014-26017	the	_	
113-24	26018-26030	premeditated	_	
113-25	26031-26037	action	_	
113-26	26038-26043	group	_	
113-27	26043-26044	.	_	

#Text=The initial voxel threshold: uncorrected
#Text=p = 0.001, the cluster-level FWE correction, and a cluster-corrected p(FWE) < 0.05.
114-1	26045-26048	The	_	
114-2	26049-26056	initial	_	
114-3	26057-26062	voxel	_	
114-4	26063-26072	threshold	_	
114-5	26072-26073	:	_	
114-6	26074-26085	uncorrected	_	
114-7	26086-26087	p	_	
114-8	26087-26088	 	_	
114-9	26088-26089	=	_	
114-10	26089-26090	 	_	
114-11	26090-26095	0.001	_	
114-12	26095-26096	,	_	
114-13	26097-26100	the	_	
114-14	26101-26114	cluster-level	_	
114-15	26115-26118	FWE	_	
114-16	26119-26129	correction	_	
114-17	26129-26130	,	_	
114-18	26131-26134	and	_	
114-19	26135-26136	a	_	
114-20	26137-26154	cluster-corrected	_	
114-21	26155-26156	p	_	
114-22	26156-26157	(	_	
114-23	26157-26160	FWE	_	
114-24	26160-26161	)	_	
114-25	26161-26162	 	_	
114-26	26162-26163	<	_	
114-27	26163-26164	 	_	
114-28	26164-26168	0.05	_	
114-29	26168-26169	.	_	

#Text=Left: Montage of coronal slices y = −18 to 24 (MNI space).
115-1	26170-26174	Left	_	
115-2	26174-26175	:	_	
115-3	26176-26183	Montage	_	
115-4	26184-26186	of	_	
115-5	26187-26194	coronal	_	
115-6	26195-26201	slices	_	
115-7	26202-26203	y	_	
115-8	26203-26204	 	_	
115-9	26204-26205	=	_	
115-10	26205-26206	 	_	
115-11	26206-26207	−	_	
115-12	26207-26209	18	_	
115-13	26210-26212	to	_	
115-14	26213-26215	24	_	
115-15	26216-26217	(	_	
115-16	26217-26220	MNI	_	
115-17	26221-26226	space	_	
115-18	26226-26227	)	_	
115-19	26227-26228	.	_	

#Text=Right: Montage of sagittal slices x = −12 to 14 (MNI space).
116-1	26229-26234	Right	_	
116-2	26234-26235	:	_	
116-3	26236-26243	Montage	_	
116-4	26244-26246	of	_	
116-5	26247-26255	sagittal	_	
116-6	26256-26262	slices	_	
116-7	26263-26264	x	_	
116-8	26264-26265	 	_	
116-9	26265-26266	=	_	
116-10	26266-26267	 	_	
116-11	26267-26268	−	_	
116-12	26268-26270	12	_	
116-13	26271-26273	to	_	
116-14	26274-26276	14	_	
116-15	26277-26278	(	_	
116-16	26278-26281	MNI	_	
116-17	26282-26287	space	_	
116-18	26287-26288	)	_	
116-19	26288-26289	.	_	

#Text=The maps were overlaid on the images of a single subject provided in SPM12.
117-1	26290-26293	The	_	
117-2	26294-26298	maps	_	
117-3	26299-26303	were	_	
117-4	26304-26312	overlaid	_	
117-5	26313-26315	on	_	
117-6	26316-26319	the	_	
117-7	26320-26326	images	_	
117-8	26327-26329	of	_	
117-9	26330-26331	a	_	
117-10	26332-26338	single	_	
117-11	26339-26346	subject	_	
117-12	26347-26355	provided	_	
117-13	26356-26358	in	_	
117-14	26359-26364	SPM12	_	
117-15	26364-26365	.	_	

#Text=Cluster Prem-1 (Left, Table 3
#Text=): The area including the right temporal pole, the inferior temporal gyrus, the fusiform gyrus, insula, and the ventral diencephalon.
118-1	26366-26373	Cluster	_	
118-2	26374-26378	Prem	_	
118-3	26378-26379	-	_	
118-4	26379-26380	1	_	
118-5	26381-26382	(	_	
118-6	26382-26386	Left	_	
118-7	26386-26387	,	_	
118-8	26388-26393	Table	_	
118-9	26394-26395	3	_	
118-10	26396-26397	)	_	
118-11	26397-26398	:	_	
118-12	26399-26402	The	_	
118-13	26403-26407	area	_	
118-14	26408-26417	including	_	
118-15	26418-26421	the	_	
118-16	26422-26427	right	_	
118-17	26428-26436	temporal	_	
118-18	26437-26441	pole	_	
118-19	26441-26442	,	_	
118-20	26443-26446	the	_	
118-21	26447-26455	inferior	_	
118-22	26456-26464	temporal	_	
118-23	26465-26470	gyrus	_	
118-24	26470-26471	,	_	
118-25	26472-26475	the	_	
118-26	26476-26484	fusiform	_	
118-27	26485-26490	gyrus	_	
118-28	26490-26491	,	_	
118-29	26492-26498	insula	_	
118-30	26498-26499	,	_	
118-31	26500-26503	and	_	
118-32	26504-26507	the	_	
118-33	26508-26515	ventral	_	
118-34	26516-26528	diencephalon	_	
118-35	26528-26529	.	_	

#Text=Cluster Prem-2 (Left, Table 3
#Text=): The left planum polare and insula.
119-1	26530-26537	Cluster	_	
119-2	26538-26542	Prem	_	
119-3	26542-26543	-	_	
119-4	26543-26544	2	_	
119-5	26545-26546	(	_	
119-6	26546-26550	Left	_	
119-7	26550-26551	,	_	
119-8	26552-26557	Table	_	
119-9	26558-26559	3	_	
119-10	26560-26561	)	_	
119-11	26561-26562	:	_	
119-12	26563-26566	The	_	
119-13	26567-26571	left	_	
119-14	26572-26578	planum	_	
119-15	26579-26585	polare	_	
119-16	26586-26589	and	_	
119-17	26590-26596	insula	_	
119-18	26596-26597	.	_	

#Text=Cluster Prem-3 (Right, Table 3
#Text=): Bilateral precuneus and posterior cingulate gyrus
#Text=
#Text=
#Text=Brain regions of low gray matter volume in the impulsive group.
120-1	26598-26605	Cluster	_	
120-2	26606-26610	Prem	_	
120-3	26610-26611	-	_	
120-4	26611-26612	3	_	
120-5	26613-26614	(	_	
120-6	26614-26619	Right	_	
120-7	26619-26620	,	_	
120-8	26621-26626	Table	_	
120-9	26627-26628	3	_	
120-10	26629-26630	)	_	
120-11	26630-26631	:	_	
120-12	26632-26641	Bilateral	_	
120-13	26642-26651	precuneus	_	
120-14	26652-26655	and	_	
120-15	26656-26665	posterior	_	
120-16	26666-26675	cingulate	_	
120-17	26676-26681	gyrus	_	
120-18	26684-26689	Brain	_	
120-19	26690-26697	regions	_	
120-20	26698-26700	of	_	
120-21	26701-26704	low	_	
120-22	26705-26709	gray	_	
120-23	26710-26716	matter	_	
120-24	26717-26723	volume	_	
120-25	26724-26726	in	_	
120-26	26727-26730	the	_	
120-27	26731-26740	impulsive	_	
120-28	26741-26746	group	_	
120-29	26746-26747	.	_	

#Text=The initial voxel threshold: uncorrected
#Text=p = 0.001, the cluster-level FWE correction, and a cluster-corrected p(FWE) < 0.05.
121-1	26748-26751	The	_	
121-2	26752-26759	initial	_	
121-3	26760-26765	voxel	_	
121-4	26766-26775	threshold	_	
121-5	26775-26776	:	_	
121-6	26777-26788	uncorrected	_	
121-7	26789-26790	p	_	
121-8	26790-26791	 	_	
121-9	26791-26792	=	_	
121-10	26792-26793	 	_	
121-11	26793-26798	0.001	_	
121-12	26798-26799	,	_	
121-13	26800-26803	the	_	
121-14	26804-26817	cluster-level	_	
121-15	26818-26821	FWE	_	
121-16	26822-26832	correction	_	
121-17	26832-26833	,	_	
121-18	26834-26837	and	_	
121-19	26838-26839	a	_	
121-20	26840-26857	cluster-corrected	_	
121-21	26858-26859	p	_	
121-22	26859-26860	(	_	
121-23	26860-26863	FWE	_	
121-24	26863-26864	)	_	
121-25	26864-26865	 	_	
121-26	26865-26866	<	_	
121-27	26866-26867	 	_	
121-28	26867-26871	0.05	_	
121-29	26871-26872	.	_	

#Text=Montage of coronal slices y = −18 to 24 (MNI space).
122-1	26873-26880	Montage	_	
122-2	26881-26883	of	_	
122-3	26884-26891	coronal	_	
122-4	26892-26898	slices	_	
122-5	26899-26900	y	_	
122-6	26900-26901	 	_	
122-7	26901-26902	=	_	
122-8	26902-26903	 	_	
122-9	26903-26904	−	_	
122-10	26904-26906	18	_	
122-11	26907-26909	to	_	
122-12	26910-26912	24	_	
122-13	26913-26914	(	_	
122-14	26914-26917	MNI	_	
122-15	26918-26923	space	_	
122-16	26923-26924	)	_	
122-17	26924-26925	.	_	

#Text=The maps were overlaid on the images of a single subject provided in SPM12
#Text=
#Text=Cluster Imp-1 (Table 3): The right inferior temporal gyrus expanded to the temporal pole
#Text=The premeditated action group showed significantly lower GMV in the wide area including the right temporal pole, the inferior temporal gyrus, the fusiform gyrus, insula, the ventral diencephalon (Table 3 cluster Prem-1, Fig. 2 left), the left planum polare and insula (Table 3 cluster Prem-2, Fig. 2 left), and the bilateral precuneus and posterior cingulate gyrus (Table 3 cluster Prem-3, Fig. 2 right) compared to the control patient group.
123-1	26926-26929	The	_	
123-2	26930-26934	maps	_	
123-3	26935-26939	were	_	
123-4	26940-26948	overlaid	_	
123-5	26949-26951	on	_	
123-6	26952-26955	the	_	
123-7	26956-26962	images	_	
123-8	26963-26965	of	_	
123-9	26966-26967	a	_	
123-10	26968-26974	single	_	
123-11	26975-26982	subject	_	
123-12	26983-26991	provided	_	
123-13	26992-26994	in	_	
123-14	26995-27000	SPM12	_	
123-15	27002-27009	Cluster	_	
123-16	27010-27013	Imp	_	
123-17	27013-27014	-	_	
123-18	27014-27015	1	_	
123-19	27016-27017	(	_	
123-20	27017-27022	Table	_	
123-21	27023-27024	3	_	
123-22	27024-27025	)	_	
123-23	27025-27026	:	_	
123-24	27027-27030	The	_	
123-25	27031-27036	right	_	
123-26	27037-27045	inferior	_	
123-27	27046-27054	temporal	_	
123-28	27055-27060	gyrus	_	
123-29	27061-27069	expanded	_	
123-30	27070-27072	to	_	
123-31	27073-27076	the	_	
123-32	27077-27085	temporal	_	
123-33	27086-27090	pole	_	
123-34	27091-27094	The	_	
123-35	27095-27107	premeditated	_	
123-36	27108-27114	action	_	
123-37	27115-27120	group	_	
123-38	27121-27127	showed	_	
123-39	27128-27141	significantly	_	
123-40	27142-27147	lower	_	
123-41	27148-27151	GMV	_	
123-42	27152-27154	in	_	
123-43	27155-27158	the	_	
123-44	27159-27163	wide	_	
123-45	27164-27168	area	_	
123-46	27169-27178	including	_	
123-47	27179-27182	the	_	
123-48	27183-27188	right	_	
123-49	27189-27197	temporal	_	
123-50	27198-27202	pole	_	
123-51	27202-27203	,	_	
123-52	27204-27207	the	_	
123-53	27208-27216	inferior	_	
123-54	27217-27225	temporal	_	
123-55	27226-27231	gyrus	_	
123-56	27231-27232	,	_	
123-57	27233-27236	the	_	
123-58	27237-27245	fusiform	_	
123-59	27246-27251	gyrus	_	
123-60	27251-27252	,	_	
123-61	27253-27259	insula	_	
123-62	27259-27260	,	_	
123-63	27261-27264	the	_	
123-64	27265-27272	ventral	_	
123-65	27273-27285	diencephalon	_	
123-66	27286-27287	(	_	
123-67	27287-27292	Table	_	
123-68	27293-27294	3	_	
123-69	27295-27302	cluster	_	
123-70	27303-27307	Prem	_	
123-71	27307-27308	-	_	
123-72	27308-27309	1	_	
123-73	27309-27310	,	_	
123-74	27311-27314	Fig	_	
123-75	27314-27315	.	_	
123-76	27316-27317	2	_	
123-77	27318-27322	left	_	
123-78	27322-27323	)	_	
123-79	27323-27324	,	_	
123-80	27325-27328	the	_	
123-81	27329-27333	left	_	
123-82	27334-27340	planum	_	
123-83	27341-27347	polare	_	
123-84	27348-27351	and	_	
123-85	27352-27358	insula	_	
123-86	27359-27360	(	_	
123-87	27360-27365	Table	_	
123-88	27366-27367	3	_	
123-89	27368-27375	cluster	_	
123-90	27376-27380	Prem	_	
123-91	27380-27381	-	_	
123-92	27381-27382	2	_	
123-93	27382-27383	,	_	
123-94	27384-27387	Fig	_	
123-95	27387-27388	.	_	
123-96	27389-27390	2	_	
123-97	27391-27395	left	_	
123-98	27395-27396	)	_	
123-99	27396-27397	,	_	
123-100	27398-27401	and	_	
123-101	27402-27405	the	_	
123-102	27406-27415	bilateral	_	
123-103	27416-27425	precuneus	_	
123-104	27426-27429	and	_	
123-105	27430-27439	posterior	_	
123-106	27440-27449	cingulate	_	
123-107	27450-27455	gyrus	_	
123-108	27456-27457	(	_	
123-109	27457-27462	Table	_	
123-110	27463-27464	3	_	
123-111	27465-27472	cluster	_	
123-112	27473-27477	Prem	_	
123-113	27477-27478	-	_	
123-114	27478-27479	3	_	
123-115	27479-27480	,	_	
123-116	27481-27484	Fig	_	
123-117	27484-27485	.	_	
123-118	27486-27487	2	_	
123-119	27488-27493	right	_	
123-120	27493-27494	)	_	
123-121	27495-27503	compared	_	
123-122	27504-27506	to	_	
123-123	27507-27510	the	_	
123-124	27511-27518	control	_	
123-125	27519-27526	patient	_	
123-126	27527-27532	group	_	
123-127	27532-27533	.	_	

#Text=The impulsive group showed significantly lower GMV only in the right inferior temporal area expanded to the right temporal pole compared to the control patient group (Table 3 cluster Imp-1, Fig. 3).
124-1	27534-27537	The	_	
124-2	27538-27547	impulsive	_	
124-3	27548-27553	group	_	
124-4	27554-27560	showed	_	
124-5	27561-27574	significantly	_	
124-6	27575-27580	lower	_	
124-7	27581-27584	GMV	_	
124-8	27585-27589	only	_	
124-9	27590-27592	in	_	
124-10	27593-27596	the	_	
124-11	27597-27602	right	_	
124-12	27603-27611	inferior	_	
124-13	27612-27620	temporal	_	
124-14	27621-27625	area	_	
124-15	27626-27634	expanded	_	
124-16	27635-27637	to	_	
124-17	27638-27641	the	_	
124-18	27642-27647	right	_	
124-19	27648-27656	temporal	_	
124-20	27657-27661	pole	_	
124-21	27662-27670	compared	_	
124-22	27671-27673	to	_	
124-23	27674-27677	the	_	
124-24	27678-27685	control	_	
124-25	27686-27693	patient	_	
124-26	27694-27699	group	_	
124-27	27700-27701	(	_	
124-28	27701-27706	Table	_	
124-29	27707-27708	3	_	
124-30	27709-27716	cluster	_	
124-31	27717-27720	Imp	_	
124-32	27720-27721	-	_	
124-33	27721-27722	1	_	
124-34	27722-27723	,	_	
124-35	27724-27727	Fig	_	
124-36	27727-27728	.	_	
124-37	27729-27730	3	_	
124-38	27730-27731	)	_	
124-39	27731-27732	.	_	

#Text=Discussion
#Text=In this study, GMV was compared between patients with schizophrenia and a history of serious violence and patients with schizophrenia and no history of violent behaviors.
125-1	27736-27746	Discussion	_	
125-2	27747-27749	In	_	
125-3	27750-27754	this	_	
125-4	27755-27760	study	_	
125-5	27760-27761	,	_	
125-6	27762-27765	GMV	_	
125-7	27766-27769	was	_	
125-8	27770-27778	compared	_	
125-9	27779-27786	between	_	
125-10	27787-27795	patients	_	
125-11	27796-27800	with	_	
125-12	27801-27814	schizophrenia	_	
125-13	27815-27818	and	_	
125-14	27819-27820	a	_	
125-15	27821-27828	history	_	
125-16	27829-27831	of	_	
125-17	27832-27839	serious	_	
125-18	27840-27848	violence	_	
125-19	27849-27852	and	_	
125-20	27853-27861	patients	_	
125-21	27862-27866	with	_	
125-22	27867-27880	schizophrenia	_	
125-23	27881-27884	and	_	
125-24	27885-27887	no	_	
125-25	27888-27895	history	_	
125-26	27896-27898	of	_	
125-27	27899-27906	violent	_	
125-28	27907-27916	behaviors	_	
125-29	27916-27917	.	_	

#Text=Patients with a history of serious violence showed lower GMV in the right inferior temporal area (the anterior part of the right inferior temporal gyrus expanded to the fusiform gyrus, the middle temporal gyrus, and the temporal pole) and the right insular area (the right insula expanded to the ventral diencephalon) than those without a history of violence after controlling for lower years of education and higher positive symptom scores.
126-1	27918-27926	Patients	_	
126-2	27927-27931	with	_	
126-3	27932-27933	a	_	
126-4	27934-27941	history	_	
126-5	27942-27944	of	_	
126-6	27945-27952	serious	_	
126-7	27953-27961	violence	_	
126-8	27962-27968	showed	_	
126-9	27969-27974	lower	_	
126-10	27975-27978	GMV	_	
126-11	27979-27981	in	_	
126-12	27982-27985	the	_	
126-13	27986-27991	right	_	
126-14	27992-28000	inferior	_	
126-15	28001-28009	temporal	_	
126-16	28010-28014	area	_	
126-17	28015-28016	(	_	
126-18	28016-28019	the	_	
126-19	28020-28028	anterior	_	
126-20	28029-28033	part	_	
126-21	28034-28036	of	_	
126-22	28037-28040	the	_	
126-23	28041-28046	right	_	
126-24	28047-28055	inferior	_	
126-25	28056-28064	temporal	_	
126-26	28065-28070	gyrus	_	
126-27	28071-28079	expanded	_	
126-28	28080-28082	to	_	
126-29	28083-28086	the	_	
126-30	28087-28095	fusiform	_	
126-31	28096-28101	gyrus	_	
126-32	28101-28102	,	_	
126-33	28103-28106	the	_	
126-34	28107-28113	middle	_	
126-35	28114-28122	temporal	_	
126-36	28123-28128	gyrus	_	
126-37	28128-28129	,	_	
126-38	28130-28133	and	_	
126-39	28134-28137	the	_	
126-40	28138-28146	temporal	_	
126-41	28147-28151	pole	_	
126-42	28151-28152	)	_	
126-43	28153-28156	and	_	
126-44	28157-28160	the	_	
126-45	28161-28166	right	_	
126-46	28167-28174	insular	_	
126-47	28175-28179	area	_	
126-48	28180-28181	(	_	
126-49	28181-28184	the	_	
126-50	28185-28190	right	_	
126-51	28191-28197	insula	_	
126-52	28198-28206	expanded	_	
126-53	28207-28209	to	_	
126-54	28210-28213	the	_	
126-55	28214-28221	ventral	_	
126-56	28222-28234	diencephalon	_	
126-57	28234-28235	)	_	
126-58	28236-28240	than	_	
126-59	28241-28246	those	_	
126-60	28247-28254	without	_	
126-61	28255-28256	a	_	
126-62	28257-28264	history	_	
126-63	28265-28267	of	_	
126-64	28268-28276	violence	_	
126-65	28277-28282	after	_	
126-66	28283-28294	controlling	_	
126-67	28295-28298	for	_	
126-68	28299-28304	lower	_	
126-69	28305-28310	years	_	
126-70	28311-28313	of	_	
126-71	28314-28323	education	_	
126-72	28324-28327	and	_	
126-73	28328-28334	higher	_	
126-74	28335-28343	positive	_	
126-75	28344-28351	symptom	_	
126-76	28352-28358	scores	_	
126-77	28358-28359	.	_	

#Text=Of note, the difference in the right inferior temporal area (the anterior part of the right inferior temporal gyrus and temporal pole) was not able to be explained by a history of substance abuse.
127-1	28360-28362	Of	_	
127-2	28363-28367	note	_	
127-3	28367-28368	,	_	
127-4	28369-28372	the	_	
127-5	28373-28383	difference	_	
127-6	28384-28386	in	_	
127-7	28387-28390	the	_	
127-8	28391-28396	right	_	
127-9	28397-28405	inferior	_	
127-10	28406-28414	temporal	_	
127-11	28415-28419	area	_	
127-12	28420-28421	(	_	
127-13	28421-28424	the	_	
127-14	28425-28433	anterior	_	
127-15	28434-28438	part	_	
127-16	28439-28441	of	_	
127-17	28442-28445	the	_	
127-18	28446-28451	right	_	
127-19	28452-28460	inferior	_	
127-20	28461-28469	temporal	_	
127-21	28470-28475	gyrus	_	
127-22	28476-28479	and	_	
127-23	28480-28488	temporal	_	
127-24	28489-28493	pole	_	
127-25	28493-28494	)	_	
127-26	28495-28498	was	_	
127-27	28499-28502	not	_	
127-28	28503-28507	able	_	
127-29	28508-28510	to	_	
127-30	28511-28513	be	_	
127-31	28514-28523	explained	_	
127-32	28524-28526	by	_	
127-33	28527-28528	a	_	
127-34	28529-28536	history	_	
127-35	28537-28539	of	_	
127-36	28540-28549	substance	_	
127-37	28550-28555	abuse	_	
127-38	28555-28556	.	_	

#Text=GMV was also compared between three patient groups divided based on types of violent behaviors (i.e., patients with premeditated violent behaviors, patients with impulsive violent behaviors, and patients with schizophrenia and no history of violence).
128-1	28557-28560	GMV	_	
128-2	28561-28564	was	_	
128-3	28565-28569	also	_	
128-4	28570-28578	compared	_	
128-5	28579-28586	between	_	
128-6	28587-28592	three	_	
128-7	28593-28600	patient	_	
128-8	28601-28607	groups	_	
128-9	28608-28615	divided	_	
128-10	28616-28621	based	_	
128-11	28622-28624	on	_	
128-12	28625-28630	types	_	
128-13	28631-28633	of	_	
128-14	28634-28641	violent	_	
128-15	28642-28651	behaviors	_	
128-16	28652-28653	(	_	
128-17	28653-28656	i.e	_	
128-18	28656-28657	.	_	
128-19	28657-28658	,	_	
128-20	28659-28667	patients	_	
128-21	28668-28672	with	_	
128-22	28673-28685	premeditated	_	
128-23	28686-28693	violent	_	
128-24	28694-28703	behaviors	_	
128-25	28703-28704	,	_	
128-26	28705-28713	patients	_	
128-27	28714-28718	with	_	
128-28	28719-28728	impulsive	_	
128-29	28729-28736	violent	_	
128-30	28737-28746	behaviors	_	
128-31	28746-28747	,	_	
128-32	28748-28751	and	_	
128-33	28752-28760	patients	_	
128-34	28761-28765	with	_	
128-35	28766-28779	schizophrenia	_	
128-36	28780-28783	and	_	
128-37	28784-28786	no	_	
128-38	28787-28794	history	_	
128-39	28795-28797	of	_	
128-40	28798-28806	violence	_	
128-41	28806-28807	)	_	
128-42	28807-28808	.	_	

#Text=Both the premeditated action and impulsive group showed significantly lower GMV in the right inferior temporal area (the right inferior temporal gyrus expanded to the temporal pole) than the control patient group, whereas only the premeditated action group had significantly lower GMV in the right insular area (the right insula expanded to the ventral diencephalon), the left planum polare area (the left planum polare expanded to the insula), and the bilateral precuneus area (bilateral precuneus and posterior cingulate gyrus) than the control patient group.
129-1	28809-28813	Both	_	
129-2	28814-28817	the	_	
129-3	28818-28830	premeditated	_	
129-4	28831-28837	action	_	
129-5	28838-28841	and	_	
129-6	28842-28851	impulsive	_	
129-7	28852-28857	group	_	
129-8	28858-28864	showed	_	
129-9	28865-28878	significantly	_	
129-10	28879-28884	lower	_	
129-11	28885-28888	GMV	_	
129-12	28889-28891	in	_	
129-13	28892-28895	the	_	
129-14	28896-28901	right	_	
129-15	28902-28910	inferior	_	
129-16	28911-28919	temporal	_	
129-17	28920-28924	area	_	
129-18	28925-28926	(	_	
129-19	28926-28929	the	_	
129-20	28930-28935	right	_	
129-21	28936-28944	inferior	_	
129-22	28945-28953	temporal	_	
129-23	28954-28959	gyrus	_	
129-24	28960-28968	expanded	_	
129-25	28969-28971	to	_	
129-26	28972-28975	the	_	
129-27	28976-28984	temporal	_	
129-28	28985-28989	pole	_	
129-29	28989-28990	)	_	
129-30	28991-28995	than	_	
129-31	28996-28999	the	_	
129-32	29000-29007	control	_	
129-33	29008-29015	patient	_	
129-34	29016-29021	group	_	
129-35	29021-29022	,	_	
129-36	29023-29030	whereas	_	
129-37	29031-29035	only	_	
129-38	29036-29039	the	_	
129-39	29040-29052	premeditated	_	
129-40	29053-29059	action	_	
129-41	29060-29065	group	_	
129-42	29066-29069	had	_	
129-43	29070-29083	significantly	_	
129-44	29084-29089	lower	_	
129-45	29090-29093	GMV	_	
129-46	29094-29096	in	_	
129-47	29097-29100	the	_	
129-48	29101-29106	right	_	
129-49	29107-29114	insular	_	
129-50	29115-29119	area	_	
129-51	29120-29121	(	_	
129-52	29121-29124	the	_	
129-53	29125-29130	right	_	
129-54	29131-29137	insula	_	
129-55	29138-29146	expanded	_	
129-56	29147-29149	to	_	
129-57	29150-29153	the	_	
129-58	29154-29161	ventral	_	
129-59	29162-29174	diencephalon	_	
129-60	29174-29175	)	_	
129-61	29175-29176	,	_	
129-62	29177-29180	the	_	
129-63	29181-29185	left	_	
129-64	29186-29192	planum	_	
129-65	29193-29199	polare	_	
129-66	29200-29204	area	_	
129-67	29205-29206	(	_	
129-68	29206-29209	the	_	
129-69	29210-29214	left	_	
129-70	29215-29221	planum	_	
129-71	29222-29228	polare	_	
129-72	29229-29237	expanded	_	
129-73	29238-29240	to	_	
129-74	29241-29244	the	_	
129-75	29245-29251	insula	_	
129-76	29251-29252	)	_	
129-77	29252-29253	,	_	
129-78	29254-29257	and	_	
129-79	29258-29261	the	_	
129-80	29262-29271	bilateral	_	
129-81	29272-29281	precuneus	_	
129-82	29282-29286	area	_	
129-83	29287-29288	(	_	
129-84	29288-29297	bilateral	_	
129-85	29298-29307	precuneus	_	
129-86	29308-29311	and	_	
129-87	29312-29321	posterior	_	
129-88	29322-29331	cingulate	_	
129-89	29332-29337	gyrus	_	
129-90	29337-29338	)	_	
129-91	29339-29343	than	_	
129-92	29344-29347	the	_	
129-93	29348-29355	control	_	
129-94	29356-29363	patient	_	
129-95	29364-29369	group	_	
129-96	29369-29370	.	_	

#Text=Only a few studies have reported significant differences in regional volume among individuals with schizophrenia and a history of serious violent behaviors, particularly when compared to individuals with schizophrenia and no history of serious violence.
130-1	29371-29375	Only	_	
130-2	29376-29377	a	_	
130-3	29378-29381	few	_	
130-4	29382-29389	studies	_	
130-5	29390-29394	have	_	
130-6	29395-29403	reported	_	
130-7	29404-29415	significant	_	
130-8	29416-29427	differences	_	
130-9	29428-29430	in	_	
130-10	29431-29439	regional	_	
130-11	29440-29446	volume	_	
130-12	29447-29452	among	_	
130-13	29453-29464	individuals	_	
130-14	29465-29469	with	_	
130-15	29470-29483	schizophrenia	_	
130-16	29484-29487	and	_	
130-17	29488-29489	a	_	
130-18	29490-29497	history	_	
130-19	29498-29500	of	_	
130-20	29501-29508	serious	_	
130-21	29509-29516	violent	_	
130-22	29517-29526	behaviors	_	
130-23	29526-29527	,	_	
130-24	29528-29540	particularly	_	
130-25	29541-29545	when	_	
130-26	29546-29554	compared	_	
130-27	29555-29557	to	_	
130-28	29558-29569	individuals	_	
130-29	29570-29574	with	_	
130-30	29575-29588	schizophrenia	_	
130-31	29589-29592	and	_	
130-32	29593-29595	no	_	
130-33	29596-29603	history	_	
130-34	29604-29606	of	_	
130-35	29607-29614	serious	_	
130-36	29615-29623	violence	_	
130-37	29623-29624	.	_	

#Text=The right inferior temporal area, including the temporal pole and the middle temporal gyrus, and the right insular area were newly reported in this study as associated with violent behavior.
131-1	29625-29628	The	_	
131-2	29629-29634	right	_	
131-3	29635-29643	inferior	_	
131-4	29644-29652	temporal	_	
131-5	29653-29657	area	_	
131-6	29657-29658	,	_	
131-7	29659-29668	including	_	
131-8	29669-29672	the	_	
131-9	29673-29681	temporal	_	
131-10	29682-29686	pole	_	
131-11	29687-29690	and	_	
131-12	29691-29694	the	_	
131-13	29695-29701	middle	_	
131-14	29702-29710	temporal	_	
131-15	29711-29716	gyrus	_	
131-16	29716-29717	,	_	
131-17	29718-29721	and	_	
131-18	29722-29725	the	_	
131-19	29726-29731	right	_	
131-20	29732-29739	insular	_	
131-21	29740-29744	area	_	
131-22	29745-29749	were	_	
131-23	29750-29755	newly	_	
131-24	29756-29764	reported	_	
131-25	29765-29767	in	_	
131-26	29768-29772	this	_	
131-27	29773-29778	study	_	
131-28	29779-29781	as	_	
131-29	29782-29792	associated	_	
131-30	29793-29797	with	_	
131-31	29798-29805	violent	_	
131-32	29806-29814	behavior	_	
131-33	29814-29815	.	_	

#Text=The right insular area was extended to the medial temporal area including the hippocampus as previously reported, but only in the premeditated action group.
132-1	29816-29819	The	_	
132-2	29820-29825	right	_	
132-3	29826-29833	insular	_	
132-4	29834-29838	area	_	
132-5	29839-29842	was	_	
132-6	29843-29851	extended	_	
132-7	29852-29854	to	_	
132-8	29855-29858	the	_	
132-9	29859-29865	medial	_	
132-10	29866-29874	temporal	_	
132-11	29875-29879	area	_	
132-12	29880-29889	including	_	
132-13	29890-29893	the	_	
132-14	29894-29905	hippocampus	_	
132-15	29906-29908	as	_	
132-16	29909-29919	previously	_	
132-17	29920-29928	reported	_	
132-18	29928-29929	,	_	
132-19	29930-29933	but	_	
132-20	29934-29938	only	_	
132-21	29939-29941	in	_	
132-22	29942-29945	the	_	
132-23	29946-29958	premeditated	_	
132-24	29959-29965	action	_	
132-25	29966-29971	group	_	
132-26	29971-29972	.	_	

#Text=The forensic subjects in this study had committed serious harm to others while in a state of insanity or diminished responsibility.
133-1	29973-29976	The	_	
133-2	29977-29985	forensic	_	
133-3	29986-29994	subjects	_	
133-4	29995-29997	in	_	
133-5	29998-30002	this	_	
133-6	30003-30008	study	_	
133-7	30009-30012	had	_	
133-8	30013-30022	committed	_	
133-9	30023-30030	serious	_	
133-10	30031-30035	harm	_	
133-11	30036-30038	to	_	
133-12	30039-30045	others	_	
133-13	30046-30051	while	_	
133-14	30052-30054	in	_	
133-15	30055-30056	a	_	
133-16	30057-30062	state	_	
133-17	30063-30065	of	_	
133-18	30066-30074	insanity	_	
133-19	30075-30077	or	_	
133-20	30078-30088	diminished	_	
133-21	30089-30103	responsibility	_	
133-22	30103-30104	.	_	

#Text=Due to the nature of this act, their relevant actions were strongly related to their psychiatric illness and were less related to an antisocial personality trait.
134-1	30105-30108	Due	_	
134-2	30109-30111	to	_	
134-3	30112-30115	the	_	
134-4	30116-30122	nature	_	
134-5	30123-30125	of	_	
134-6	30126-30130	this	_	
134-7	30131-30134	act	_	
134-8	30134-30135	,	_	
134-9	30136-30141	their	_	
134-10	30142-30150	relevant	_	
134-11	30151-30158	actions	_	
134-12	30159-30163	were	_	
134-13	30164-30172	strongly	_	
134-14	30173-30180	related	_	
134-15	30181-30183	to	_	
134-16	30184-30189	their	_	
134-17	30190-30201	psychiatric	_	
134-18	30202-30209	illness	_	
134-19	30210-30213	and	_	
134-20	30214-30218	were	_	
134-21	30219-30223	less	_	
134-22	30224-30231	related	_	
134-23	30232-30234	to	_	
134-24	30235-30237	an	_	
134-25	30238-30248	antisocial	_	
134-26	30249-30260	personality	_	
134-27	30261-30266	trait	_	
134-28	30266-30267	.	_	

#Text=Thus, the characteristics of the subjects in this study contribute to the available knowledge on violent behaviors in schizophrenia.
135-1	30268-30272	Thus	_	
135-2	30272-30273	,	_	
135-3	30274-30277	the	_	
135-4	30278-30293	characteristics	_	
135-5	30294-30296	of	_	
135-6	30297-30300	the	_	
135-7	30301-30309	subjects	_	
135-8	30310-30312	in	_	
135-9	30313-30317	this	_	
135-10	30318-30323	study	_	
135-11	30324-30334	contribute	_	
135-12	30335-30337	to	_	
135-13	30338-30341	the	_	
135-14	30342-30351	available	_	
135-15	30352-30361	knowledge	_	
135-16	30362-30364	on	_	
135-17	30365-30372	violent	_	
135-18	30373-30382	behaviors	_	
135-19	30383-30385	in	_	
135-20	30386-30399	schizophrenia	_	
135-21	30399-30400	.	_	

#Text=The inferior temporal gyrus is well known as the ventral stream of visual processing, referred to as the “what” stream, which processes the color and form of an object.
136-1	30401-30404	The	_	
136-2	30405-30413	inferior	_	
136-3	30414-30422	temporal	_	
136-4	30423-30428	gyrus	_	
136-5	30429-30431	is	_	
136-6	30432-30436	well	_	
136-7	30437-30442	known	_	
136-8	30443-30445	as	_	
136-9	30446-30449	the	_	
136-10	30450-30457	ventral	_	
136-11	30458-30464	stream	_	
136-12	30465-30467	of	_	
136-13	30468-30474	visual	_	
136-14	30475-30485	processing	_	
136-15	30485-30486	,	_	
136-16	30487-30495	referred	_	
136-17	30496-30498	to	_	
136-18	30499-30501	as	_	
136-19	30502-30505	the	_	
136-20	30506-30507	“	_	
136-21	30507-30511	what	_	
136-22	30511-30512	”	_	
136-23	30513-30519	stream	_	
136-24	30519-30520	,	_	
136-25	30521-30526	which	_	
136-26	30527-30536	processes	_	
136-27	30537-30540	the	_	
136-28	30541-30546	color	_	
136-29	30547-30550	and	_	
136-30	30551-30555	form	_	
136-31	30556-30558	of	_	
136-32	30559-30561	an	_	
136-33	30562-30568	object	_	
136-34	30568-30569	.	_	

#Text=The ventral stream is suggested to work with the amygdala and other brain regions and contribute to the evaluation of biological significance of affective stimuli.
137-1	30570-30573	The	_	
137-2	30574-30581	ventral	_	
137-3	30582-30588	stream	_	
137-4	30589-30591	is	_	
137-5	30592-30601	suggested	_	
137-6	30602-30604	to	_	
137-7	30605-30609	work	_	
137-8	30610-30614	with	_	
137-9	30615-30618	the	_	
137-10	30619-30627	amygdala	_	
137-11	30628-30631	and	_	
137-12	30632-30637	other	_	
137-13	30638-30643	brain	_	
137-14	30644-30651	regions	_	
137-15	30652-30655	and	_	
137-16	30656-30666	contribute	_	
137-17	30667-30669	to	_	
137-18	30670-30673	the	_	
137-19	30674-30684	evaluation	_	
137-20	30685-30687	of	_	
137-21	30688-30698	biological	_	
137-22	30699-30711	significance	_	
137-23	30712-30714	of	_	
137-24	30715-30724	affective	_	
137-25	30725-30732	stimuli	_	
137-26	30732-30733	.	_	

#Text=The fusiform gyrus is part of the ventral stream and is involved in face recognition; this region is also suggested to be involved in the recognition of emotional stimuli, working together with the amygdala.
138-1	30734-30737	The	_	
138-2	30738-30746	fusiform	_	
138-3	30747-30752	gyrus	_	
138-4	30753-30755	is	_	
138-5	30756-30760	part	_	
138-6	30761-30763	of	_	
138-7	30764-30767	the	_	
138-8	30768-30775	ventral	_	
138-9	30776-30782	stream	_	
138-10	30783-30786	and	_	
138-11	30787-30789	is	_	
138-12	30790-30798	involved	_	
138-13	30799-30801	in	_	
138-14	30802-30806	face	_	
138-15	30807-30818	recognition	_	
138-16	30818-30819	;	_	
138-17	30820-30824	this	_	
138-18	30825-30831	region	_	
138-19	30832-30834	is	_	
138-20	30835-30839	also	_	
138-21	30840-30849	suggested	_	
138-22	30850-30852	to	_	
138-23	30853-30855	be	_	
138-24	30856-30864	involved	_	
138-25	30865-30867	in	_	
138-26	30868-30871	the	_	
138-27	30872-30883	recognition	_	
138-28	30884-30886	of	_	
138-29	30887-30896	emotional	_	
138-30	30897-30904	stimuli	_	
138-31	30904-30905	,	_	
138-32	30906-30913	working	_	
138-33	30914-30922	together	_	
138-34	30923-30927	with	_	
138-35	30928-30931	the	_	
138-36	30932-30940	amygdala	_	
138-37	30940-30941	.	_	

#Text=The temporal pole plays a role in top-down modulation of the ventral stream and is involved in emotional processing associated with stimuli of various modalities.
139-1	30942-30945	The	_	
139-2	30946-30954	temporal	_	
139-3	30955-30959	pole	_	
139-4	30960-30965	plays	_	
139-5	30966-30967	a	_	
139-6	30968-30972	role	_	
139-7	30973-30975	in	_	
139-8	30976-30984	top-down	_	
139-9	30985-30995	modulation	_	
139-10	30996-30998	of	_	
139-11	30999-31002	the	_	
139-12	31003-31010	ventral	_	
139-13	31011-31017	stream	_	
139-14	31018-31021	and	_	
139-15	31022-31024	is	_	
139-16	31025-31033	involved	_	
139-17	31034-31036	in	_	
139-18	31037-31046	emotional	_	
139-19	31047-31057	processing	_	
139-20	31058-31068	associated	_	
139-21	31069-31073	with	_	
139-22	31074-31081	stimuli	_	
139-23	31082-31084	of	_	
139-24	31085-31092	various	_	
139-25	31093-31103	modalities	_	
139-26	31103-31104	.	_	

#Text=Reduced GMV in the right temporal pole and inferior temporal gyrus is shown in both the premeditated action and impulsive groups, indicating that the disturbance of integrated visual and other information processing and related emotional processing may be relatively common in individuals with schizophrenia and a history of serious violence.
140-1	31105-31112	Reduced	_	
140-2	31113-31116	GMV	_	
140-3	31117-31119	in	_	
140-4	31120-31123	the	_	
140-5	31124-31129	right	_	
140-6	31130-31138	temporal	_	
140-7	31139-31143	pole	_	
140-8	31144-31147	and	_	
140-9	31148-31156	inferior	_	
140-10	31157-31165	temporal	_	
140-11	31166-31171	gyrus	_	
140-12	31172-31174	is	_	
140-13	31175-31180	shown	_	
140-14	31181-31183	in	_	
140-15	31184-31188	both	_	
140-16	31189-31192	the	_	
140-17	31193-31205	premeditated	_	
140-18	31206-31212	action	_	
140-19	31213-31216	and	_	
140-20	31217-31226	impulsive	_	
140-21	31227-31233	groups	_	
140-22	31233-31234	,	_	
140-23	31235-31245	indicating	_	
140-24	31246-31250	that	_	
140-25	31251-31254	the	_	
140-26	31255-31266	disturbance	_	
140-27	31267-31269	of	_	
140-28	31270-31280	integrated	_	
140-29	31281-31287	visual	_	
140-30	31288-31291	and	_	
140-31	31292-31297	other	_	
140-32	31298-31309	information	_	
140-33	31310-31320	processing	_	
140-34	31321-31324	and	_	
140-35	31325-31332	related	_	
140-36	31333-31342	emotional	_	
140-37	31343-31353	processing	_	
140-38	31354-31357	may	_	
140-39	31358-31360	be	_	
140-40	31361-31371	relatively	_	
140-41	31372-31378	common	_	
140-42	31379-31381	in	_	
140-43	31382-31393	individuals	_	
140-44	31394-31398	with	_	
140-45	31399-31412	schizophrenia	_	
140-46	31413-31416	and	_	
140-47	31417-31418	a	_	
140-48	31419-31426	history	_	
140-49	31427-31429	of	_	
140-50	31430-31437	serious	_	
140-51	31438-31446	violence	_	
140-52	31446-31447	.	_	

#Text=The premeditated action group showed reduced GMV across a wide brain area including the insula compared with the impulsive group.
141-1	31448-31451	The	_	
141-2	31452-31464	premeditated	_	
141-3	31465-31471	action	_	
141-4	31472-31477	group	_	
141-5	31478-31484	showed	_	
141-6	31485-31492	reduced	_	
141-7	31493-31496	GMV	_	
141-8	31497-31503	across	_	
141-9	31504-31505	a	_	
141-10	31506-31510	wide	_	
141-11	31511-31516	brain	_	
141-12	31517-31521	area	_	
141-13	31522-31531	including	_	
141-14	31532-31535	the	_	
141-15	31536-31542	insula	_	
141-16	31543-31551	compared	_	
141-17	31552-31556	with	_	
141-18	31557-31560	the	_	
141-19	31561-31570	impulsive	_	
141-20	31571-31576	group	_	
141-21	31576-31577	.	_	

#Text=This finding cannot be simply attributed to sample size.
142-1	31578-31582	This	_	
142-2	31583-31590	finding	_	
142-3	31591-31597	cannot	_	
142-4	31598-31600	be	_	
142-5	31601-31607	simply	_	
142-6	31608-31618	attributed	_	
142-7	31619-31621	to	_	
142-8	31622-31628	sample	_	
142-9	31629-31633	size	_	
142-10	31633-31634	.	_	

#Text=The premeditated action group had higher age at scan than the control patient group, but there were no differences in duration of illness.
143-1	31635-31638	The	_	
143-2	31639-31651	premeditated	_	
143-3	31652-31658	action	_	
143-4	31659-31664	group	_	
143-5	31665-31668	had	_	
143-6	31669-31675	higher	_	
143-7	31676-31679	age	_	
143-8	31680-31682	at	_	
143-9	31683-31687	scan	_	
143-10	31688-31692	than	_	
143-11	31693-31696	the	_	
143-12	31697-31704	control	_	
143-13	31705-31712	patient	_	
143-14	31713-31718	group	_	
143-15	31718-31719	,	_	
143-16	31720-31723	but	_	
143-17	31724-31729	there	_	
143-18	31730-31734	were	_	
143-19	31735-31737	no	_	
143-20	31738-31749	differences	_	
143-21	31750-31752	in	_	
143-22	31753-31761	duration	_	
143-23	31762-31764	of	_	
143-24	31765-31772	illness	_	
143-25	31772-31773	.	_	

#Text=The premeditated action group showed higher score of negative symptoms as well as positive symptoms than the control patient group, whereas the impulsive group showed no significant differences in any clinical variables than the control patient group.
144-1	31774-31777	The	_	
144-2	31778-31790	premeditated	_	
144-3	31791-31797	action	_	
144-4	31798-31803	group	_	
144-5	31804-31810	showed	_	
144-6	31811-31817	higher	_	
144-7	31818-31823	score	_	
144-8	31824-31826	of	_	
144-9	31827-31835	negative	_	
144-10	31836-31844	symptoms	_	
144-11	31845-31847	as	_	
144-12	31848-31852	well	_	
144-13	31853-31855	as	_	
144-14	31856-31864	positive	_	
144-15	31865-31873	symptoms	_	
144-16	31874-31878	than	_	
144-17	31879-31882	the	_	
144-18	31883-31890	control	_	
144-19	31891-31898	patient	_	
144-20	31899-31904	group	_	
144-21	31904-31905	,	_	
144-22	31906-31913	whereas	_	
144-23	31914-31917	the	_	
144-24	31918-31927	impulsive	_	
144-25	31928-31933	group	_	
144-26	31934-31940	showed	_	
144-27	31941-31943	no	_	
144-28	31944-31955	significant	_	
144-29	31956-31967	differences	_	
144-30	31968-31970	in	_	
144-31	31971-31974	any	_	
144-32	31975-31983	clinical	_	
144-33	31984-31993	variables	_	
144-34	31994-31998	than	_	
144-35	31999-32002	the	_	
144-36	32003-32010	control	_	
144-37	32011-32018	patient	_	
144-38	32019-32024	group	_	
144-39	32024-32025	.	_	

#Text=More severe symptoms may be attributed to reduced GMV across a wide brain area.
145-1	32026-32030	More	_	
145-2	32031-32037	severe	_	
145-3	32038-32046	symptoms	_	
145-4	32047-32050	may	_	
145-5	32051-32053	be	_	
145-6	32054-32064	attributed	_	
145-7	32065-32067	to	_	
145-8	32068-32075	reduced	_	
145-9	32076-32079	GMV	_	
145-10	32080-32086	across	_	
145-11	32087-32088	a	_	
145-12	32089-32093	wide	_	
145-13	32094-32099	brain	_	
145-14	32100-32104	area	_	
145-15	32104-32105	.	_	

#Text=The insula is believed to play a role in recognition of the inner state of the body and is also involved in imagining, observing and executing an experience, such as another’s physical pain or feelings of disgust.
146-1	32106-32109	The	_	
146-2	32110-32116	insula	_	
146-3	32117-32119	is	_	
146-4	32120-32128	believed	_	
146-5	32129-32131	to	_	
146-6	32132-32136	play	_	
146-7	32137-32138	a	_	
146-8	32139-32143	role	_	
146-9	32144-32146	in	_	
146-10	32147-32158	recognition	_	
146-11	32159-32161	of	_	
146-12	32162-32165	the	_	
146-13	32166-32171	inner	_	
146-14	32172-32177	state	_	
146-15	32178-32180	of	_	
146-16	32181-32184	the	_	
146-17	32185-32189	body	_	
146-18	32190-32193	and	_	
146-19	32194-32196	is	_	
146-20	32197-32201	also	_	
146-21	32202-32210	involved	_	
146-22	32211-32213	in	_	
146-23	32214-32223	imagining	_	
146-24	32223-32224	,	_	
146-25	32225-32234	observing	_	
146-26	32235-32238	and	_	
146-27	32239-32248	executing	_	
146-28	32249-32251	an	_	
146-29	32252-32262	experience	_	
146-30	32262-32263	,	_	
146-31	32264-32268	such	_	
146-32	32269-32271	as	_	
146-33	32272-32279	another	_	
146-34	32279-32280	’	_	
146-35	32280-32281	s	_	
146-36	32282-32290	physical	_	
146-37	32291-32295	pain	_	
146-38	32296-32298	or	_	
146-39	32299-32307	feelings	_	
146-40	32308-32310	of	_	
146-41	32311-32318	disgust	_	
146-42	32318-32319	.	_	

#Text=Disturbance of this function may contribute to a lack of inhibition towards physically harming others.
147-1	32320-32331	Disturbance	_	
147-2	32332-32334	of	_	
147-3	32335-32339	this	_	
147-4	32340-32348	function	_	
147-5	32349-32352	may	_	
147-6	32353-32363	contribute	_	
147-7	32364-32366	to	_	
147-8	32367-32368	a	_	
147-9	32369-32373	lack	_	
147-10	32374-32376	of	_	
147-11	32377-32387	inhibition	_	
147-12	32388-32395	towards	_	
147-13	32396-32406	physically	_	
147-14	32407-32414	harming	_	
147-15	32415-32421	others	_	
147-16	32421-32422	.	_	

#Text=The precuneus is thought to be involved in the interwoven network of the neural correlates of self-consciousness, which is engaged in self-related mental representations during rest as well as other integrated tasks, including visuo-spatial imagery and episodic memory retrieval, and is also considered part of the “theory of mind (ToM)” network.
148-1	32423-32426	The	_	
148-2	32427-32436	precuneus	_	
148-3	32437-32439	is	_	
148-4	32440-32447	thought	_	
148-5	32448-32450	to	_	
148-6	32451-32453	be	_	
148-7	32454-32462	involved	_	
148-8	32463-32465	in	_	
148-9	32466-32469	the	_	
148-10	32470-32480	interwoven	_	
148-11	32481-32488	network	_	
148-12	32489-32491	of	_	
148-13	32492-32495	the	_	
148-14	32496-32502	neural	_	
148-15	32503-32513	correlates	_	
148-16	32514-32516	of	_	
148-17	32517-32535	self-consciousness	_	
148-18	32535-32536	,	_	
148-19	32537-32542	which	_	
148-20	32543-32545	is	_	
148-21	32546-32553	engaged	_	
148-22	32554-32556	in	_	
148-23	32557-32569	self-related	_	
148-24	32570-32576	mental	_	
148-25	32577-32592	representations	_	
148-26	32593-32599	during	_	
148-27	32600-32604	rest	_	
148-28	32605-32607	as	_	
148-29	32608-32612	well	_	
148-30	32613-32615	as	_	
148-31	32616-32621	other	_	
148-32	32622-32632	integrated	_	
148-33	32633-32638	tasks	_	
148-34	32638-32639	,	_	
148-35	32640-32649	including	_	
148-36	32650-32663	visuo-spatial	_	
148-37	32664-32671	imagery	_	
148-38	32672-32675	and	_	
148-39	32676-32684	episodic	_	
148-40	32685-32691	memory	_	
148-41	32692-32701	retrieval	_	
148-42	32701-32702	,	_	
148-43	32703-32706	and	_	
148-44	32707-32709	is	_	
148-45	32710-32714	also	_	
148-46	32715-32725	considered	_	
148-47	32726-32730	part	_	
148-48	32731-32733	of	_	
148-49	32734-32737	the	_	
148-50	32738-32739	“	_	
148-51	32739-32745	theory	_	
148-52	32746-32748	of	_	
148-53	32749-32753	mind	_	
148-54	32754-32755	(	_	
148-55	32755-32758	ToM	_	
148-56	32758-32759	)	_	
148-57	32759-32760	”	_	
148-58	32761-32768	network	_	
148-59	32768-32769	.	_	

#Text=The function of recognizing others’ emotional pain may depend on the recognition of ToM.
149-1	32770-32773	The	_	
149-2	32774-32782	function	_	
149-3	32783-32785	of	_	
149-4	32786-32797	recognizing	_	
149-5	32798-32804	others	_	
149-6	32804-32805	’	_	
149-7	32806-32815	emotional	_	
149-8	32816-32820	pain	_	
149-9	32821-32824	may	_	
149-10	32825-32831	depend	_	
149-11	32832-32834	on	_	
149-12	32835-32838	the	_	
149-13	32839-32850	recognition	_	
149-14	32851-32853	of	_	
149-15	32854-32857	ToM	_	
149-16	32857-32858	.	_	

#Text=Lack of empathy based on the recognition of others’ physical and/or emotional pain may be attributed to a lack of inhibition for physically violent behaviors.
150-1	32859-32863	Lack	_	
150-2	32864-32866	of	_	
150-3	32867-32874	empathy	_	
150-4	32875-32880	based	_	
150-5	32881-32883	on	_	
150-6	32884-32887	the	_	
150-7	32888-32899	recognition	_	
150-8	32900-32902	of	_	
150-9	32903-32909	others	_	
150-10	32909-32910	’	_	
150-11	32911-32919	physical	_	
150-12	32920-32923	and	_	
150-13	32923-32924	/	_	
150-14	32924-32926	or	_	
150-15	32927-32936	emotional	_	
150-16	32937-32941	pain	_	
150-17	32942-32945	may	_	
150-18	32946-32948	be	_	
150-19	32949-32959	attributed	_	
150-20	32960-32962	to	_	
150-21	32963-32964	a	_	
150-22	32965-32969	lack	_	
150-23	32970-32972	of	_	
150-24	32973-32983	inhibition	_	
150-25	32984-32987	for	_	
150-26	32988-32998	physically	_	
150-27	32999-33006	violent	_	
150-28	33007-33016	behaviors	_	
150-29	33016-33017	.	_	

#Text=More severe abnormalities in recognizing others’ pain may be attributed to not only planning the violent action towards others but also carrying out that plan.
151-1	33018-33022	More	_	
151-2	33023-33029	severe	_	
151-3	33030-33043	abnormalities	_	
151-4	33044-33046	in	_	
151-5	33047-33058	recognizing	_	
151-6	33059-33065	others	_	
151-7	33065-33066	’	_	
151-8	33067-33071	pain	_	
151-9	33072-33075	may	_	
151-10	33076-33078	be	_	
151-11	33079-33089	attributed	_	
151-12	33090-33092	to	_	
151-13	33093-33096	not	_	
151-14	33097-33101	only	_	
151-15	33102-33110	planning	_	
151-16	33111-33114	the	_	
151-17	33115-33122	violent	_	
151-18	33123-33129	action	_	
151-19	33130-33137	towards	_	
151-20	33138-33144	others	_	
151-21	33145-33148	but	_	
151-22	33149-33153	also	_	
151-23	33154-33162	carrying	_	
151-24	33163-33166	out	_	
151-25	33167-33171	that	_	
151-26	33172-33176	plan	_	
151-27	33176-33177	.	_	

#Text=It is interesting that the temporal pole and the insula, which are newly reported in this study regarding schizophrenia, were previously reported in individuals with psychopathy or antisocial behavioral problems, while our subjects were suggested to have less antisocial personality traits.
152-1	33178-33180	It	_	
152-2	33181-33183	is	_	
152-3	33184-33195	interesting	_	
152-4	33196-33200	that	_	
152-5	33201-33204	the	_	
152-6	33205-33213	temporal	_	
152-7	33214-33218	pole	_	
152-8	33219-33222	and	_	
152-9	33223-33226	the	_	
152-10	33227-33233	insula	_	
152-11	33233-33234	,	_	
152-12	33235-33240	which	_	
152-13	33241-33244	are	_	
152-14	33245-33250	newly	_	
152-15	33251-33259	reported	_	
152-16	33260-33262	in	_	
152-17	33263-33267	this	_	
152-18	33268-33273	study	_	
152-19	33274-33283	regarding	_	
152-20	33284-33297	schizophrenia	_	
152-21	33297-33298	,	_	
152-22	33299-33303	were	_	
152-23	33304-33314	previously	_	
152-24	33315-33323	reported	_	
152-25	33324-33326	in	_	
152-26	33327-33338	individuals	_	
152-27	33339-33343	with	_	
152-28	33344-33355	psychopathy	_	
152-29	33356-33358	or	_	
152-30	33359-33369	antisocial	_	
152-31	33370-33380	behavioral	_	
152-32	33381-33389	problems	_	
152-33	33389-33390	,	_	
152-34	33391-33396	while	_	
152-35	33397-33400	our	_	
152-36	33401-33409	subjects	_	
152-37	33410-33414	were	_	
152-38	33415-33424	suggested	_	
152-39	33425-33427	to	_	
152-40	33428-33432	have	_	
152-41	33433-33437	less	_	
152-42	33438-33448	antisocial	_	
152-43	33449-33460	personality	_	
152-44	33461-33467	traits	_	
152-45	33467-33468	.	_	

#Text=One possibility is that a violent trait may depend on the same function both in individuals with antisocial problems and schizophrenia.
153-1	33469-33472	One	_	
153-2	33473-33484	possibility	_	
153-3	33485-33487	is	_	
153-4	33488-33492	that	_	
153-5	33493-33494	a	_	
153-6	33495-33502	violent	_	
153-7	33503-33508	trait	_	
153-8	33509-33512	may	_	
153-9	33513-33519	depend	_	
153-10	33520-33522	on	_	
153-11	33523-33526	the	_	
153-12	33527-33531	same	_	
153-13	33532-33540	function	_	
153-14	33541-33545	both	_	
153-15	33546-33548	in	_	
153-16	33549-33560	individuals	_	
153-17	33561-33565	with	_	
153-18	33566-33576	antisocial	_	
153-19	33577-33585	problems	_	
153-20	33586-33589	and	_	
153-21	33590-33603	schizophrenia	_	
153-22	33603-33604	.	_	

#Text=There is also the possibility that an emotional processing disturbance in the temporal pole and the disturbance of recognizing another’s physical pain in the insula are common in violent traits both of schizophrenia and psychopathy/antisocial personality disorder.
154-1	33605-33610	There	_	
154-2	33611-33613	is	_	
154-3	33614-33618	also	_	
154-4	33619-33622	the	_	
154-5	33623-33634	possibility	_	
154-6	33635-33639	that	_	
154-7	33640-33642	an	_	
154-8	33643-33652	emotional	_	
154-9	33653-33663	processing	_	
154-10	33664-33675	disturbance	_	
154-11	33676-33678	in	_	
154-12	33679-33682	the	_	
154-13	33683-33691	temporal	_	
154-14	33692-33696	pole	_	
154-15	33697-33700	and	_	
154-16	33701-33704	the	_	
154-17	33705-33716	disturbance	_	
154-18	33717-33719	of	_	
154-19	33720-33731	recognizing	_	
154-20	33732-33739	another	_	
154-21	33739-33740	’	_	
154-22	33740-33741	s	_	
154-23	33742-33750	physical	_	
154-24	33751-33755	pain	_	
154-25	33756-33758	in	_	
154-26	33759-33762	the	_	
154-27	33763-33769	insula	_	
154-28	33770-33773	are	_	
154-29	33774-33780	common	_	
154-30	33781-33783	in	_	
154-31	33784-33791	violent	_	
154-32	33792-33798	traits	_	
154-33	33799-33803	both	_	
154-34	33804-33806	of	_	
154-35	33807-33820	schizophrenia	_	
154-36	33821-33824	and	_	
154-37	33825-33836	psychopathy	_	
154-38	33836-33837	/	_	
154-39	33837-33847	antisocial	_	
154-40	33848-33859	personality	_	
154-41	33860-33868	disorder	_	
154-42	33868-33869	.	_	

#Text=Another possibility is that subclinical psychopathic traits may have effects on morphometric changes even in our subjects with schizophrenia and a history of serious violence.
155-1	33870-33877	Another	_	
155-2	33878-33889	possibility	_	
155-3	33890-33892	is	_	
155-4	33893-33897	that	_	
155-5	33898-33909	subclinical	_	
155-6	33910-33922	psychopathic	_	
155-7	33923-33929	traits	_	
155-8	33930-33933	may	_	
155-9	33934-33938	have	_	
155-10	33939-33946	effects	_	
155-11	33947-33949	on	_	
155-12	33950-33962	morphometric	_	
155-13	33963-33970	changes	_	
155-14	33971-33975	even	_	
155-15	33976-33978	in	_	
155-16	33979-33982	our	_	
155-17	33983-33991	subjects	_	
155-18	33992-33996	with	_	
155-19	33997-34010	schizophrenia	_	
155-20	34011-34014	and	_	
155-21	34015-34016	a	_	
155-22	34017-34024	history	_	
155-23	34025-34027	of	_	
155-24	34028-34035	serious	_	
155-25	34036-34044	violence	_	
155-26	34044-34045	.	_	

#Text=Several reports have shown that individuals with schizophrenia and a history of violent offenses also possess psychopathic traits or antisocial traits.
156-1	34046-34053	Several	_	
156-2	34054-34061	reports	_	
156-3	34062-34066	have	_	
156-4	34067-34072	shown	_	
156-5	34073-34077	that	_	
156-6	34078-34089	individuals	_	
156-7	34090-34094	with	_	
156-8	34095-34108	schizophrenia	_	
156-9	34109-34112	and	_	
156-10	34113-34114	a	_	
156-11	34115-34122	history	_	
156-12	34123-34125	of	_	
156-13	34126-34133	violent	_	
156-14	34134-34142	offenses	_	
156-15	34143-34147	also	_	
156-16	34148-34155	possess	_	
156-17	34156-34168	psychopathic	_	
156-18	34169-34175	traits	_	
156-19	34176-34178	or	_	
156-20	34179-34189	antisocial	_	
156-21	34190-34196	traits	_	
156-22	34196-34197	.	_	

#Text=The biopsychosocial background of violence in people with schizophrenia may be heterogeneous.
157-1	34198-34201	The	_	
157-2	34202-34217	biopsychosocial	_	
157-3	34218-34228	background	_	
157-4	34229-34231	of	_	
157-5	34232-34240	violence	_	
157-6	34241-34243	in	_	
157-7	34244-34250	people	_	
157-8	34251-34255	with	_	
157-9	34256-34269	schizophrenia	_	
157-10	34270-34273	may	_	
157-11	34274-34276	be	_	
157-12	34277-34290	heterogeneous	_	
157-13	34290-34291	.	_	

#Text=Morphometric findings regarding the relationship between schizophrenia and violence may depend on the type of violent behaviors performed by subjects with schizophrenia.
158-1	34292-34304	Morphometric	_	
158-2	34305-34313	findings	_	
158-3	34314-34323	regarding	_	
158-4	34324-34327	the	_	
158-5	34328-34340	relationship	_	
158-6	34341-34348	between	_	
158-7	34349-34362	schizophrenia	_	
158-8	34363-34366	and	_	
158-9	34367-34375	violence	_	
158-10	34376-34379	may	_	
158-11	34380-34386	depend	_	
158-12	34387-34389	on	_	
158-13	34390-34393	the	_	
158-14	34394-34398	type	_	
158-15	34399-34401	of	_	
158-16	34402-34409	violent	_	
158-17	34410-34419	behaviors	_	
158-18	34420-34429	performed	_	
158-19	34430-34432	by	_	
158-20	34433-34441	subjects	_	
158-21	34442-34446	with	_	
158-22	34447-34460	schizophrenia	_	
158-23	34460-34461	.	_	

#Text=There are several limitations to this study.
159-1	34462-34467	There	_	
159-2	34468-34471	are	_	
159-3	34472-34479	several	_	
159-4	34480-34491	limitations	_	
159-5	34492-34494	to	_	
159-6	34495-34499	this	_	
159-7	34500-34505	study	_	
159-8	34505-34506	.	_	

#Text=First, the subject population included men only.
160-1	34507-34512	First	_	
160-2	34512-34513	,	_	
160-3	34514-34517	the	_	
160-4	34518-34525	subject	_	
160-5	34526-34536	population	_	
160-6	34537-34545	included	_	
160-7	34546-34549	men	_	
160-8	34550-34554	only	_	
160-9	34554-34555	.	_	

#Text=Second, several factors that may impact morphometric data were not available, such as IQ or socioeconomic status.
161-1	34556-34562	Second	_	
161-2	34562-34563	,	_	
161-3	34564-34571	several	_	
161-4	34572-34579	factors	_	
161-5	34580-34584	that	_	
161-6	34585-34588	may	_	
161-7	34589-34595	impact	_	
161-8	34596-34608	morphometric	_	
161-9	34609-34613	data	_	
161-10	34614-34618	were	_	
161-11	34619-34622	not	_	
161-12	34623-34632	available	_	
161-13	34632-34633	,	_	
161-14	34634-34638	such	_	
161-15	34639-34641	as	_	
161-16	34642-34644	IQ	_	
161-17	34645-34647	or	_	
161-18	34648-34661	socioeconomic	_	
161-19	34662-34668	status	_	
161-20	34668-34669	.	_	

#Text=There was a significant difference in the duration of education between groups, which may be reflected in these factors.
162-1	34670-34675	There	_	
162-2	34676-34679	was	_	
162-3	34680-34681	a	_	
162-4	34682-34693	significant	_	
162-5	34694-34704	difference	_	
162-6	34705-34707	in	_	
162-7	34708-34711	the	_	
162-8	34712-34720	duration	_	
162-9	34721-34723	of	_	
162-10	34724-34733	education	_	
162-11	34734-34741	between	_	
162-12	34742-34748	groups	_	
162-13	34748-34749	,	_	
162-14	34750-34755	which	_	
162-15	34756-34759	may	_	
162-16	34760-34762	be	_	
162-17	34763-34772	reflected	_	
162-18	34773-34775	in	_	
162-19	34776-34781	these	_	
162-20	34782-34789	factors	_	
162-21	34789-34790	.	_	

#Text=Although we used the duration of education as a covariate, the influence of these cofounding factors may not have been fully eliminated.
163-1	34791-34799	Although	_	
163-2	34800-34802	we	_	
163-3	34803-34807	used	_	
163-4	34808-34811	the	_	
163-5	34812-34820	duration	_	
163-6	34821-34823	of	_	
163-7	34824-34833	education	_	
163-8	34834-34836	as	_	
163-9	34837-34838	a	_	
163-10	34839-34848	covariate	_	
163-11	34848-34849	,	_	
163-12	34850-34853	the	_	
163-13	34854-34863	influence	_	
163-14	34864-34866	of	_	
163-15	34867-34872	these	_	
163-16	34873-34883	cofounding	_	
163-17	34884-34891	factors	_	
163-18	34892-34895	may	_	
163-19	34896-34899	not	_	
163-20	34900-34904	have	_	
163-21	34905-34909	been	_	
163-22	34910-34915	fully	_	
163-23	34916-34926	eliminated	_	
163-24	34926-34927	.	_	

#Text=Third, long duration of illness and medication may affect our findings.
164-1	34928-34933	Third	_	
164-2	34933-34934	,	_	
164-3	34935-34939	long	_	
164-4	34940-34948	duration	_	
164-5	34949-34951	of	_	
164-6	34952-34959	illness	_	
164-7	34960-34963	and	_	
164-8	34964-34974	medication	_	
164-9	34975-34978	may	_	
164-10	34979-34985	affect	_	
164-11	34986-34989	our	_	
164-12	34990-34998	findings	_	
164-13	34998-34999	.	_	

#Text=Most subjects in this study had long duration of illness and were taking antipsychotic for a long time.
165-1	35000-35004	Most	_	
165-2	35005-35013	subjects	_	
165-3	35014-35016	in	_	
165-4	35017-35021	this	_	
165-5	35022-35027	study	_	
165-6	35028-35031	had	_	
165-7	35032-35036	long	_	
165-8	35037-35045	duration	_	
165-9	35046-35048	of	_	
165-10	35049-35056	illness	_	
165-11	35057-35060	and	_	
165-12	35061-35065	were	_	
165-13	35066-35072	taking	_	
165-14	35073-35086	antipsychotic	_	
165-15	35087-35090	for	_	
165-16	35091-35092	a	_	
165-17	35093-35097	long	_	
165-18	35098-35102	time	_	
165-19	35102-35103	.	_	

#Text=We did not find significant differences in duration of illness, duration of untreated psychosis, and duration of medication.
166-1	35104-35106	We	_	
166-2	35107-35110	did	_	
166-3	35111-35114	not	_	
166-4	35115-35119	find	_	
166-5	35120-35131	significant	_	
166-6	35132-35143	differences	_	
166-7	35144-35146	in	_	
166-8	35147-35155	duration	_	
166-9	35156-35158	of	_	
166-10	35159-35166	illness	_	
166-11	35166-35167	,	_	
166-12	35168-35176	duration	_	
166-13	35177-35179	of	_	
166-14	35180-35189	untreated	_	
166-15	35190-35199	psychosis	_	
166-16	35199-35200	,	_	
166-17	35201-35204	and	_	
166-18	35205-35213	duration	_	
166-19	35214-35216	of	_	
166-20	35217-35227	medication	_	
166-21	35227-35228	.	_	

#Text=However, we could not fully eliminate the influence of long duration of illness and medication.
167-1	35229-35236	However	_	
167-2	35236-35237	,	_	
167-3	35238-35240	we	_	
167-4	35241-35246	could	_	
167-5	35247-35250	not	_	
167-6	35251-35256	fully	_	
167-7	35257-35266	eliminate	_	
167-8	35267-35270	the	_	
167-9	35271-35280	influence	_	
167-10	35281-35283	of	_	
167-11	35284-35288	long	_	
167-12	35289-35297	duration	_	
167-13	35298-35300	of	_	
167-14	35301-35308	illness	_	
167-15	35309-35312	and	_	
167-16	35313-35323	medication	_	
167-17	35323-35324	.	_	

#Text=Fourth, we could not fully eliminate the influence of substance abuse.
168-1	35325-35331	Fourth	_	
168-2	35331-35332	,	_	
168-3	35333-35335	we	_	
168-4	35336-35341	could	_	
168-5	35342-35345	not	_	
168-6	35346-35351	fully	_	
168-7	35352-35361	eliminate	_	
168-8	35362-35365	the	_	
168-9	35366-35375	influence	_	
168-10	35376-35378	of	_	
168-11	35379-35388	substance	_	
168-12	35389-35394	abuse	_	
168-13	35394-35395	.	_	

#Text=Significant differences were found between the forensic group excluding subjects with substance abuse and the control patient group, but these differences were limited to the right inferior temporal area.
169-1	35396-35407	Significant	_	
169-2	35408-35419	differences	_	
169-3	35420-35424	were	_	
169-4	35425-35430	found	_	
169-5	35431-35438	between	_	
169-6	35439-35442	the	_	
169-7	35443-35451	forensic	_	
169-8	35452-35457	group	_	
169-9	35458-35467	excluding	_	
169-10	35468-35476	subjects	_	
169-11	35477-35481	with	_	
169-12	35482-35491	substance	_	
169-13	35492-35497	abuse	_	
169-14	35498-35501	and	_	
169-15	35502-35505	the	_	
169-16	35506-35513	control	_	
169-17	35514-35521	patient	_	
169-18	35522-35527	group	_	
169-19	35527-35528	,	_	
169-20	35529-35532	but	_	
169-21	35533-35538	these	_	
169-22	35539-35550	differences	_	
169-23	35551-35555	were	_	
169-24	35556-35563	limited	_	
169-25	35564-35566	to	_	
169-26	35567-35570	the	_	
169-27	35571-35576	right	_	
169-28	35577-35585	inferior	_	
169-29	35586-35594	temporal	_	
169-30	35595-35599	area	_	
169-31	35599-35600	.	_	

#Text=We were unable to distinguish whether this finding was due to the sample size or not or whether a history of substance abuse was attributed to the other findings of our study.
170-1	35601-35603	We	_	
170-2	35604-35608	were	_	
170-3	35609-35615	unable	_	
170-4	35616-35618	to	_	
170-5	35619-35630	distinguish	_	
170-6	35631-35638	whether	_	
170-7	35639-35643	this	_	
170-8	35644-35651	finding	_	
170-9	35652-35655	was	_	
170-10	35656-35659	due	_	
170-11	35660-35662	to	_	
170-12	35663-35666	the	_	
170-13	35667-35673	sample	_	
170-14	35674-35678	size	_	
170-15	35679-35681	or	_	
170-16	35682-35685	not	_	
170-17	35686-35688	or	_	
170-18	35689-35696	whether	_	
170-19	35697-35698	a	_	
170-20	35699-35706	history	_	
170-21	35707-35709	of	_	
170-22	35710-35719	substance	_	
170-23	35720-35725	abuse	_	
170-24	35726-35729	was	_	
170-25	35730-35740	attributed	_	
170-26	35741-35743	to	_	
170-27	35744-35747	the	_	
170-28	35748-35753	other	_	
170-29	35754-35762	findings	_	
170-30	35763-35765	of	_	
170-31	35766-35769	our	_	
170-32	35770-35775	study	_	
170-33	35775-35776	.	_	

#Text=Fifth, we did not evaluate psychopathic traits, and we do not know to what extent psychopathic traits were associated with our findings.
171-1	35777-35782	Fifth	_	
171-2	35782-35783	,	_	
171-3	35784-35786	we	_	
171-4	35787-35790	did	_	
171-5	35791-35794	not	_	
171-6	35795-35803	evaluate	_	
171-7	35804-35816	psychopathic	_	
171-8	35817-35823	traits	_	
171-9	35823-35824	,	_	
171-10	35825-35828	and	_	
171-11	35829-35831	we	_	
171-12	35832-35834	do	_	
171-13	35835-35838	not	_	
171-14	35839-35843	know	_	
171-15	35844-35846	to	_	
171-16	35847-35851	what	_	
171-17	35852-35858	extent	_	
171-18	35859-35871	psychopathic	_	
171-19	35872-35878	traits	_	
171-20	35879-35883	were	_	
171-21	35884-35894	associated	_	
171-22	35895-35899	with	_	
171-23	35900-35903	our	_	
171-24	35904-35912	findings	_	
171-25	35912-35913	.	_	

#Text=Moreover, classified the forensic patients based on how long they held the plan for their relevant violent actions; however, at the time of their relevant actions, impulsivity was likely attributed to these actions to a certain extent even in the premeditated action group.
172-1	35914-35922	Moreover	_	
172-2	35922-35923	,	_	
172-3	35924-35934	classified	_	
172-4	35935-35938	the	_	
172-5	35939-35947	forensic	_	
172-6	35948-35956	patients	_	
172-7	35957-35962	based	_	
172-8	35963-35965	on	_	
172-9	35966-35969	how	_	
172-10	35970-35974	long	_	
172-11	35975-35979	they	_	
172-12	35980-35984	held	_	
172-13	35985-35988	the	_	
172-14	35989-35993	plan	_	
172-15	35994-35997	for	_	
172-16	35998-36003	their	_	
172-17	36004-36012	relevant	_	
172-18	36013-36020	violent	_	
172-19	36021-36028	actions	_	
172-20	36028-36029	;	_	
172-21	36030-36037	however	_	
172-22	36037-36038	,	_	
172-23	36039-36041	at	_	
172-24	36042-36045	the	_	
172-25	36046-36050	time	_	
172-26	36051-36053	of	_	
172-27	36054-36059	their	_	
172-28	36060-36068	relevant	_	
172-29	36069-36076	actions	_	
172-30	36076-36077	,	_	
172-31	36078-36089	impulsivity	_	
172-32	36090-36093	was	_	
172-33	36094-36100	likely	_	
172-34	36101-36111	attributed	_	
172-35	36112-36114	to	_	
172-36	36115-36120	these	_	
172-37	36121-36128	actions	_	
172-38	36129-36131	to	_	
172-39	36132-36133	a	_	
172-40	36134-36141	certain	_	
172-41	36142-36148	extent	_	
172-42	36149-36153	even	_	
172-43	36154-36156	in	_	
172-44	36157-36160	the	_	
172-45	36161-36173	premeditated	_	
172-46	36174-36180	action	_	
172-47	36181-36186	group	_	
172-48	36186-36187	.	_	

#Text=We also did not evaluate cognitive aspects in this study.
173-1	36188-36190	We	_	
173-2	36191-36195	also	_	
173-3	36196-36199	did	_	
173-4	36200-36203	not	_	
173-5	36204-36212	evaluate	_	
173-6	36213-36222	cognitive	_	
173-7	36223-36230	aspects	_	
173-8	36231-36233	in	_	
173-9	36234-36238	this	_	
173-10	36239-36244	study	_	
173-11	36244-36245	.	_	

#Text=Thus, we do not know the psychological functions associated with holding the plan aimed at harming others.
174-1	36246-36250	Thus	_	
174-2	36250-36251	,	_	
174-3	36252-36254	we	_	
174-4	36255-36257	do	_	
174-5	36258-36261	not	_	
174-6	36262-36266	know	_	
174-7	36267-36270	the	_	
174-8	36271-36284	psychological	_	
174-9	36285-36294	functions	_	
174-10	36295-36305	associated	_	
174-11	36306-36310	with	_	
174-12	36311-36318	holding	_	
174-13	36319-36322	the	_	
174-14	36323-36327	plan	_	
174-15	36328-36333	aimed	_	
174-16	36334-36336	at	_	
174-17	36337-36344	harming	_	
174-18	36345-36351	others	_	
174-19	36351-36352	.	_	

#Text=Conclusions
#Text=Morphometric differences were identified between patients with schizophrenia with or without a history of serious violent acts, and such differences may depend on the type of violent actions committed.
175-1	36353-36364	Conclusions	_	
175-2	36365-36377	Morphometric	_	
175-3	36378-36389	differences	_	
175-4	36390-36394	were	_	
175-5	36395-36405	identified	_	
175-6	36406-36413	between	_	
175-7	36414-36422	patients	_	
175-8	36423-36427	with	_	
175-9	36428-36441	schizophrenia	_	
175-10	36442-36446	with	_	
175-11	36447-36449	or	_	
175-12	36450-36457	without	_	
175-13	36458-36459	a	_	
175-14	36460-36467	history	_	
175-15	36468-36470	of	_	
175-16	36471-36478	serious	_	
175-17	36479-36486	violent	_	
175-18	36487-36491	acts	_	
175-19	36491-36492	,	_	
175-20	36493-36496	and	_	
175-21	36497-36501	such	_	
175-22	36502-36513	differences	_	
175-23	36514-36517	may	_	
175-24	36518-36524	depend	_	
175-25	36525-36527	on	_	
175-26	36528-36531	the	_	
175-27	36532-36536	type	_	
175-28	36537-36539	of	_	
175-29	36540-36547	violent	_	
175-30	36548-36555	actions	_	
175-31	36556-36565	committed	_	
175-32	36565-36566	.	_	

#Text=Abnormalities in the right inferior temporal gyrus expanded to the temporal pole were common but did not depend on whether the violent actions were premeditated or not, while abnormalities in a wider range of brain areas may be attributed to not only planning a violent action against others but also holding that plan.
176-1	36567-36580	Abnormalities	_	
176-2	36581-36583	in	_	
176-3	36584-36587	the	_	
176-4	36588-36593	right	_	
176-5	36594-36602	inferior	_	
176-6	36603-36611	temporal	_	
176-7	36612-36617	gyrus	_	
176-8	36618-36626	expanded	_	
176-9	36627-36629	to	_	
176-10	36630-36633	the	_	
176-11	36634-36642	temporal	_	
176-12	36643-36647	pole	_	
176-13	36648-36652	were	_	
176-14	36653-36659	common	_	
176-15	36660-36663	but	_	
176-16	36664-36667	did	_	
176-17	36668-36671	not	_	
176-18	36672-36678	depend	_	
176-19	36679-36681	on	_	
176-20	36682-36689	whether	_	
176-21	36690-36693	the	_	
176-22	36694-36701	violent	_	
176-23	36702-36709	actions	_	
176-24	36710-36714	were	_	
176-25	36715-36727	premeditated	_	
176-26	36728-36730	or	_	
176-27	36731-36734	not	_	
176-28	36734-36735	,	_	
176-29	36736-36741	while	_	
176-30	36742-36755	abnormalities	_	
176-31	36756-36758	in	_	
176-32	36759-36760	a	_	
176-33	36761-36766	wider	_	
176-34	36767-36772	range	_	
176-35	36773-36775	of	_	
176-36	36776-36781	brain	_	
176-37	36782-36787	areas	_	
176-38	36788-36791	may	_	
176-39	36792-36794	be	_	
176-40	36795-36805	attributed	_	
176-41	36806-36808	to	_	
176-42	36809-36812	not	_	
176-43	36813-36817	only	_	
176-44	36818-36826	planning	_	
176-45	36827-36828	a	_	
176-46	36829-36836	violent	_	
176-47	36837-36843	action	_	
176-48	36844-36851	against	_	
176-49	36852-36858	others	_	
176-50	36859-36862	but	_	
176-51	36863-36867	also	_	
176-52	36868-36875	holding	_	
176-53	36876-36880	that	_	
176-54	36881-36885	plan	_	
176-55	36885-36886	.	_	

#Text=Patients with schizophrenia and a history of serious premeditated violent actions may have different risk for violent actions from those with other types of violent actions, and different treatment strategy may be needed for them.
177-1	36887-36895	Patients	_	
177-2	36896-36900	with	_	
177-3	36901-36914	schizophrenia	_	
177-4	36915-36918	and	_	
177-5	36919-36920	a	_	
177-6	36921-36928	history	_	
177-7	36929-36931	of	_	
177-8	36932-36939	serious	_	
177-9	36940-36952	premeditated	_	
177-10	36953-36960	violent	_	
177-11	36961-36968	actions	_	
177-12	36969-36972	may	_	
177-13	36973-36977	have	_	
177-14	36978-36987	different	_	
177-15	36988-36992	risk	_	
177-16	36993-36996	for	_	
177-17	36997-37004	violent	_	
177-18	37005-37012	actions	_	
177-19	37013-37017	from	_	
177-20	37018-37023	those	_	
177-21	37024-37028	with	_	
177-22	37029-37034	other	_	
177-23	37035-37040	types	_	
177-24	37041-37043	of	_	
177-25	37044-37051	violent	_	
177-26	37052-37059	actions	_	
177-27	37059-37060	,	_	
177-28	37061-37064	and	_	
177-29	37065-37074	different	_	
177-30	37075-37084	treatment	_	
177-31	37085-37093	strategy	_	
177-32	37094-37097	may	_	
177-33	37098-37100	be	_	
177-34	37101-37107	needed	_	
177-35	37108-37111	for	_	
177-36	37112-37116	them	_	
177-37	37116-37117	.	_	

#Text=Morphometric measurement may be useful for assessment of violent patients in the future.
178-1	37118-37130	Morphometric	_	
178-2	37131-37142	measurement	_	
178-3	37143-37146	may	_	
178-4	37147-37149	be	_	
178-5	37150-37156	useful	_	
178-6	37157-37160	for	_	
178-7	37161-37171	assessment	_	
178-8	37172-37174	of	_	
178-9	37175-37182	violent	_	
178-10	37183-37191	patients	_	
178-11	37192-37194	in	_	
178-12	37195-37198	the	_	
178-13	37199-37205	future	_	
178-14	37205-37206	.	_	

#Text=Further studies are needed to determine which cognitive functions are related to these differences, and these findings may contribute to a more theoretical therapy for patients with schizophrenia and a history of serious violence.
179-1	37207-37214	Further	_	
179-2	37215-37222	studies	_	
179-3	37223-37226	are	_	
179-4	37227-37233	needed	_	
179-5	37234-37236	to	_	
179-6	37237-37246	determine	_	
179-7	37247-37252	which	_	
179-8	37253-37262	cognitive	_	
179-9	37263-37272	functions	_	
179-10	37273-37276	are	_	
179-11	37277-37284	related	_	
179-12	37285-37287	to	_	
179-13	37288-37293	these	_	
179-14	37294-37305	differences	_	
179-15	37305-37306	,	_	
179-16	37307-37310	and	_	
179-17	37311-37316	these	_	
179-18	37317-37325	findings	_	
179-19	37326-37329	may	_	
179-20	37330-37340	contribute	_	
179-21	37341-37343	to	_	
179-22	37344-37345	a	_	
179-23	37346-37350	more	_	
179-24	37351-37362	theoretical	_	
179-25	37363-37370	therapy	_	
179-26	37371-37374	for	_	
179-27	37375-37383	patients	_	
179-28	37384-37388	with	_	
179-29	37389-37402	schizophrenia	_	
179-30	37403-37406	and	_	
179-31	37407-37408	a	_	
179-32	37409-37416	history	_	
179-33	37417-37419	of	_	
179-34	37420-37427	serious	_	
179-35	37428-37436	violence	_	
179-36	37436-37437	.	_	

#Text=Abbreviations
#Text=GMV
#Text=Gray matter volume
#Text=ICV
#Text=Intracranial volume
#Text=MTSA
#Text=The Medical Treatment and Supervision Act, also known as the Act on Medical Care and Treatment for Persons Who Have Caused Serious Cases Under the Condition of Insanity
#Text=References
#Text=Schizophrenia, substance abuse, and violent crime
#Text=A national study of violent behavior in persons with schizophrenia
#Text=Alternative pathways to violence in persons with schizophrenia: the role of childhood antisocial behavior problems
#Text=Sariaslan A, Larsson H, Fazel S.
180-1	37438-37451	Abbreviations	_	
180-2	37452-37455	GMV	_	
180-3	37456-37460	Gray	_	
180-4	37461-37467	matter	_	
180-5	37468-37474	volume	_	
180-6	37475-37478	ICV	_	
180-7	37479-37491	Intracranial	_	
180-8	37492-37498	volume	_	
180-9	37499-37503	MTSA	_	
180-10	37504-37507	The	_	
180-11	37508-37515	Medical	_	
180-12	37516-37525	Treatment	_	
180-13	37526-37529	and	_	
180-14	37530-37541	Supervision	_	
180-15	37542-37545	Act	_	
180-16	37545-37546	,	_	
180-17	37547-37551	also	_	
180-18	37552-37557	known	_	
180-19	37558-37560	as	_	
180-20	37561-37564	the	_	
180-21	37565-37568	Act	_	
180-22	37569-37571	on	_	
180-23	37572-37579	Medical	_	
180-24	37580-37584	Care	_	
180-25	37585-37588	and	_	
180-26	37589-37598	Treatment	_	
180-27	37599-37602	for	_	
180-28	37603-37610	Persons	_	
180-29	37611-37614	Who	_	
180-30	37615-37619	Have	_	
180-31	37620-37626	Caused	_	
180-32	37627-37634	Serious	_	
180-33	37635-37640	Cases	_	
180-34	37641-37646	Under	_	
180-35	37647-37650	the	_	
180-36	37651-37660	Condition	_	
180-37	37661-37663	of	_	
180-38	37664-37672	Insanity	_	
180-39	37673-37683	References	_	
180-40	37684-37697	Schizophrenia	_	
180-41	37697-37698	,	_	
180-42	37699-37708	substance	_	
180-43	37709-37714	abuse	_	
180-44	37714-37715	,	_	
180-45	37716-37719	and	_	
180-46	37720-37727	violent	_	
180-47	37728-37733	crime	_	
180-48	37734-37735	A	_	
180-49	37736-37744	national	_	
180-50	37745-37750	study	_	
180-51	37751-37753	of	_	
180-52	37754-37761	violent	_	
180-53	37762-37770	behavior	_	
180-54	37771-37773	in	_	
180-55	37774-37781	persons	_	
180-56	37782-37786	with	_	
180-57	37787-37800	schizophrenia	_	
180-58	37801-37812	Alternative	_	
180-59	37813-37821	pathways	_	
180-60	37822-37824	to	_	
180-61	37825-37833	violence	_	
180-62	37834-37836	in	_	
180-63	37837-37844	persons	_	
180-64	37845-37849	with	_	
180-65	37850-37863	schizophrenia	_	
180-66	37863-37864	:	_	
180-67	37865-37868	the	_	
180-68	37869-37873	role	_	
180-69	37874-37876	of	_	
180-70	37877-37886	childhood	_	
180-71	37887-37897	antisocial	_	
180-72	37898-37906	behavior	_	
180-73	37907-37915	problems	_	
180-74	37916-37925	Sariaslan	_	
180-75	37926-37927	A	_	
180-76	37927-37928	,	_	
180-77	37929-37936	Larsson	_	
180-78	37937-37938	H	_	
180-79	37938-37939	,	_	
180-80	37940-37945	Fazel	_	
180-81	37946-37947	S	_	
180-82	37947-37948	.	_	

#Text=Genetic and environmental determinants of violence risk in psychotic disorders: a multivariate quantitative genetic study of 1.8 million Swedish twins and siblings.
181-1	37949-37956	Genetic	_	
181-2	37957-37960	and	_	
181-3	37961-37974	environmental	_	
181-4	37975-37987	determinants	_	
181-5	37988-37990	of	_	
181-6	37991-37999	violence	_	
181-7	38000-38004	risk	_	
181-8	38005-38007	in	_	
181-9	38008-38017	psychotic	_	
181-10	38018-38027	disorders	_	
181-11	38027-38028	:	_	
181-12	38029-38030	a	_	
181-13	38031-38043	multivariate	_	
181-14	38044-38056	quantitative	_	
181-15	38057-38064	genetic	_	
181-16	38065-38070	study	_	
181-17	38071-38073	of	_	
181-18	38074-38077	1.8	_	
181-19	38078-38085	million	_	
181-20	38086-38093	Swedish	_	
181-21	38094-38099	twins	_	
181-22	38100-38103	and	_	
181-23	38104-38112	siblings	_	
181-24	38112-38113	.	_	

#Text=Mol Psychiatry. 2016;21:1251–6.
182-1	38114-38117	Mol	_	
182-2	38118-38128	Psychiatry	_	
182-3	38128-38129	.	_	
182-4	38130-38134	2016	_	
182-5	38134-38135	;	_	
182-6	38135-38137	21	_	
182-7	38137-38138	:	_	
182-8	38138-38142	1251	_	
182-9	38142-38143	–	_	
182-10	38143-38144	6	_	
182-11	38144-38145	.	_	

#Text=Brain damage in relation to psychiatric disability after head injury
#Text=A neural basis for sociopathy
#Text=ffytche D, Simmons A, Kumari V, Howard M, Hodgins S, et al.
183-1	38146-38151	Brain	_	
183-2	38152-38158	damage	_	
183-3	38159-38161	in	_	
183-4	38162-38170	relation	_	
183-5	38171-38173	to	_	
183-6	38174-38185	psychiatric	_	
183-7	38186-38196	disability	_	
183-8	38197-38202	after	_	
183-9	38203-38207	head	_	
183-10	38208-38214	injury	_	
183-11	38215-38216	A	_	
183-12	38217-38223	neural	_	
183-13	38224-38229	basis	_	
183-14	38230-38233	for	_	
183-15	38234-38244	sociopathy	_	
183-16	38245-38252	ffytche	_	
183-17	38253-38254	D	_	
183-18	38254-38255	,	_	
183-19	38256-38263	Simmons	_	
183-20	38264-38265	A	_	
183-21	38265-38266	,	_	
183-22	38267-38273	Kumari	_	
183-23	38274-38275	V	_	
183-24	38275-38276	,	_	
183-25	38277-38283	Howard	_	
183-26	38284-38285	M	_	
183-27	38285-38286	,	_	
183-28	38287-38294	Hodgins	_	
183-29	38295-38296	S	_	
183-30	38296-38297	,	_	
183-31	38298-38300	et	_	
183-32	38301-38303	al	_	
183-33	38303-38304	.	_	

#Text=The antisocial brain: psychopathy matters
#Text=Brain volumes differ between diagnostic groups of violent criminal offenders
#Text=Disentangling possible effects of childhood physical abuse on gray matter changes in violent offenders with psychopathy
#Text=Lower anterior cingulate volume in seriously violent men with antisocial personality disorder or schizophrenia and a history of childhood abuse
#Text=Atypical nucleus accumbens morphology in psychopathy: another limbic piece in the puzzle
#Text=Cortex and amygdala morphology in psychopathy
#Text=Abnormal hippocampal shape in offenders with psychopathy
#Text=Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder
#Text=Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder
#Text=Cortical thinning, functional connectivity, and mood-related impulsivity in schizophrenia: relationship to aggressive attitudes and behavior
#Text=Volumetric structural brain abnormalities in men with schizophrenia or antisocial personality disorder
#Text=Dysfunctional, but not functional, impulsivity is associated with a history of seriously violent behaviour and reduced orbitofrontal and hippocampal volumes in schizophrenia
#Text=Reduced hippocampal and parahippocampal volumes in murderers with schizophrenia
#Text=Reduced thalamic volume in men with antisocial personality disorder or schizophrenia and a history of serious violence and childhood abuse
#Text=Regional cortical thinning in subjects with violent antisocial personality disorder or schizophrenia
#Text=Ministry of Internal Affairs and Communications.
184-1	38305-38308	The	_	
184-2	38309-38319	antisocial	_	
184-3	38320-38325	brain	_	
184-4	38325-38326	:	_	
184-5	38327-38338	psychopathy	_	
184-6	38339-38346	matters	_	
184-7	38347-38352	Brain	_	
184-8	38353-38360	volumes	_	
184-9	38361-38367	differ	_	
184-10	38368-38375	between	_	
184-11	38376-38386	diagnostic	_	
184-12	38387-38393	groups	_	
184-13	38394-38396	of	_	
184-14	38397-38404	violent	_	
184-15	38405-38413	criminal	_	
184-16	38414-38423	offenders	_	
184-17	38424-38437	Disentangling	_	
184-18	38438-38446	possible	_	
184-19	38447-38454	effects	_	
184-20	38455-38457	of	_	
184-21	38458-38467	childhood	_	
184-22	38468-38476	physical	_	
184-23	38477-38482	abuse	_	
184-24	38483-38485	on	_	
184-25	38486-38490	gray	_	
184-26	38491-38497	matter	_	
184-27	38498-38505	changes	_	
184-28	38506-38508	in	_	
184-29	38509-38516	violent	_	
184-30	38517-38526	offenders	_	
184-31	38527-38531	with	_	
184-32	38532-38543	psychopathy	_	
184-33	38544-38549	Lower	_	
184-34	38550-38558	anterior	_	
184-35	38559-38568	cingulate	_	
184-36	38569-38575	volume	_	
184-37	38576-38578	in	_	
184-38	38579-38588	seriously	_	
184-39	38589-38596	violent	_	
184-40	38597-38600	men	_	
184-41	38601-38605	with	_	
184-42	38606-38616	antisocial	_	
184-43	38617-38628	personality	_	
184-44	38629-38637	disorder	_	
184-45	38638-38640	or	_	
184-46	38641-38654	schizophrenia	_	
184-47	38655-38658	and	_	
184-48	38659-38660	a	_	
184-49	38661-38668	history	_	
184-50	38669-38671	of	_	
184-51	38672-38681	childhood	_	
184-52	38682-38687	abuse	_	
184-53	38688-38696	Atypical	_	
184-54	38697-38704	nucleus	_	
184-55	38705-38714	accumbens	_	
184-56	38715-38725	morphology	_	
184-57	38726-38728	in	_	
184-58	38729-38740	psychopathy	_	
184-59	38740-38741	:	_	
184-60	38742-38749	another	_	
184-61	38750-38756	limbic	_	
184-62	38757-38762	piece	_	
184-63	38763-38765	in	_	
184-64	38766-38769	the	_	
184-65	38770-38776	puzzle	_	
184-66	38777-38783	Cortex	_	
184-67	38784-38787	and	_	
184-68	38788-38796	amygdala	_	
184-69	38797-38807	morphology	_	
184-70	38808-38810	in	_	
184-71	38811-38822	psychopathy	_	
184-72	38823-38831	Abnormal	_	
184-73	38832-38843	hippocampal	_	
184-74	38844-38849	shape	_	
184-75	38850-38852	in	_	
184-76	38853-38862	offenders	_	
184-77	38863-38867	with	_	
184-78	38868-38879	psychopathy	_	
184-79	38880-38892	Quantitative	_	
184-80	38893-38896	MRI	_	
184-81	38897-38905	measures	_	
184-82	38906-38908	of	_	
184-83	38909-38922	orbitofrontal	_	
184-84	38923-38929	cortex	_	
184-85	38930-38932	in	_	
184-86	38933-38941	patients	_	
184-87	38942-38946	with	_	
184-88	38947-38954	chronic	_	
184-89	38955-38968	schizophrenia	_	
184-90	38969-38971	or	_	
184-91	38972-38987	schizoaffective	_	
184-92	38988-38996	disorder	_	
184-93	38997-39007	Aggression	_	
184-94	39008-39011	and	_	
184-95	39012-39024	quantitative	_	
184-96	39025-39028	MRI	_	
184-97	39029-39037	measures	_	
184-98	39038-39040	of	_	
184-99	39041-39048	caudate	_	
184-100	39049-39051	in	_	
184-101	39052-39060	patients	_	
184-102	39061-39065	with	_	
184-103	39066-39073	chronic	_	
184-104	39074-39087	schizophrenia	_	
184-105	39088-39090	or	_	
184-106	39091-39106	schizoaffective	_	
184-107	39107-39115	disorder	_	
184-108	39116-39124	Cortical	_	
184-109	39125-39133	thinning	_	
184-110	39133-39134	,	_	
184-111	39135-39145	functional	_	
184-112	39146-39158	connectivity	_	
184-113	39158-39159	,	_	
184-114	39160-39163	and	_	
184-115	39164-39176	mood-related	_	
184-116	39177-39188	impulsivity	_	
184-117	39189-39191	in	_	
184-118	39192-39205	schizophrenia	_	
184-119	39205-39206	:	_	
184-120	39207-39219	relationship	_	
184-121	39220-39222	to	_	
184-122	39223-39233	aggressive	_	
184-123	39234-39243	attitudes	_	
184-124	39244-39247	and	_	
184-125	39248-39256	behavior	_	
184-126	39257-39267	Volumetric	_	
184-127	39268-39278	structural	_	
184-128	39279-39284	brain	_	
184-129	39285-39298	abnormalities	_	
184-130	39299-39301	in	_	
184-131	39302-39305	men	_	
184-132	39306-39310	with	_	
184-133	39311-39324	schizophrenia	_	
184-134	39325-39327	or	_	
184-135	39328-39338	antisocial	_	
184-136	39339-39350	personality	_	
184-137	39351-39359	disorder	_	
184-138	39360-39373	Dysfunctional	_	
184-139	39373-39374	,	_	
184-140	39375-39378	but	_	
184-141	39379-39382	not	_	
184-142	39383-39393	functional	_	
184-143	39393-39394	,	_	
184-144	39395-39406	impulsivity	_	
184-145	39407-39409	is	_	
184-146	39410-39420	associated	_	
184-147	39421-39425	with	_	
184-148	39426-39427	a	_	
184-149	39428-39435	history	_	
184-150	39436-39438	of	_	
184-151	39439-39448	seriously	_	
184-152	39449-39456	violent	_	
184-153	39457-39466	behaviour	_	
184-154	39467-39470	and	_	
184-155	39471-39478	reduced	_	
184-156	39479-39492	orbitofrontal	_	
184-157	39493-39496	and	_	
184-158	39497-39508	hippocampal	_	
184-159	39509-39516	volumes	_	
184-160	39517-39519	in	_	
184-161	39520-39533	schizophrenia	_	
184-162	39534-39541	Reduced	_	
184-163	39542-39553	hippocampal	_	
184-164	39554-39557	and	_	
184-165	39558-39573	parahippocampal	_	
184-166	39574-39581	volumes	_	
184-167	39582-39584	in	_	
184-168	39585-39594	murderers	_	
184-169	39595-39599	with	_	
184-170	39600-39613	schizophrenia	_	
184-171	39614-39621	Reduced	_	
184-172	39622-39630	thalamic	_	
184-173	39631-39637	volume	_	
184-174	39638-39640	in	_	
184-175	39641-39644	men	_	
184-176	39645-39649	with	_	
184-177	39650-39660	antisocial	_	
184-178	39661-39672	personality	_	
184-179	39673-39681	disorder	_	
184-180	39682-39684	or	_	
184-181	39685-39698	schizophrenia	_	
184-182	39699-39702	and	_	
184-183	39703-39704	a	_	
184-184	39705-39712	history	_	
184-185	39713-39715	of	_	
184-186	39716-39723	serious	_	
184-187	39724-39732	violence	_	
184-188	39733-39736	and	_	
184-189	39737-39746	childhood	_	
184-190	39747-39752	abuse	_	
184-191	39753-39761	Regional	_	
184-192	39762-39770	cortical	_	
184-193	39771-39779	thinning	_	
184-194	39780-39782	in	_	
184-195	39783-39791	subjects	_	
184-196	39792-39796	with	_	
184-197	39797-39804	violent	_	
184-198	39805-39815	antisocial	_	
184-199	39816-39827	personality	_	
184-200	39828-39836	disorder	_	
184-201	39837-39839	or	_	
184-202	39840-39853	schizophrenia	_	
184-203	39854-39862	Ministry	_	
184-204	39863-39865	of	_	
184-205	39866-39874	Internal	_	
184-206	39875-39882	Affairs	_	
184-207	39883-39886	and	_	
184-208	39887-39901	Communications	_	
184-209	39901-39902	.	_	

#Text=Act on Medical Care and Treatment for Persons Who Have Caused Serious Cases Under the Condition of Insanity.
185-1	39903-39906	Act	_	
185-2	39907-39909	on	_	
185-3	39910-39917	Medical	_	
185-4	39918-39922	Care	_	
185-5	39923-39926	and	_	
185-6	39927-39936	Treatment	_	
185-7	39937-39940	for	_	
185-8	39941-39948	Persons	_	
185-9	39949-39952	Who	_	
185-10	39953-39957	Have	_	
185-11	39958-39964	Caused	_	
185-12	39965-39972	Serious	_	
185-13	39973-39978	Cases	_	
185-14	39979-39984	Under	_	
185-15	39985-39988	the	_	
185-16	39989-39998	Condition	_	
185-17	39999-40001	of	_	
185-18	40002-40010	Insanity	_	
185-19	40010-40011	.	_	

#Text=In: e-Gov Japan.
186-1	40012-40014	In	_	
186-2	40014-40015	:	_	
186-3	40016-40021	e-Gov	_	
186-4	40022-40027	Japan	_	
186-5	40027-40028	.	_	

#Text=Ministry of Internal Affairs and Communications. 2003. http://law.e-gov.go.jp/htmldata/H15/H15HO110.html.
187-1	40029-40037	Ministry	_	
187-2	40038-40040	of	_	
187-3	40041-40049	Internal	_	
187-4	40050-40057	Affairs	_	
187-5	40058-40061	and	_	
187-6	40062-40076	Communications	_	
187-7	40076-40077	.	_	
187-8	40078-40082	2003	_	
187-9	40082-40083	.	_	
187-10	40084-40088	http	_	
187-11	40088-40089	:	_	
187-12	40089-40090	/	_	
187-13	40090-40091	/	_	
187-14	40091-40106	law.e-gov.go.jp	_	
187-15	40106-40107	/	_	
187-16	40107-40115	htmldata	_	
187-17	40115-40116	/	_	
187-18	40116-40119	H15	_	
187-19	40119-40120	/	_	
187-20	40120-40128	H15HO110	_	
187-21	40128-40129	.	_	
187-22	40129-40133	html	_	
187-23	40133-40134	.	_	

#Text=Accessed 22 Oct 2016.
188-1	40135-40143	Accessed	_	
188-2	40144-40146	22	_	
188-3	40147-40150	Oct	_	
188-4	40151-40155	2016	_	
188-5	40155-40156	.	_	

#Text=New legislation for offenders with mental disorders in Japan
#Text=
#Text=Drawing a criminal profile
#Text=Dose equivalence of psychotropic drugs.
189-1	40157-40160	New	_	
189-2	40161-40172	legislation	_	
189-3	40173-40176	for	_	
189-4	40177-40186	offenders	_	
189-5	40187-40191	with	_	
189-6	40192-40198	mental	_	
189-7	40199-40208	disorders	_	
189-8	40209-40211	in	_	
189-9	40212-40217	Japan	_	
189-10	40219-40226	Drawing	_	
189-11	40227-40228	a	_	
189-12	40229-40237	criminal	_	
189-13	40238-40245	profile	_	
189-14	40246-40250	Dose	_	
189-15	40251-40262	equivalence	_	
189-16	40263-40265	of	_	
189-17	40266-40278	psychotropic	_	
189-18	40279-40284	drugs	_	
189-19	40284-40285	.	_	

#Text=Part 18: dose equivalence of psychotropic drugs: 2006-version
#Text=
#Text=Interrater reliability of the Japanese version of the positive and negative syndrome scale and the appraisal of its training effect
#Text=Searching for a consensus five-factor model of the positive and negative syndrome scale for schizophrenia
#Text=Unified segmentation
#Text=A fast diffeomorphic image registration algorithm
#Text=Issues with threshold masking in voxel-based morphometry of atrophied brains
#Text=The ventral visual pathway: an expanded neural framework for the processing of object quality
#Text=Emotion processing and the amygdala: from a ‘low road’ to ‘many roads’ of evaluating biological significance
#Text=Revisiting the role of the fusiform face area in expertise
#Text=Effect of emotional valence on retrieval-related recapitulation of encoding activity in the ventral visual stream
#Text=The Enigmatic temporal pole: a review of findings on social and emotional processing
#Text=The temporal pole top-down modulates the ventral visual stream during social cognition
#Text=Emotional responses to pleasant and unpleasant olfactory, visual, and auditory stimuli: a positron emission tomography study
#Text=The compassionate brain: humans detect intensity of pain from another's face
#Text=A common anterior insula representation of disgust observation, experience and imagination shows divergent functional connectivity pathways
#Text=The precuneus: a review of its functional anatomy and behavioural correlates
#Text=Processing of false belief passages during natural story comprehension: an fMRI study
#Text=Anti-social personality characteristics and psychotic symptoms: two pathways associated with offending in schizophrenia
#Text=Neuropsychological impairment and its association with violence risk in japanese forensic psychiatric patients: a case-control study
190-1	40286-40290	Part	_	
190-2	40291-40293	18	_	
190-3	40293-40294	:	_	
190-4	40295-40299	dose	_	
190-5	40300-40311	equivalence	_	
190-6	40312-40314	of	_	
190-7	40315-40327	psychotropic	_	
190-8	40328-40333	drugs	_	
190-9	40333-40334	:	_	
190-10	40335-40339	2006	_	
190-11	40339-40340	-	_	
190-12	40340-40347	version	_	
190-13	40349-40359	Interrater	_	
190-14	40360-40371	reliability	_	
190-15	40372-40374	of	_	
190-16	40375-40378	the	_	
190-17	40379-40387	Japanese	_	
190-18	40388-40395	version	_	
190-19	40396-40398	of	_	
190-20	40399-40402	the	_	
190-21	40403-40411	positive	_	
190-22	40412-40415	and	_	
190-23	40416-40424	negative	_	
190-24	40425-40433	syndrome	_	
190-25	40434-40439	scale	_	
190-26	40440-40443	and	_	
190-27	40444-40447	the	_	
190-28	40448-40457	appraisal	_	
190-29	40458-40460	of	_	
190-30	40461-40464	its	_	
190-31	40465-40473	training	_	
190-32	40474-40480	effect	_	
190-33	40481-40490	Searching	_	
190-34	40491-40494	for	_	
190-35	40495-40496	a	_	
190-36	40497-40506	consensus	_	
190-37	40507-40518	five-factor	_	
190-38	40519-40524	model	_	
190-39	40525-40527	of	_	
190-40	40528-40531	the	_	
190-41	40532-40540	positive	_	
190-42	40541-40544	and	_	
190-43	40545-40553	negative	_	
190-44	40554-40562	syndrome	_	
190-45	40563-40568	scale	_	
190-46	40569-40572	for	_	
190-47	40573-40586	schizophrenia	_	
190-48	40587-40594	Unified	_	
190-49	40595-40607	segmentation	_	
190-50	40608-40609	A	_	
190-51	40610-40614	fast	_	
190-52	40615-40628	diffeomorphic	_	
190-53	40629-40634	image	_	
190-54	40635-40647	registration	_	
190-55	40648-40657	algorithm	_	
190-56	40658-40664	Issues	_	
190-57	40665-40669	with	_	
190-58	40670-40679	threshold	_	
190-59	40680-40687	masking	_	
190-60	40688-40690	in	_	
190-61	40691-40702	voxel-based	_	
190-62	40703-40714	morphometry	_	
190-63	40715-40717	of	_	
190-64	40718-40727	atrophied	_	
190-65	40728-40734	brains	_	
190-66	40735-40738	The	_	
190-67	40739-40746	ventral	_	
190-68	40747-40753	visual	_	
190-69	40754-40761	pathway	_	
190-70	40761-40762	:	_	
190-71	40763-40765	an	_	
190-72	40766-40774	expanded	_	
190-73	40775-40781	neural	_	
190-74	40782-40791	framework	_	
190-75	40792-40795	for	_	
190-76	40796-40799	the	_	
190-77	40800-40810	processing	_	
190-78	40811-40813	of	_	
190-79	40814-40820	object	_	
190-80	40821-40828	quality	_	
190-81	40829-40836	Emotion	_	
190-82	40837-40847	processing	_	
190-83	40848-40851	and	_	
190-84	40852-40855	the	_	
190-85	40856-40864	amygdala	_	
190-86	40864-40865	:	_	
190-87	40866-40870	from	_	
190-88	40871-40872	a	_	
190-89	40873-40874	‘	_	
190-90	40874-40877	low	_	
190-91	40878-40882	road	_	
190-92	40882-40883	’	_	
190-93	40884-40886	to	_	
190-94	40887-40888	‘	_	
190-95	40888-40892	many	_	
190-96	40893-40898	roads	_	
190-97	40898-40899	’	_	
190-98	40900-40902	of	_	
190-99	40903-40913	evaluating	_	
190-100	40914-40924	biological	_	
190-101	40925-40937	significance	_	
190-102	40938-40948	Revisiting	_	
190-103	40949-40952	the	_	
190-104	40953-40957	role	_	
190-105	40958-40960	of	_	
190-106	40961-40964	the	_	
190-107	40965-40973	fusiform	_	
190-108	40974-40978	face	_	
190-109	40979-40983	area	_	
190-110	40984-40986	in	_	
190-111	40987-40996	expertise	_	
190-112	40997-41003	Effect	_	
190-113	41004-41006	of	_	
190-114	41007-41016	emotional	_	
190-115	41017-41024	valence	_	
190-116	41025-41027	on	_	
190-117	41028-41045	retrieval-related	_	
190-118	41046-41060	recapitulation	_	
190-119	41061-41063	of	_	
190-120	41064-41072	encoding	_	
190-121	41073-41081	activity	_	
190-122	41082-41084	in	_	
190-123	41085-41088	the	_	
190-124	41089-41096	ventral	_	
190-125	41097-41103	visual	_	
190-126	41104-41110	stream	_	
190-127	41111-41114	The	_	
190-128	41115-41124	Enigmatic	_	
190-129	41125-41133	temporal	_	
190-130	41134-41138	pole	_	
190-131	41138-41139	:	_	
190-132	41140-41141	a	_	
190-133	41142-41148	review	_	
190-134	41149-41151	of	_	
190-135	41152-41160	findings	_	
190-136	41161-41163	on	_	
190-137	41164-41170	social	_	
190-138	41171-41174	and	_	
190-139	41175-41184	emotional	_	
190-140	41185-41195	processing	_	
190-141	41196-41199	The	_	
190-142	41200-41208	temporal	_	
190-143	41209-41213	pole	_	
190-144	41214-41222	top-down	_	
190-145	41223-41232	modulates	_	
190-146	41233-41236	the	_	
190-147	41237-41244	ventral	_	
190-148	41245-41251	visual	_	
190-149	41252-41258	stream	_	
190-150	41259-41265	during	_	
190-151	41266-41272	social	_	
190-152	41273-41282	cognition	_	
190-153	41283-41292	Emotional	_	
190-154	41293-41302	responses	_	
190-155	41303-41305	to	_	
190-156	41306-41314	pleasant	_	
190-157	41315-41318	and	_	
190-158	41319-41329	unpleasant	_	
190-159	41330-41339	olfactory	_	
190-160	41339-41340	,	_	
190-161	41341-41347	visual	_	
190-162	41347-41348	,	_	
190-163	41349-41352	and	_	
190-164	41353-41361	auditory	_	
190-165	41362-41369	stimuli	_	
190-166	41369-41370	:	_	
190-167	41371-41372	a	_	
190-168	41373-41381	positron	_	
190-169	41382-41390	emission	_	
190-170	41391-41401	tomography	_	
190-171	41402-41407	study	_	
190-172	41408-41411	The	_	
190-173	41412-41425	compassionate	_	
190-174	41426-41431	brain	_	
190-175	41431-41432	:	_	
190-176	41433-41439	humans	_	
190-177	41440-41446	detect	_	
190-178	41447-41456	intensity	_	
190-179	41457-41459	of	_	
190-180	41460-41464	pain	_	
190-181	41465-41469	from	_	
190-182	41470-41479	another's	_	
190-183	41480-41484	face	_	
190-184	41485-41486	A	_	
190-185	41487-41493	common	_	
190-186	41494-41502	anterior	_	
190-187	41503-41509	insula	_	
190-188	41510-41524	representation	_	
190-189	41525-41527	of	_	
190-190	41528-41535	disgust	_	
190-191	41536-41547	observation	_	
190-192	41547-41548	,	_	
190-193	41549-41559	experience	_	
190-194	41560-41563	and	_	
190-195	41564-41575	imagination	_	
190-196	41576-41581	shows	_	
190-197	41582-41591	divergent	_	
190-198	41592-41602	functional	_	
190-199	41603-41615	connectivity	_	
190-200	41616-41624	pathways	_	
190-201	41625-41628	The	_	
190-202	41629-41638	precuneus	_	
190-203	41638-41639	:	_	
190-204	41640-41641	a	_	
190-205	41642-41648	review	_	
190-206	41649-41651	of	_	
190-207	41652-41655	its	_	
190-208	41656-41666	functional	_	
190-209	41667-41674	anatomy	_	
190-210	41675-41678	and	_	
190-211	41679-41690	behavioural	_	
190-212	41691-41701	correlates	_	
190-213	41702-41712	Processing	_	
190-214	41713-41715	of	_	
190-215	41716-41721	false	_	
190-216	41722-41728	belief	_	
190-217	41729-41737	passages	_	
190-218	41738-41744	during	_	
190-219	41745-41752	natural	_	
190-220	41753-41758	story	_	
190-221	41759-41772	comprehension	_	
190-222	41772-41773	:	_	
190-223	41774-41776	an	_	
190-224	41777-41781	fMRI	_	
190-225	41782-41787	study	_	
190-226	41788-41799	Anti-social	_	
190-227	41800-41811	personality	_	
190-228	41812-41827	characteristics	_	
190-229	41828-41831	and	_	
190-230	41832-41841	psychotic	_	
190-231	41842-41850	symptoms	_	
190-232	41850-41851	:	_	
190-233	41852-41855	two	_	
190-234	41856-41864	pathways	_	
190-235	41865-41875	associated	_	
190-236	41876-41880	with	_	
190-237	41881-41890	offending	_	
190-238	41891-41893	in	_	
190-239	41894-41907	schizophrenia	_	
190-240	41908-41926	Neuropsychological	_	
190-241	41927-41937	impairment	_	
190-242	41938-41941	and	_	
190-243	41942-41945	its	_	
190-244	41946-41957	association	_	
190-245	41958-41962	with	_	
190-246	41963-41971	violence	_	
190-247	41972-41976	risk	_	
190-248	41977-41979	in	_	
190-249	41980-41988	japanese	_	
190-250	41989-41997	forensic	_	
190-251	41998-42009	psychiatric	_	
190-252	42010-42018	patients	_	
190-253	42018-42019	:	_	
190-254	42020-42021	a	_	
190-255	42022-42034	case-control	_	
190-256	42035-42040	study	_	
